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Major histocompatibility complex (MHC) matching is essential to reduce the risk of graft versus 
host disease (GvHD) but minor histocompatibility antigens (mHags) also affect the outcome of 
hematopoietic stem cell transplantation (HSCT). In addition, single nucleotide polymorphisms 
(SNPs), which do not give rise to mHags, can influence the result of HSCT. In addition to 
genotyping, profiling of gene expression in tissues affected by GvHD might identify genes, which 
are important for the development of GvHD. 
 
Previously, 11 non-class I/II MHC and 174 other genes were identified to be regulated during GvH 
reactions in rat skin explant assays, which provide an in vitro model of GvHD as well as in rat 
GvHD models. The expression of 27 of these genes was tested in human skin explant assays and in 
human GvHD skin biopsies and several genes were confirmed to be regulated also in the human 
skin biopsies. In this study, we aimed to validate the regulation of these candidate genes in tissues 
affected by acute GvHD (aGvHD) in two animal models and compare their regulation in 186 
gastrointestinal biopsies from patients after HSCT. Notably, the candidate genes HCLS1, UBD and 
TGM2 were strongly upregulated in all the mice aGvHD tissues compared to controls. A similar 
trend in regulation was observed in the rat aGvHD tissues and human GI GvHD biopsies.   
 
In addition several cytokines, chemokines and other molecules have been implicated in GvHD 
pathophysiology. In this study we selected several genes that are expected to be important in HSCT 
outcome in view of previous reports or known functions and determined their regulation in 
different tissues affected by aGvHD. We wanted to compare the regulation of these genes during 
aGvHD and after preconditioning and transplantation not leading to aGvHD. In addition, we 
analysed the regulation of these genes in human GI aGvHD. In the mouse model, an upregulation 
of Th1, Th2 and Th17 cytokines in the lung, small and large intestines was associated with aGvHD. 
Genes associated with Treg regulation and activation were increased in the liver, lung and both 
intestines during aGvHD. Overall, we observed that aGvHD in both the mouse tissues and human 
GI biopsies was associated with a marked chemokine regulation. Several chemokines Cxcl9, 
Cxcl10, Cxcl11 and their receptor Cxcr3, Ccl4, Ccl9 and their receptors Ccr5, Ccr1 were 
upregulated in mouse tissues affected by aGvHD compared to the healthy controls, whereas a 
strong downregulation was observed in the expression of the chemokines Ccl5, Cx3cl1 and 
chemokine receptors Ccr4 and Cxcr4. These genes showed a similar trend of expression in the 





In view of previous data of our group and others, we also studied the gene expression profiles of 
KLRK1, encoding NKG2D and CD226, encoding DNAM-1, and their ligands in the animal models 
of aGvHD and human GI GvHD. NKG2D and DNAM-1 are activating NK receptors on NK and 
CD8
+
 T cells. They control cytotoxicity and interferon-γ production by NK cells and serve as co-
stimulatory molecules on CD8
+
 T cells. NKG2D and DNAM-1 ligands can be up-regulated in 
several pathological conditions. Blockade or deficiency of either DNAM-1 or NKG2D in donor 
cells, has been shown to reduce the intensity of aGvHD in mice. Both NKG2D and DNAM-1 have 
also been implicated in inducing aGvHD by co-stimulating allogeneic cytotoxic T cells (CTL) 
directly via upregulation of their ligands on non-professional antigen presenting cells (APCs). 
Moreover, we recently described that a polymorphism in the human NKG2D ligand MICA has a 
major impact on the risk of aGvHD after allogeneic hematopoietic stem cell transplantation 
(HSCT) by modulating NKG2D signalling. The mRNA expression of KLRK1 and CD226 was 
increased significantly in all the mouse tissues affected by aGvHD, and showed an increased 
expression trend in the rat and human GvHD biopsies. Additionally, we observed a strong 
upregulation of their ligands, Ulbp1, Pvr and Pvrl2 in mouse aGvHD and Rae1l in the rat. MICA 
was upregulated in patients with aGvHD that were treated with steroids. On the other hand, Rae1 
was downregulated in the different aGvHD mice tissues and MICB was downregulated in human 
GI aGvHD. PVR and PVRL2 showed a trend of upregulation in rats, however they were not 
differentially regulated in the human aGvHD biopsies. Additionally, the expression of MICA was 
increased whereas PVRL2 was decreased in patients who died due to transplant related causes 
compared to patients who were still alive or died due to other causes including relapse of 
malignancy. 
 
In conclusion, we confirmed that several candidate genes previously suggested to be regulated 
during aGvHD were indeed significantly regulated in the different tissues in both animal models 
and human GI biopsies, and a number of genes showed similar expression trends. Moreover, we 
successfully showed that the regulation of many of our focus genes was significantly altered due to 
preconditioning, and their regulation was frequently exacerbated due to aGvHD in the different 
mouse tissues. Conditioning regimens that are less likely to induce these genes could be beneficial 
for attenuating the aGvHD response. Ligands of the activating NK receptors NKG2D showed a 
complex expression pattern during GvHD that might be important for the activation of allogeneic 
CTL in target tissues of aGvHD. 
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IHC immunohistochemistry 
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IL1R1 Interleukin 1 receptor 1 
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IL33 Interleukin 33 
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LST1 Leukocyte-specific transcript 1 
M molar 
M-MLV Moloney murine leukemia virus 
MDS Myelodysplastic syndrome 
MDSCs myeloid-derived stem cells  
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MHC major histocompatibility antigen 
MICA MHC Class I polypeptide-related sequence A 
MICB MHC Class I polypeptide-related sequence B 
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TCR T cell receptor 
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1.1 Allogeneic hematopoietic stem cell transplantation 
Allogeneic hematopoietic stem cell transplantation (HSCT) is a widely used and effective 
treatment for several hematological malignancies as well as other acquired or inherited fatal 
disorders affecting the hematopoietic system (Shlomchik, 2007). Thomas and colleagues, carried 
out the first human allo-HSCT in 1959 (Thomas et al., 1959). Over the last decade, the number of 
patients receiving HSCTs has increased dramatically, currently at around 55000-60000 transplant 
every year (Pasquini MC, Wang Z, 2007). However, the five year survival rate post transplant is 
still only at 50 % due to several complications, such as acute graft-versus-host disease (aGvHD) 
(Appelbaum, 2001; Gooley et al., 2010). Prior to the transplantation procedure, patients are 
typically subjected to conditioning regimen of chemotherapy or radiotherapy and suppression of 
the immune system. This allows for engraftment in the recipient, thus reducing the risk of graft 
rejection and lowers the number of malignant cells. After transplantation, the donor hematopoietic 
stem cells replace the immune system of the host gradually over time (Deeg and Storb, 1985). 
However, patients undergoing allo-HSCT are prone to develop serious complications such as 
relapse of disease, GvHD, graft rejection and a variety of infections that can be fatal (Welniak et 
al., 2007). Several factors can affect the extent of the complications post transplant, such as patient 
gender, age, type of disease, health status of patient, relationship to donor, etc (Gratwohl, 2012). 
 
1.1.1 Conditioning therapy prior to HSCT 
Prior to HSCT, conditioning regimens eradicate host stem cells to make room for the recipient graft 
to proliferate and differentiate. Also, it is crucial that the recipients are immunocompromised 
before receiving the graft to prevent graft rejection. The suppressed host immune system allows the 
donor stem cells from the graft to home in the bone marrow (BM) microenvironment without the 
risk of graft rejection. Finally, the conditioning regimen is beneficial for tackling the underlying 
disease and providing a long term control of the disease or in any case, reducing the leukemic cells 
enough to achieve graft versus leukemia (GvL) effects. This is mainly important for patients with 
hematological malignancies. Conditioning regimens are generally classified as myeloablative 






1.1.2 Source of HSCs 
Initially, the source of most hematopoietic stem cells (HSCs) was the BM. BM cells are generally 
obtained from the anterior and posterior iliac crest of the donor while they are under spinal or 
general anaesthesia (Thomas et al., 1975). However, BM is no longer the only source of stem cells. 
Peripheral blood stem cells (PBSCs) as well as placental blood obtained from the umbilical cord 
after birth, have increasingly become the stem cell sources for HSCT (Bensinger et al., 1996; 
Gluckman et al., 1999; Ringdén et al., 2000). 
Granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood has been shown in a 
large randomized trial, to lead to a more rapid engraftment post-transplant than the use of marrow, 
without increasing the incidence of aGvHD (Bensinger et al., 2001; Hägglund et al., 1998). The use 
of PBSCs has been associated with a trend towards higher chronic GvHD (cGvHD), especially in 
cases of high cell numbers used (Ringdén et al., 2002; Storek et al., 1997). However, in patients 
with matched unrelated donors, PBSCs can be used safely without any increase in aGvHD 
incidence (Remberger et al., 2001). Cord blood on the other hand, is associated with a lower rate of 
engraftment and an increased risk of graft failure (Kurtzberg et al., 1996; Wagner et al., 1996), but 
a lower risk of aGvHD and cGvHD. Unfortunately, cord blood involves a relatively low cell count, 
thereby limiting its use mainly to children and small adults.  
 
1.2 Classification of GvHD  
GvHD is still the most critical risk factor of any allo-HSCT. The incidence of GvHD in patents 
post-transplant is still high. GvHD is classified into acute and chronic GvHD.  
1.2.1 Acute graft-versus-host disease 
Acute GvHD (aGvHD) is a severe reaction, typically occurring within 100 days post-transplant 
when alloreactive donor T cells recognize a genetic disparity compared to the host and mount an 
immune response against various host tissues, mainly the skin, gastrointestinal (GI) tract, liver and 
lungs (Ferrara et al., 2009). It is characterized as a T helper (Th)-1 type cellular response (Mohty et 
al., 2005). The severity of aGvHD as well as the incidence of graft failure is directly associated 
with the level of mismatch between human leukocyte antigen (HLA) genes between the donor and 
recipient (Atkinson et al., 1990; Loiseau et al., 2007; Petersdorf, 2007). Although even in cases of 
HLA identical donor-recipient pairs, approximately 50 % of the recipients still require treatment 
for aGvHD due to mismatches in the minor histocompatibility antigens (mHags) (Ferrara et al., 




formed due to SNPs or gene deletions. These mHags are highly immunogenic peptides that can 
bind to either HLA class I or class II molecules and can subsequently be presented to T cells 
(Dzierzak-Mietla et al. 2012). Disparity of mHags between the donor and recipient further 
increases the incidence of GvHD in HLA-matched, unrelated patient-donor pairs (Welniak et al. 
2007).  
 
1.2.2 Chronic graft-versus-host disease 
Chronic GvHD (cGvHD), which typically occurs after 100 days post-transplant. The mechanisms 
contributing to cGvHD are not well understood, and involve a diverse range of symptoms 
(Shlomchik, 2007). Chronic GvHD can either be progressive, occurring in patients who already 
have acute GvHD, or quiescent, occurring in patients that had aGvHD previously, or finally de 
novo, occurring in recipients that did not develop aGvHD (Ferrara et al., 2009). It is characterized 
by the polarization of CD4
+
 T cells towards a Th2 type response (Skert et al., 2009) and by the 
elevation of B cell activating factor (BAFF) (Sarantopoulos et al., 2009).  
Even though aGvHD and cGvHD are generally considered as different conditions, evidence 
indicates the presence of a close relationship between the risk factors for both types of GvHD 
(Atkinson et al., 1990). Acute GvHD frequently occurs after day 100 as late acute GvHD, 
occurring after the cessation of immunosuppression or after donor lymphocyte infusion. 
Alternatively, GvHD can present with symptoms of both acute and chronic GvHD, known as 
overlap syndrome (Filipovich et al., 2005). Moreover, the pathophysiology of GvHD is further 
complicated due to involvement of regulatory T cells (Treg), antigen presenting cells (APCs), 
regulatory B cells (Bregs) (Shimabukuro-Vornhagen et al., 2009) and mesenchymal stem cells 
(MSCs). In our study, we will focus on different models of aGvHD. 
 
1.2.3 Pathophysiology of aGvHD  
Several years ago, Billingham postulated three requirements for GvHD development, namely a 
graft containing immunologically competent cells, expression of tissue antigens by the recipient 
that are not present in the donor and inability of the recipient to mount an effective response to 
eliminate the transplanted cells (Billingham, 1996). This model was modified later by adding 





The pathophysiology of aGvHD is described as a three phase process.  Phase I involves the effects 
of conditioning, followed by donor T cell activation during phase II and finally a cellular and 
inflammatory effector phase III (Jaksch and Mattsson, 2005).  
Phase I 
Phase I mainly involves activation of APCs. Conditioning regimens, prior to HSCT, lead to tissue 
injury in GvHD target tissues, mainly the liver and intestinal mucosa. The tissue damage induces 
expression of proinflammatory cytokines, chemokines and adhesion molecules (Ferrara et al., 
2009), which in turn can activate APCs (Matzinger, 2002). The main cytokines involved in this 
phase are TNF-α, IL-1 and IL-6, released by damaged host tissue, described as the “cytokine 
storm” (Hill and Ferrara, 2000; Hill et al., 1997). The cytokine storm is responsible for activating 
host APCs, and subsequently activate the donor T cells (Matzinger, 2002; Shlomchik et al., 1999). 
Damage to the intestinal mucosa is of particular importance as it allows the translocation of 
lipopolysaccharides (LPS) into the intestine further enhances the activation of host APCs and 
exacerbates production of TNF-α and IL-1 by macrophages (Nestel et al., 1992). This process is 
associated with increase in GvHD severity (Hill and Ferrara, 2000; Hill et al., 1999). In addition to 
activating APCs, these cytokines can also promote antigen presentation by non-professional APCs 
in the host tissue and cause direct inflammation of the tissue allowing T cells to access the target 
tissues (Hill, 2009). Non-professional APCs can directly activate cytotoxic T cells and these cause 
tissue damage. 
Phase II  
In this phase, donor T cells are activated after the transplantation procedure. Donor T cells 
proliferate and secrete cytokines including IL-2 and IFN-γ, that increases antigen presentation and 
T cell recruitment, events that are crucial to aGvHD pathophysiology (Jaksch and Mattsson, 2005). 
Naïve donor CD4
+
 T cells are primed by dendritic cells (DCs) initiating GvHD (Matzinger, 2002). 
The intensity of the T cell response is dependent on the MHC and minor histocompatibility 
disparity between donor and recipient. After HSCT, both donor and host derived APCs are present 
in the secondary lymphoid organs  (Korngold and Sprent, 1980). The donor T cells can recognize 
alloantigens presented by both host APCs (direct presentation) and donor APCs (indirect 






Figure 1.1 Pathophysiology of aGvHD; adopted from (Reddy, P. and Ferrara J.L.M).            
Prior to transplant, the conditioning causes tissue damage, which activates APCs and increases APC 
function. Damage to the gut, releases bacteria, which leads to an activation of innate immune cells by 
PAMPs and chemokines, leading to direct damage to tissue and initiation of the cytokine storm. The 
cytokines further promote antigen presentation and the recruitment of effector T cells and innate immune 
cells, further augmenting the pro-inflammatory cytokine response. Finally, effector T cells, NK cells, 
macrophages and pro-inflammatory cytokines such as TNF-α, IL-1 result in damage to target tissues such as 
skin, gut, liver and lung, leading to multi-organ failure and aGvHD.  
 
Phase III 
Phase III otherwise known as the efferent phase, involves a complex cascade of effector processes 
that cause further tissue injury in the host. The important mediators in this phase are the cytokines 
TNF-α and IL-1 and macrophage derived nitric oxide (NO). In addition cytotoxic T lymphocytes 
(CTLs) and Fas- and perforin-mediated mechanisms and NK cells are involved in the complex 
cascade leading to development of GvHD (Ferrara 2003). TNF-α and IL-1 produced by APCs 
further activate DCs, increasing allo-antigen presentation, further induce cytokines and recruitment 
of more effector cells that migrate to target organs of GvHD (Jaksch and Mattsson, 2005), causing 
an exacerbated tissue damage by inducing apoptosis in the target organs, such as gut, liver, lung 
and skin and resulting in multi-organ failure (Ferrara 1992). The mechanism of tissue injury by 
infiltrating alloreactive T cells is shown in Figure 1.2. Several chemokines and their receptors 






Figure 1.2: Tissue injury by infiltrating alloreactive T cells; adopted from (Shlomchik et al. 2007). 
Mechanisms of tissue injury in the target aGvHD tissues by infiltrating alloreactive T cells. Activated 
alloreactive CD8
+ 
T cells directly induce tissue injury via expression of CD95 ligand and producing cytolytic 
granules. By contrast, CD4
+
T cells can be activated by tissue macrophages and DCs, and subsequently 
release TNF-α, IL-1 and IFN-γ. Alternatively, they can activate antigen bearing macrophages that can 
directly induce tissue injury.  
 
The main pathways involved in the tissue damage to the aGvHD target tissues are: the FAS/FASL 
pathway, the perforin/granzyme pathway and direct tissue injury mediated by cytokines. Knockout 
mouse models have elucidated the importance of each of the pathways (Jaksch and Mattsson, 
2005).  
 
In the perforin/granzyme pathway, following direct cell contact, perforin penetrates the cell 
membrane, in turn leading to the activation of the caspase cascade and cytolysis of the cell (Goker 
et al., 2001). The FAS receptor (CD95) is expressed on many tissues and its expression levels are 
further induced in the presence of inflammation. On the other hand, the FAS receptor ligand 
(FASL/CD95L) is predominantly expressed on activated T cells, macrophages and neutrophils. The 
interaction between FAS and the FASL causes FAS-mediated apoptosis (Nagata and Golstein, 








the serum levels of both FAS and FASL correlate with a severe grade of GvHD (Jaksch and 
Mattsson, 2005). The FAS/FASL mechanism is mostly important in hepatic GvHD, since it has 
been shown that FAS-deficient recipient mice were protected from hepatic GvHD (van Den Brink 
et al., 2000). 
 
1.2.4 Histopathological manifestation of GvHD in target organs  
In 1956, Barnes and colleagues showed that when irradiated mice were infused with allogeneic 
bone marrow and splenic cells, they could recover from the subsequent aplasia and irradiation 
injury. However, the mice developed skin changes, liver abnormalities, weight loss and diarrhoea, 
subsequently dying from a “secondary disease” called the “runt disease” (Barnes et al., 1956), 
which later came to be known as GvHD. This disease mainly manifests clinically in the skin, liver 
and GI tract. 
The first clinical symptoms of aGvHD usually present as a skin rash, which could be pruritic, 
occurring on the palms and soles, neck or shoulders (Ferrara et al., 2009). As the disease 
progresses, the rash can spread to other parts of the body and can form bullous lesions during 
severe aGvHD (Ferrara et al., 2009). However during cGvHD, the skin appears scleradermous and 
lesions are characterized by immunoglobulin deposits (Griffith et al., 2008).  
The second most commonly involved organ during aGvHD is the liver. Damage to the liver 
typically leads to an increase in conjugated bilirubin and alkaline phosphatase, eventually leading 
to cholestasis. In addition, other histopathological manifestations in the liver include infiltration of 
lymphocytes into the bile ducts and degeneration of the biliary and epithelial cells (Snover et al., 
1984).  
Another organ that is affected by GvHD is the GI tract, which is clinically characterized by 
diarrhoea, abdominal cramp, nausea and vomiting (Ferrara et al., 2009). The GI tract is also most 
affected after conditioning. These symptoms can be accompanied by blood and mucosa in stool, as 
well as weight loss. The histopathology of the damage to the GI tract presents with necrosis of 
individual cells, loss of individual crypts, lymphocyte infiltration in the lamina propria and mucosal 







1.3 Important HLA and non-HLA related risk factors involved in aGvHD 
1.3.1 Human leukocyte antigens  
The Major Histocompatibility Complex (MHC) encoding Human Leukocyte Antigens (HLAs) is 
located on the chromosome 6 in humans (Beck and Trowsdale, 2000). HLA genes are classified 
into three classes, namely HLA class I, HLA class II and HLA class III. The class I region is 
comprised of the classical HLA-A, HLA-B and HLA-C genes, that are present on all nucleated 
cells, whereas the class II region contains the HLA DR, DQ and DP genes that are expressed by 
professional APCs (Beck and Trowsdale, 2000). Under certain conditions such as inflammation 
and cell damage, the HLA class II proteins can be expressed by other cell types as well. The 
manifestation of aGvHD is predominantly a result of mismatch between donor and recipient HLA 
proteins (Lee et al., 2007). Even siblings only have a 25 % possibility of being matched for the 
MHC. However, even when siblings are matched for the MHC, around 40 % of patients that 
undergo HSCT still develop GvHD (Ferrara et al., 2009), as a consequence of mismatched in the 
mHags. Differences in the mHags between MHC-matched donor and recipients leads to the risk of 
GvHD in matched donors (Welniak et al., 2007). 
 
1.3.2 Killer immunoglobulin receptors 
Killer immunoglobulin receptors (KIRs) are present on NK cells, and subpopulations of γδ and αβ 
T cells (Uhrberg et al., 2001) and are inherited independent of the HLA (Welniak et al., 2007). 
KIRs are comprised of both activatory and inhibitory receptors responsible for regulating NK cell 
activation. They can recognize HLA-A, B and C molecules. The relevance of KIRs for HSCT 
outcome has been emphasized by several studies. Lack of engagement of inhibitory NK cell 
receptors by recipient ligands, was associated with beneficial NK cell alloreactivity (Ruggeri et al., 
2002). KIR/KIR ligand incompatibilities have been associated with effects in graft rejection, 
GvHD and GvL effects (Ruggeri et al., 2002). 
 
1.3.3 Co-stimulatory molecules  
The stimulation of T cells involves the recognition of peptides presented on APCs as well as a 
second co-stimulatory signal. The expression of co-stimulatory molecules is important for 
regulating the differentiation, proliferation and activation of T cells. Both activating CD28 and 




cells, while their ligands CD80 (B7-1) and CD86 (B7-2) are expressed primarily on APCs 
(Manickasingham et al., 1998). Binding of costimulatory molecules to their ligands promotes 
differentiation and survival of T cells stimulation (Alegre et al., 2001). Other pathways involved in 
T cell activation, NKG2D-NKG2D-L (Karimi et al. 2015), DNAM-1/DNAM-1-L (Nabekura et al., 
2010), and the ICOS/ICOS-L (Taylor et al., 2005) have also been implicated in aGvHD severity.  
 
1.4 Effector cells involved in GvHD  
1.4.1 T cells  
Mature T cells present in the bone marrow are crucial in inducing GvHD, since elimination of T 
cells from the graft prevents GvHD (Trentin and Judd, 1973; Tyan, 1973). The exact T cell subsets 
that are involved in GvHD induction largely depend on the histocompatibility disparity between the 
donor and recipient. Donors and recipients that are fully MHC-mismatched elicit a severe GvHD 




 donor T cells (Müller-Ruchholtz et al., 1976), while an MHC-II 
mismatched model requires only donor CD4
+
 T cells to induce a GvHD response (Korngold and 
Sprent, 1985). Similarly, when the donor and recipient are MHC-I mismatched, donor CD8
+
 T cells 
alone, without any participation from donor CD4
+
 T cells are enough to induce a GvHD response 
(Sprent et al., 1986, 1988; Theiss-Suennemann et al., 2015). However, the severity of the response is 
heightened with the presence of CD4
+
 T cells in addition to the CD8
+
 T cells in the graft, despite no 
mismatches in the MHC-II molecules (Korngold and Sprent, 1982; Sprent et al., 1988). In addition, 
CD4
+
 T cells further exacerbate the alloreactivity of CD8
+
 T cells during GvHD, due to infections 
by endogenous viruses such as herpes simplex, cytomegalovirus (CMV) and varicella zoster virus 
(Cray & Levy 1990; Cray & Levy 1990; Ringdén 1992), causing a more intense GvHD reaction 
(Cray and Levy, 1993). Across mismatches in mHags, GvHD is mostly induced by donor CD8
+
 T 
cells (Korngold and Sprent, 1982), although CD4
+
 T cells are mainly involved in production of 
immune-regulatory cytokines (OKunewick et al., 1987). Cytokines released drive the differentiation 
of donor CD4
+
 T cells into distinct Th subsets. DCs or NK cells secrete IFN-γ, IL-12, and IL-18 
cytokines that drive Th1 differentiation, which in turn leads to the production of IL-2 and IFN-γ 
(Kurt-Jones et al., 1987). Th2 cells are induced by IL-4 produced by basophils and mast cells, and 
secrete IL-4, IL-5, IL-10 and IL-13 (Heinzel et al. 1991). Moreover, while Th1 cells respond to 
chemokines up-regulated in response to Th1 cytokines via their expression of chemokine receptors 
CCR-5 and CXCR-3 (Moser et al., 2004; Sallusto et al., 1998), Th2 cells express the skin-homing 
chemokine receptor CCR-4 together with the CCR-3 receptor (Campbell et al., 1999; Sallusto et al., 




are induced by either IL-23 or a combination of IL-6 and TGF-β , and produce IL-17, IL-21 and IL-
22 (Harrington et al., 2005).  
 
1.4.2 Regulatory T cells 
Another important subset of T cells, the regulatory T cells (Tregs) have been the focus of several 





 forkheadbox protein 3 (FOXP3)
+
 T cells, are involved in the maintenance of 
immunological tolerance by secreting anti-inflammatory cytokines such as TGF-β and IL-10 (Beres 
and Drobyski, 2013). Tregs can be divided into two populations, thymus-derived naturally 
occurring Tregs (nTregs) (Sakaguchi et al., 1995) and adaptive or induced Tregs (iTregs) generated 
in the peripheral lymphoid organs in the presence of TGF-β (Cobbold et al., 2004). However its 










 Tregs was correlated to increased severity of GvHD (Li et al., 2010). In contrast, 
Foxp3
+
 cells were upregulated significantly in GvHD intestinal mucosa when compared to non 
GvHD mucosa in another study (Lord et al., 2011). 
 
1.4.3 NK Cells  
NK cells are crucial for successful engraftment after HSCT. As in T cells, NK cells can also 
migrate to and proliferate in lymphoid organs, and can also reach target tissues during aGvHD. In 
HSCT, NK cells reduce GvHD by producing TGF-β or stimulate its production in other cells 
(Ruggeri et al., 2002). NK cells are also known to inhibit activated alloreactive T cells, and thereby 
reduce GvHD while maintaining GvL effects (Olson et al., 2010). On the other hand, they also 
produce IFN-γ, TNF-α and NO upon induction, resulting in subsequent tissue injury during aGvHD 








1.4.4 B cells  
Antigen presentation by B cells also plays an important role during immune responses. B 
lymphocytes become potent antigen-presenting cells (APCs) on activation via the B-cell receptor 
(BCR) and co-stimulatory receptors such as CD40 (Von Bergwelt-Baildon et al., 2002). 




 T cells, and the T cell response 
is dependent on antigen presentation by B cells (Von Bergwelt-Baildon et al., 2002; Constant et al., 
1995). Regulatory B lymphocytes can also induce the secretion of several cytokines such as TGF-β 
and chemokines, and reduce T cell responses (Mauri and Ehrenstein, 2008). B cells have mainly 
been associated with cGvHD. Elevated mRNA expression levels of the B cell-activating factor 
(BAFF) is associated with clinical cGvHD in patient biopsies (Ahmed et al., 2015; Allen et al., 
2012). Moreover, the depletion of B cells reduced the incidence of cGvHD in mice (Schultz et al., 
1995). 
 
1.4.5 Other inflammatory effectors affecting aGvHD  
1.4.5.1   Nitric Oxide 
Nitric oxide (NO) plays a crucial role in host defense and anti-microbial function of macrophages. 
IFN-γ also induces the production of NO. Exposure to increased amounts of IFN-γ reduces the 
amount of LPS needed to trigger synthesis of inflammatory mediators by macrophages (Ding et al., 
1988; Gifford and Lohmann-Matthes, 1987). As a result, even small quantities of LPS can trigger 
NO and TNF-α production (Kichian et al., 1996; Nestel et al., 1992). 
Elevated serum levels of NO precede GvHD symptoms in both human and animal aGvHD 
(Langrehr et al., 1992; Weiss et al., 1995). NO induces immunosuppression and inhibiting 
mechanisms that repair the target tissues, by inactivating non-heme-iron containing enzymes, in 
turn inhibiting epithelial stem cell proliferation in the skin and gut (Krenger et al., 1996; Nestel et 
al., 1992), and causing direct tissue damage (Halliwell and Gutteridge, 1992).  
 
1.4.5.2 Cytokines and chemokines 
During the pathophysiology of aGvHD, in addition to LPS, several proinflammatory cytokines 
such as IL-1, TNF-α or IFN-γ, are involved in stimulating different cells such as macrophages, 




TNF-α is involved in activating DCs and enhancing the presentation of alloantigens. As a result of 
stimulation, inflammatory chemokines are expressed in the infiltrating cells, and the chemokines 
recruit effector T cells, monocytes and granulocytes to the sites of inflammation. On reaching the 
target organs, T cells cause damage to target tissues via cytotoxic activity directly, leading to 
recruitment of other leukocytes. The cytotoxic activity of the T cells is mediated mainly by the Fas 
ligand/Fas and the perforin-granzyme pathways (Braun et al., 1996). However, CTLs deficient for 
both pathways exhibit residual cytolytic activity, suggesting that other pathways, like the TNF-
related apoptosis inducing ligand (TRAIL) might be involved in mediating GvL but not GvHD 
(Schmaltz et al., 2002). TNF-α can be expressed and secreted by activated CTLs, contributes to the 
cytotoxicity mediated by CTLs (Ware et al., 1995). The TNF-α can be derived from monocytes and 
macrophages of either the donor or the host (Ferrara et al., 1999). Moreover, TNF-α derived from 
donor T cells have been associated with morbidity and mortality due to aGvHD as well as GvL 
(Schmaltz et al., 2003). TNF-α is involved in both, the induction and the effector phases of GvHD 
(Ferrara and Deeg, 1991). Furthermore, activated macrophages can secrete inflammatory cytokines 
that can strongly contribute to the tissue damage during the last phase of aGvHD. Interestingly, 
TNF-α has also been associated with direct tissue damage by inducing necrosis of target cells and 
apoptosis (Wall and Sheehan, 1994).  
IL-1 is another important cytokine that plays an important role in the effector phase of acute 
GvHD. Mice receiving IL-1 after allo-SCT, had an increased frequency of mortality, which was 
augmented in aGvHD (Atkinson et al., 1991). Moreover, IL1 mRNA was significantly increased in 
mononuclear cells during clinical aGvHD (Tanaka et al., 1995a). Administration of an IL-1 
receptor antagonist (IL-1Ra) was shown to attenuate aGvHD in mice (Eisenberg et al., 1990; 
Hannum et al., 1990), however the treatment was not successful in preventing aGvHD in a 
randomized clinical trial (Antin et al., 2002).  
Several cytokines and chemokines have been implicated during aGvHD. Moreover, several therapy 
strategies for aGvHD focus on blocking interactions between chemokines and their receptors. For 
example, an ameliorated gastrointestinal aGvHD in mouse models was observed on administration 
of anti-CXCR-3 antibodies (He et al., 2008).  
 
1.4.5.2.1 Regulation of cytokine genes in aGvHD 
Several studies have elucidated the importance of cytokine expression during HSCT. A number of 




TNF-α that are involved in the initiation of aGvHD (Reddy, 2003). Several SNPs in the cytokine 
genes encoding IL-10, TNF-α and IL-6 have been associated with an increased risk of GvHD.  
The activation of cytokines is determined by the difference in polarization of T cells into mainly 
type 1 and type 2 responses, which in turn determines the immune response during aGvHD, and 
IL-12 is involved in the activation of type 1 cytokines (Yang et al., 1997). Several gene expression 
studies have reported the involvement of several cytokines that are involved in aGvHD (Buzzeo et 
al., 2008; Das et al., 2001; Tanaka et al., 1995a). 
IL-2 is a Th1 cytokine that serves as a T cell growth factor. The treatment and prophylaxis of 
aGvHD frequently involves the inhibition of IL-2 production by using cyclosporine A (Qian et al., 
2013). In both animal and clinical studies, the administration of monoclonal antibodies against the 
IL-2 receptor after transplant prevented aGvHD (Blaise et al. 1991; Ferrara et al. 1986). IL-2 is also 
necessary for the generation and maintenance of Tregs, suggesting that inhibition of IL-2 could 
have a negative effect on the long-term tolerance after HSCT (Gavin et al., 2007; Zeiser et al., 
2006).  
IFN-γ is a pro-inflammatory cytokine that is of crucial importance during aGvHD. Several cell 
types, such as activated T cells, NK and NKT cells, produce IFN-γ. Both IFN-γ and IL-2 are 
involved in the proliferation of T cells, stimulation of cytotoxic T lymphocyte (CTL) and NK cell 
responses and production of IL-1 and TNF-α (Jaksch and Mattsson, 2005). A number of studies 
have reported a correlation between the expression of IFN-γ and severity of aGvHD (Das et al., 
2001; Dickinson et al., 1994; Tanaka et al., 1995a). IFN-γ is induced early in the cytokine cascade 
of aGvHD, and augments the disease, leading to the maturation of DCs and stimulation of 
macrophages to produce cytokines and NO (Jaksch and Mattsson, 2005). Moreover, the mRNA 
expression of IFNG and IL2 was increased in the PBMCs of GvHD patients and the expression of 
IL2 mRNA correlated with the progression of GvHD (Das et al., 2001). TNF-α is another pro-
inflammatory cytokine involved in the pathogenesis of aGvHD. Neutralization of TNF-α can 
reduce aGvHD symptoms (Cooke et al., 1998).  
 
1.4.5.2.2 Regulation of chemokine genes in aGvHD 
All inflammatory reactions are associated with a recruitment of leukocytes to sites of inflammation. 
Many genes encoding chemokines and their receptors are regulated during GvHD. The Th1 
chemokine receptor, CXCR-3 is an important chemokine receptor involved in lymphocyte 
recruitment and is expressed on T cells. CXCL-9, CXCL-10 and CXCL-11, the ligands for CXCR-




expressed by effector CD4
+
 Th1 cells and CD8
+
 CTL, and has been shown to affect the migration 
of effector T cells to inflamed tissue during progression of GvHD (Groom and Luster, 2011). 
Several studies have reported the regulation of the CXCR-3 and its ligands during aGvHD (Ahmed 
et al. 2015; Bouazzaoui et al. 2009;  Zhou et al. 2007; Ichiba et al. 2003; Sadeghi et al. 2013). 
Furthermore, the use of CXCR-3-transfected Tregs, as a novel therapeutic strategy, resulted in 
decreased severity of GvHD due to attraction of Tregs to the target tissues of GvHD (Hasegawa et 
al., 2008). CCR-5 mediates the recruitment of effector T cells, as well as regulatory T cells, to 
many different target organs (Murai et al., 1999; Wysocki et al., 2004, 2005b). Additionally, in 
gastrointestinal aGvHD, the chemokine receptors CXCR-3 (Duffner et al., 2004) and CCR-6 
(Varona et al., 2006) and chemokine CX3CL1 (Ueha et al., 2007), have been shown to play 
important roles. CCL-2, CCL-3, CCL-4 and CCL-5 are involved in the migration of donor cells to 
the target organs during GvHD (Castor et al., 2012). The mRNA expression of the chemokines 
(Cxcl1, Cxcl2, Cxcl9 and Cxcl20, Ccl2, Ccl5, Ccl6, Ccl7, Ccl8, Ccl9, Ccl11, Ccl17, and Ccl29) and 
chemokine receptors (Ccr1 and Ccr5) were reported to be increased in the skin during aGvHD 
(Sugerman et al. 2004; Zhou et al. 2007). Ccl5 was also profoundly up regulated during hepatic 
aGvHD in a mouse model (Ichiba et al. 2003).  
 
1.5 MRNA expression during aGvHD 
Several studies have shown the importance of determining the regulation of genes involved in 
different aspects of HSCT and in aGvHD. A number of gene expression-profiling studies have 
identified candidate genes that could be associated with the disease diagnosis, prognosis and 
outcome aGvHD (Bouazzaoui et al., 2009; Novota et al., 2011; Sadeghi et al., 2013; Sugerman et 
al., 2004; Verner et al., 2012). Moreover, identification of the genes that are regulated during the 
different phases of aGvHD, have been important in determining potential therapeutic strategies. 
For example, blocking cytokines, such as TNF-α (Cooke et al., 1998) and cytokine receptors such 
as IL-6R (Chen et al., 2009; Tawara et al., 2011) was associated with a reduction in aGvHD. 
Alternatively, some cytokines are protective against aGvHD, such as IL-22 (Hanash et al., 2012). 
In this study, we aimed to compare the gene expression patterns in different aGvHD target organs 







1.5.1 Expression of previously identified candidate genes in rat skin and 
clinical aGvHD skin biopsies  
MHC matching is essential to reduce the risk GvHD but mHags also affect the outcome of HSCT. 
In addition, SNPs, even if not giving rise to mHags, can influence the result of HSCT. Previously, 
11 non-class I/II MHC and 174 other genes were found to be regulated during GvH reactions 
(Novota et al., 2011) in rat skin explant assays, which provide an in vitro model of GvHD (Novota 
et al., 2008) as well as in rat GvHD models (Zinöcker et al., 2011). The expression of 27 genes was 
tested in human skin explant assays and in human GvHD skin biopsies (Norden et al., unpublished 
data). The candidate genes selected from their study can be divided into three groups. The first 
group includes genes regulated by IFN-γ, TAP1, LILRA5, UBD, TREM2, PTGER2 and MSR1. In 
this group, the gene expressions of these genes were increased in the rat and skin biopsies, while 
LST1 mRNA was downregulated. The second group of candidate include genes regulated by B and 
T cell activation, CARD11, HCLS1, PIK3AP1, PSTPIP1 and PTPN7, which were all increased in 
the rat skin and human clinical aGvHD skin biopsies (Dressel et al., 2013; Novota et al., 2011). 
The last group consists of genes that are associated with innate immune responses. In this group, 
ANP32A, C1QTNF7, HTRA1, LGALS7 were downregulated, whereas TGM2 was upregulated in 
the human and rat aGvHD skin (Dressel et al., 2013; Novota et al., 2011).  
In this study, we wanted to validate the regulation of these candidate genes in different tissues 
using a larger sample size, and to confirm the trend of regulation of these genes in aGvHD. 
Therefore, we compared their expression patterns in the different target organs of mice, and 
determined the effect of preconditioning on their regulation patterns. We already know these genes 
are differentially regulated in the human and rat skin during aGvHD. Additionally, we wanted to 
determine if these genes are also regulated in a different rat (MHC congenic) model in the different 
aGvHD tissues, and more importantly, to compare their expression patterns to the GI biopsies from 
out human aGvHD cohort. Identifying genes that are similarly regulated in the different target 
organs, or more importantly in the different species can help us to better understand the 









Table 1.1: Previously identified candidate genes from (Novota et al., 2011) and patent (Publication 
Number: 20130338035) (Dressel et al., 2013).  
Genes are listed in alphabetical order 
Symbol Entrez Gene Name Location of protein 
ANP32A 
acidic (leucine-rich) nuclear phosphoprotein 32 
family, member A 
Nucleus 
C1QTNF7 C1q and tumor necrosis factor related protein 7 Extracellular Space 
CARD11 caspase recruitment domain family member 11 Cytoplasm 
CXCL9 chemokine (C-X-C motif) ligand 9 Extracellular Space 
HCLS1 hematopoietic cell-specific Lyn substrate 1 Nucleus 
HTRA1 HtrA serine peptidase 1 Extracellular Space 
IL1RL2 interleukin 1 receptor like 2 Plasma Membrane 
LGALS7/LGALS7B lectin, galactoside-binding, soluble, 7 Extracellular Space 
LILRA5 leukocyte immunoglobulin like receptor A5 Plasma Membrane 
LST1 leukocyte specific transcript 1 Cytoplasm 
MSR1 macrophage scavenger receptor 1 Plasma Membrane 
PIK3AP1 phosphoinositide-3-kinase adaptor protein 1 Cytoplasm 
PSTPIP1 
proline-serine-threonine phosphatase interacting 
protein 1 
Cytoplasm 
PTGER2 prostaglandin E receptor 2 Plasma Membrane 
PTPN7 protein tyrosine phosphatase, non-receptor type 7 Cytoplasm 
TAP1 
transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
Cytoplasm 
TGM2 transglutaminase 2 Cytoplasm 
TREM2 triggering receptor expressed on myeloid cells 2 Plasma Membrane 
UBD ubiquitin D Nucleus 
 
 
1.5.2 Other selected focus genes  
In addition, we also selected several cytokines, chemokines and their receptors, and genes associated 
with immune cells in aGvHD, listed in Table 1.2. Secretion of inflammatory cytokines and 
chemokine expression are important in activation of lymphocytes and their migration to sites of 
inflammation (Ebert et al., 2005; Hill et al., 1997; New et al., 2002). Previously, studies have shown 
an increased expression of recruiting chemokines in target tissues of aGvHD in mice (Ma et al., 
2011; Mapara et al., 2006). Therefore, we expect these genes to be significantly regulated during 
aGvHD in one more of the target organs as many of the chemokines and cytokines have been 
implicated to be important in aGvHD pathophysiology previously. The importance of this study is to 
elucidate the regulation patterns of these genes in different tissues of the mouse aGvHD model, and 
more importantly, assess the effects of preconditioning on the expression pattern of these genes in 




different target organs to spleen, the non-target organ, could potentially help us understand the 
varying mechanisms of T cell trafficking in the different organs in aGvHD.  
 
Table 1.2: List of further selected focus genes. 
Symbol Entrez Gene Name Location of protein 
CCL4 chemokine (C-C motif) ligand 4 Extracellular Space 
CCL5 chemokine (C-C motif) ligand 5 Extracellular Space 
CCL9 chemokine (C-C motif) ligand 9 Extracellular Space 
CCR1 chemokine (C-C motif) receptor 1 Plasma Membrane 
CCR4 chemokine (C-C motif) receptor 4 Plasma Membrane 
CCR5 
chemokine (C-C motif) receptor 5 
(gene/pseudogene) 
Plasma Membrane 
CX3CL1 chemokine (C-X3-C motif) ligand 1 Extracellular Space 
CX3CR1 chemokine (C-X3-C motif) receptor 1 Plasma Membrane 
CXCL10 chemokine (C-X-C motif) ligand 10 Extracellular Space 
CXCL11 chemokine (C-X-C motif) ligand 11 Extracellular Space 
CXCL15 chemokine (C-X-C motif) ligand 15 Extracellular Space 
CXCL16 chemokine (C-X-C motif) ligand 16 Extracellular Space 
CXCR3 chemokine (C-X-C motif) receptor 3 Plasma Membrane 
CXCR4 chemokine (C-X-C motif) receptor 4 Plasma Membrane 
IFNG interferon, gamma Extracellular Space 
IL10 interleukin 10 Extracellular Space 
IL12A interleukin 12A Extracellular Space 
IL13 interleukin 13 Extracellular Space 
IL15 interleukin 15 Extracellular Space 
IL17A interleukin 17A Extracellular Space 
IL1R1 interleukin 1 receptor, type I Plasma Membrane 
IL2 interleukin 2 Extracellular Space 
IL22 interleukin 22 Extracellular Space 
IL23A interleukin 23 subunit alpha Extracellular Space 
IL2RA interleukin 2 receptor subunit alpha Plasma Membrane 
IL33 interleukin 33 Extracellular Space 
IL4 interleukin 4 Extracellular Space 
IL4R interleukin 4 receptor Plasma Membrane 
IL5 interleukin 5 Extracellular Space 
IL6 interleukin 6 Extracellular Space 
TGFB1 transforming growth factor beta 1 Extracellular Space 
TGFB2 transforming growth factor beta 2 Extracellular Space 
TGFBR1 transforming growth factor beta receptor I Plasma Membrane 
TNF tumor necrosis factor Extracellular Space 
FOXP3 forkhead box P3 Nucleus 




ARG1 arginase 1 Cytoplasm 
LGALS3 lectin, galactoside-binding, soluble, 3 Extracellular Space 





FCER1G Fc fragment of IgE receptor Ig Plasma Membrane 
FCGR2A Fc fragment of IgG receptor IIa Plasma Membrane 
ICAM1 intercellular adhesion molecule 1 Plasma Membrane 
UBC ubiquitin C Cytoplasm 
 
In addition, our research group previously studied the effect of MHC class I chain-related molecule 
A (MICA)-129Met/Val dimorphism on the outcome of HSCT (Isernhagen et al., 2015). Presence 
of the Met allele in patients decreased the risk of death and lowered the mortality due to aGvHD, 
despite a higher risk to experience this complication. The functional consequences of this SNP for 
NKG2D signaling on NK and T cells were characterized and they suggest a causative effect of this 
SNP on the outcome of HSCT (Isernhagen et al., 2015, 2016a). Also, we found the expression 
intensity of the MICA-129 polymorphisms affected NKG2D function and cytotoxicity on NK and 
CD8
+
 T cells. This could suggest that the gene expression of NKG2D and its ligands could be 
important for the HSCT outcome and aGvHD (Isernhagen et al., 2016b). 
 
 
NKG2D and DNAM-1 are both activating NK receptors. In addition, they also serve as co-
stimulatory molecules on CD8
+
 T cells. NKG2D is expressed on subsets of NK cells, NKT-cells, T 
cells, and CD8
+ 
T cells (Bauer et al. 1999; Raulet 2003; Groh et al. 1996). Similarly, DNAM-1 is 
Figure 1.3: Upregulation 
of NKG2D and DNAM-1 
adopted from (Cerboni et al., 
2014) 
Upregulation of NKG2D and 
DNAM-1 on interaction with 
their ligands, upon activation 
by DNA damage response 
(DDR) of stressed cells, 






expressed on all NK cells, NKT cells, a subset of γδ T cells and all CD8
+
 T cells, in humans and on 
activated CD8
+
 T cells and a subset of CD4
+
 T cells in mice.  Both these co-stimulatory molecules 
have been implicated in aGvHD. Mice deficient in either NKG2D (Karimi et al., 2015) or DNAM-
1 (Nabekura et al., 2010) show an attenuated aGvHD response. Their co-stimulatory function has 
been attributed to interactions between NKG2D/NKG2D-L and DNAM-1/DNAM-1L. NKG2D 
binds to several ligands in humans; MICA, MICB and ULBP1-6, also known as the RAET1 
family, given their homology to mouse RAE1 proteins (Cerwenka et al., 2001). The MICA and 
MICB ligands are encoded in the human MHC (Bauer et al., 1999), but lack β2 microglobulin and 
cannot bind to antigens. However, rodents lack MIC genes, and NKG2D binds to the RAE1 family, 
H60 family (a,b and c) (Takada et al., 2008), of which H60a is a minor histocompatibility antigen 
(Malarkannan et al., 1998) and UL16-protein like transcript 1 (MULT-1) (Carayannopoulos et al., 
2002; Diefenbach et al., 2003) in mice. Similarly, in rats, NKG2D binds to two members of the 
RAE1 family, RAE1L and RRLT (Zhuo et al., 2010). On the other hand, the leukocyte adhesion 
molecule, DNAM-1 binds to CD112 encoded by PVRL2 or Nectin-2 and CD155 encoded by PVR 
in all three species (Bottino et al., 2003).  
 
The engagement of NKG2D and DNAM-1, with their respective ligands, can provide co-
stimulatory signals to T cells from non-professional APCs, in a non-classical MHC I restricted 
manner and can promote CD8
+
T cell activity under specific conditions (Groh et al. 1996; Gilfillan 
et al., 2008). NKG2D also facilitates activation of CD8
+
 T cells during inflammation (Ogasawara et 
al., 2004), and its ligands are upregulated prior to allogeneic HSCT as a result of myeloblative 
conditioning (Ho et al., 2009). Karimi et al. showed that blockade of NKG2D on donor CD8
+
 T 
cells ameliorated aGvHD in mice, while maintaining GvL effects (Karimi et al., 2015). Moreover, 
it was recently shown that a polymorphism in its ligand, MICA-129 was important in HSCT 
outcome and occurrence of aGvHD (Isernhagen et al., 2015, 2016b). Interestingly, the NKG2D 
dependent activation of NK cells and the co-stimulation of CD8
+
 T cells was significantly 
influenced by the expression intensity of the MICA-129 variants (Isernhagen et al., 2016a). 
Therefore, we wanted to investigate the regulation of mRNA expression of NKG2D and its ligands 
in two models of aGvHD.   
The ligands are stress-induced and not expressed under normal conditions, becoming upregulated 
under cellular or genotoxic stress during disease or infection, such as cytomegalovirus (CMV) 
(Cosman et al., 2001), in turn leading to activation of NK cells and stimulation of CD8
+
 T cells 
(Groh et al. 1996). To assess the gene expression pattern of these receptors and their ligands, we 
also studied the regulation the KLRK1, encoding NKG2D and CD226, encoding DNAM-1, and 
their ligands in different target tissues and compared their regulation in the different species in this 





Table 1.3: Genes encoding NKG2D, DNAM-1 and their ligands. 
Symbol Entrez Gene Name Location 
KLRK1   killer cell lectin-like receptor subfamily       K, member 
1 
Plasma Membrane 
MICA MHC Class I chain related protein A Plasma Membrane 
MICB MHC Class I chain related protein B Plasma Membrane 
ULBP1 UL16 binding protein 1 Plasma Membrane 
ULBP2 UL16 binding protein 2 Plasma Membrane 
ULBP3 UL16 binding protein 3 Plasma Membrane 
H60a histocompatibility 60a Plasma Membrane 
Rae1 retinoic acid early transcript 1, alpha Plasma Membrane 
Ulbp1 UL16 binding protein  Plasma Membrane 
Rrlt retinoic acid Plasma Membrane 
Raet1 Rat similar to retinoic acid early transcript 1L Plasma Membrane 
CD226 CD226 molecule, (DNAM-1) Plasma Membrane 
PVRL2 poliovirus receptor-related 2 (herpesvirus entry mediator 
B) 
Plasma Membrane 















1.6  Objectives 
The aims of this study are listed below: 
a. To study the regulation of genes selected in different mouse tissues affected by aGvHD 
b. To assess the difference in gene regulation due to preconditioning and aGvHD in the 
different mouse tissues 
c. To validate the gene expression of previously identified candidate genes in the different 
species; mouse, rat and human GI aGvHD  
d. To study the gene expression patterns of important genes associated with different immune 
cells during aGvHD during mouse aGvHD and compare it to human clinical 
gastrointestinal biopsies 
e. To study the regulation of the NK receptors KLRK1 and CD226 and their ligands in the 
different species during aGvHD. 
f. To study the regulation of genes and their effects on HSCT outcome in a patient cohort 
Gene expression studies frequently use blood, whereas conjunctiva is commonly used to study 
cGvHD for the mRNA studies. The advantage of using animal models for studying the gene 
expression is the broad availability of specific target tissues of GvHD, such as liver and gut. In our 
study, we had a unique opportunity to study the expression patterns of several genes not only in the 
different target tissues during aGvHD in two different animal models of aGvHD, as well as in 














2 Materials and methods  
2.1 Materials  
2.1.1 Enzymes 
Table 2.1: List of Enzymes. 
Enzyme                 Supplier 
DNase I NEB 
M-MLV Reverse Transcriptase Promega 
RevertAid Reverse Transcriptase Thermo Scientific 
Proteinase K Merck 
RNAse A Roche Diagnostics 
RNAsin NEB 
RiboLock RNAse Inhibitor Thermo Scientific 
Taq DNA Polymerase NEB 
Exo I NEB 
 
2.1.2 Antibodies 
Table 2.2: List of antibodies. 
Antigen               Supplier  
Rat anti-mouse CD3  Bio-Rad 
Biotin goat anti-rat IgG Biolegend 
Rat IgG1  Biolegend 
 
 
2.1.3 Chemicals and Reagents 
Table 2.3: List of chemicals and reagents. 
Chemical/Reagent                  Supplier    
Acetic acid Merck 
Chloroform Merck 




Dithiothreitol (DTT) Promega 
dNTPs NEB 
dNTP mix Thermo Scientific 
Eosin Y Merck Millipore 
Ethanol (analytical grade) UMG Pharmacy 
Ethanol (EtOH) UMG Pharmacy 
Ethidium bromide HyClon 
EDTA Carl Roth 
GeneRuler 1kb DNA ladder Thermo Scientific 
Hydrochloric acid (HCl) Merck 
Hydrogen peroxide (H2O2) Merck 
Isoamylalcohol Merck 
Isopropanol Merck 
Magnesium chloride (MgCl2) Merck 
Mayer's hemalum solution Merck Millipore 
MLV-RT Buffer Promega 
RT Buffer Thermo Scientific 
Paraffin Carl Roth 
PCR Buffer 10X NEB 
Random Primer Promega 
Random Hexamers Thermo Scientific 
Roti-Histokitt Carl Roth 
Roti-Phenol Carl Roth 
Sodium carbonate (Na2CO3 / NaHCO3) Merck 
Sodium chloride (NaOH) Carl Roth 
Streptavidin-horseradish peroxidase (HRP) BioLegend 
Tris Carl Roth 
TRIzol reagent Invitrogen 
TRI reagent Ambion 
UltraPure Agarose Invitrogen 












Table 2.4: List of consumables. 
Label                       Supplier    
96 - well plates for qPCR Applied Biosystems  
96 - well plates for PCR Thermo Scientific 
Cover slips glass Roth 
Cover slips plastic Sarstedt  
Cryo tubes Greiner 
Microscope slides Menzel  
Multipette plus Combitips Eppendorf 
Reaction Tubes (0.2 ml, 1 ml, 2 ml) Greiner/Sarstedt  
Sterile pipettes (1 ml, 2 ml, 5 ml, 10 ml, 25 ml) Greiner  
Superfrost Plus glass slides Thermo 
Top Seal for qPCR plates Applied Biosystems 
Wheighing paper  Eppendorf  
 
2.1.5 Commercial Kits 
Table 2.5: List of commercial kits. 
Label                     Supplier    
ABsolute Blue QPCR SYBR Green Low ROX Mix  Thermo Fisher 
2X SsoFasr EvaGreen Supermix with Low ROX Fluidigm 
20X DNA Binding Dye Sample Loading Reagent Fluidigm 
2X Assay Loading Reagent Fluidigm 
Fluidigm 48.48 Dynamic Arrays Fluidigm 
Fluidigm 96.96 Dynamic Arrays Fluidigm 
Taqman PreAmp Master Mix Applied Biosystems 
 
 





Table 2.6: List of devices. 
Description         Label     Supplier  
Agarose gel trays and chambers Perfect Blue Gel System  Peglab  
Autoclave 
High pressure steam sterilisator 
FVS  
Integra Biosciences  







Centrifuge Multifuge 3 S-R Heraeus 
Centrifuge  Mini Centrifuge MCF-2360 Heraeus 
Centrifuge 3K30 LMS Consult 
Centrifuge RC 3B Plus Sigma 
Centrifuge 
Mini Centrifuge MCF-2360 
Neubauer improved 
Sorvall 
Dispenser Multipette plus Eppendorf 
Freezer HERA freeze -80°C  Heraeus 
Freezer Liebherr Comfort -20°C Liebherr GmbH 
Freezer VIP plus -150°C  
SANYO Electric Co., 
Japan  
Imaging devices UV workbench GelImager  Intas 
Imaging devices Chemilux Blot Detection Imager  Intas 
Incubator shaker Incubators Unitron-plus  Infors 
Microscope LSCM 510 Axioplan 2 Zeiss 
Microscope Leica RM2255 Leica Biosystems  






Pipettor IBS PIPETBOY acu Integra Biosciences  
Power supply EPS-301/-3501 XL GE Healthcare 
Scales ACCULAB Vicon Sartorius 






Thermal Cycler ABI 7500 Real-Time PCR System  Applied Biosystems 
Thermal Cycler MasterCycler epgradient  Eppendorf 
Thermal Cycler Fluidigm Biomark 
Thermoblock Thermomixer comfort Eppendorf 
Homogenizer Tissue Lyser LT Qiagen 
Vortex MS1 Minishaker IKA 









Table 2.7: List of software. 
 Product                             Company    
7500 System SDS Software Applied Biosystems 
MFE primer-2.0 GitHub Inc. 
Microsoft Office Professional Plus 2013 Microsoft 
NCBI database 
National Center for 
Biotechnology 
Information (NCBI) 





Real-Time PCR Analysis Biomark 
 
2.1.8 Laboratory Animals  
Table 2.8: List of laboratory animals.  
  Product    Species            Description   
C57BL/6 Mouse MHC Haplotype: H2
b
 














All primers were synthesized by biomers.net GmbH. Primers were designed using primer BLAST 
from the National Center for Biotechnology Information (NCBI), and verified using MFE 2.0 
software. The primers were designed to span exon-exon junctions, if feasible. In case of targets with 
two or more isoforms the primers were designed to target all transcripts. The sequences for the 
mouse, rat and human primers have been listed separately below in alphabetical order. 
  





 Table 2.9: Mouse primer pairs for Real-Time PCR.  
















































































































































































































































































































Table 2.10: Rat primer pairs for Real-Time PCR. 




































































































Table 2.11: Human primer pairs for Real-Time PCR. 



































































































    




























































































PSTPIP1 F: GGCCTCCTTTGACTCCTTGA NM_003978.3 145 












































































2.2   Methods 
2.2.1 Animal aGvHD models 
2.2.1.1   Mouse aGvHD model 
The mouse experiment have been done by Prof. Reichardts research group, at the Institute of 
Cellular and Molecular Immunology, UMG in Göttingen, Germany (Theiss-Suennemann et al., 
2015). All interventions were approved by the authorities of Lower Saxony and Baden- 
Württemberg. C57BL/6 (B6, H-2
b
) and BALB/c (H-2
d
) were purchased from Charles River 
(Sulzfeld, Germany). We obtained the biopsies from the sacrificed mice for gene expression studies.  
Preparation of bone marrow (BM) 
BM was isolated from the femur and tibia of C57BL/6 mice, and T cells were depleted using anti-
CD90.2 microbeads and autoMACS separator (Miltenyl Biotech, Bergisch Gladbach, Germany) or 
by incubation with anti-Thy-1.2 antibodies followed by lysis with TOX-M rabbit complement 
(Cederlane, Burlington, CA).  
Purification of T cells 
The T cells were isolated from the spleen and lymph nodes of C57BL/6 mice using 40 μm cell 
strainers. Sorting was done with the Pan T cell isolation Kit II and the autoMACs system (Miltenyi). 
MHC-mismatched aGvHD mouse model  
16 hours prior to transplantation, the BALB/c mice were subjected to total body irradiation with a 
dose of 8.5 Gy and injected via the tail vein with either 1x10
7
 T cell-depleted (TCD) BM cells or 
2x10
6
 purified T cells from C57BL/6 mice. 25μg/ml neomycin was provided to the mice via the 
drinking water from day -1 to 28. The mice were treated i.p. with PBS from day 3 to 6. The severity 
of disease was assessed using a five parameter scoring system: posture, activity, ruffling of the fur, 
diarrhea and loss of weight. Each parameter was assigned an increasing score from 0 to 2, with 
increase in severity of the symptoms. Mice that had severe weight loss or had scores greater than 7 








2.2.1.2   aGvHD rat model 
Animals and ethical considerations 
The rat aGvHD model was done by Prof. Rolstads research group, at the University of Oslo (UIO), 
Norway. All the animal experiments were approved by the Norwegian Animal Research Authority 
under the Ministry of Agriculture of Norway, license number 6060, and conducted in conformity 
with "the Norwegian Regulations on Animal Experimentation" and "The European Convention for 
the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes”. 
During my secondment to UIO, Norway, I participated in the in vivo rat experiments. We received 
the rat aGvHD biopsies from UIO to perform gene expression analysis.  
Preparation of bone marrow  
Bone marrow was isolated from rat tibia and femur and depleted of T cells using anti-CD5 (OX19) 
and anti-T cell receptor (TCR) αβ antibodies and anti-mouse IgG coated Dynabeads. 
Purification of T cells  
Cells were isolated from cervical and mesenteric lymph node cells (approx. ~60 % T cells), and 
infused into the recipients 14 days after transplant.  
MHC-congenic rat aGvHD model 
T cell-depleted bone marrow from PVG.7B rats was transplanted into recipient PVG.1N or PVG 
rats, previously irradiated with 8.5 Gy and subsequently injected i.v. with 30x10
6
 T cell-depleted 
bone marrow. To induce aGvHD, 1x10
7
 cervical and mesenteric lymph node cells from PVG.7B rats 
were infused into recipients 14 days post transplantation. Weight and GvHD symptoms (activity, 
kyphosis, skin, and fur integrity) were assessed twice a week. Rats with severe weight loss or 
evident signs of disease were sacrificed. 
 
2.2.2 Molecular biology methods 
2.2.2.1   RNA preparation 
Total RNA was isolated from the different tissues. 2-5 mm length of snap frozen tissue was 
homogenized in 1 ml Trizol reagent using a homogenizer. 200 μl chloroform was added for phase 
separation. The colorless upper phase containing the RNA was transferred to a new reaction tube, to 




which 500 μl isopropanol was added to precipitate the RNA. The RNA pellet was then washed with 
75 % ethanol and air-dried. The pellet was then dissolved in 50 μl nuclease-free water and cleaned 
up for contaminants.  
DNA clean up 
To eliminate protein contaminants from the RNA, a cleanup step was carried out. To each of the 50 
μl of RNA, the following reagents were added, and incubated at room temperature. 
6 μl     DNAse I buffer 
1 μl   DNAse I (10 U/μl) 
1 μl  RNAse Inhibitor (40 U/μl) 
Subsequently, 100μl phenol-chloroform-isoamylalcohol (25:24:1) was added to the RNA. The clean 
phase containing the RNA was transferred to a new reaction tube with 150 μl isopropanol and 15 μl 
NaOAc. Following this, the RNA was washed twice with 75 % Ethanol, air-dried and dissolved in 
20 μl nuclease-free water. The RNA was stored in -80 °C. The quality of RNA was checked by 
determining the integrity of the 28S and 18S RNA by loading RNA on a 1 % agarose gel. The RNA 
was quantified with a spectrophotometer, Nanodrop 2000 at a wavelength of 260 nm.  
 
2.2.2.2   cDNA synthesis 
Transcription of RNA into cDNA was carried out by cDNA synthesis kit from Thermo Scientific. 
To 200 ng RNA, 1.75 μl random hexamers were added, and each reaction tube was filled up to a 
final volume of 15 μl with nuclease-free water. The tubes were incubated at 70 °C for 10 min to 
break up RNA secondary structures. The RNA was placed immediately on ice to prevent reforming 
of these structures. Following this, the following reagents were added to each reaction tube: 
5 μl   5X Reverse Transcriptase Buffer 
1 μl   Reverse Transcriptase (200 U/μl) 
2 μl   dNTPs (10mM) 
1 μl   RNAse Inhibitor (40 U/μl) 
1 μl   DTT (100mM) 




The reaction tubes were subsequently incubated at 42 °C for 1 hr for the transcription of RNA into 
cDNA. The cDNA was stored at -20 °C.  
2.2.2.3   Polymerase Chain Reaction (PCR) 
PCR was used to check the specificity of the primers and size of amplified product. The reaction 
includes 3 steps; denaturation of the double-stranded DNA (dsDNA), annealing of the primer to the 
single-stranded DNA (ssDNA) template followed by the elongation of the ssDNA by a DNA 
polymerase.  
The PCR reaction was set up as follows: 
2.5 μl   10X Taq PCR Buffer 
0.2 μl   Taq DNA polymerase 
0.5 μl   dNTP mix (10mM) 
0.5 μl   sense primer (10pmol/ μl) 
0.5 μl   anti-sense primer (10pmol/ μl) 
   1 μl   DNA template (200ng) 
    up to 25 μl dH20 
The denaturation and elongation temperatures were set in the PCR program, based on the 
manufacturer’s instructions. Annealing temperatures were set according to the specific melting 












Step      Temperature     Time 
Initial denaturation     95 °C      5 min 
Denaturation*     95 °C      30 sec 
Primer annealing*    57.5°C      25 sec 
Elongation*     72 °C      30 sec 
Final elongation    72 °C      5 min 
*in 30 cycles  
 
2.2.2.4   Quantitative real-time PCR (qRT-PCR) 
qRT-PCR was performed to determine the relative amount of specific mRNA transcripts of the gene 





green mix, comprising of the polymerase buffer, dNTPs, a hot start 
polymerase and a green fluorescent dye, was used to amplify and detect the DNA respectively. For 
the qPCR, the cDNA was diluted 1:4 with dH20 and the following reagents were added per reaction: 
 
10 μl   Absolute Blue QPCR SYBR
 
green mix 
0.5 μl  sense primer (10pmol/ μl) 
0.5 μl   anti-sense primer (10pmol/ μl) 
   8 μl   dH20 








The qRT-PCR program used is indicated below: 
Step      Temperature     Time 
Enzyme activation   50 °C       2 min 
Initial denaturation*    95 °C      10 min 
Denaturation*     95 °C      15 sec 
Annealing/ elongation*   60 °C       1 min 
Dissociation stage    95 °C      15 sec 
     60 °C      20 sec 
Recording of the dissociation  stepwise rising of the    20 sec curve  
     temperature to 95 °C    
*in 40 cycles  
 
2.2.3 Gene expression using Biomark Fluidigm dynamic Arrays 
2.2.3.1   Preamplification of cDNA 
Pooled STA (Specific Target Amplification) Master Mix  
The pooled STA master mix comprised of 100 μM of each primer pair (up to 96 primer pairs) mixed 
together for the preamplification of specific products on each template. DNA suspension buffer was 
added to the master mix to make the volume upto 200 μl. 
1 μl of each primer pair  100 μM Primer Stock (up to 96 primer pairs) 












Volume for 48 
reactions + 
overage (μl) 





   Pre-mix 
Taqman PreAmp 
Master Mix 
2.5 μl 125 μl 245 μl 
Pooled STA Master 
Mix 
0.5 μl 25 μl 49 μl 
DNA Suspension 
Buffer 
0.75 μl 37.5 μl 73.5 μl 
cDNA 1.25   
Total Volume 5 μl   
3.75 μl of the Pre-mix was aliquoted onto a 96 well PCR plate. To each well 1.25 μl cDNA was 
added, making a total volume of 5 μl. The plate was vortexed and centrifuged.  
 
2.2.3.2   Thermal Cycling  
The plate was placed in the thermal cycler for the following PCR program. 
Condition    Temperature     Time 
Hold      95 °C      2 min 
Denaturation*     95 °C      15 sec 
Primer annealing/ elongation*   60 °C      4 min 
Hold     4 °C    
*in 14 cycles  




2.2.3.3   Exonuclease I Treatment  
To remove unincorporated primers after preamplification of each template, an exonuclease I step 




Volume for 48 
reactions + 
overage (μl) 
Volume for 96 
reactions + 
overage (μl) 
Water 1.4 μl 70 μl 137.2 μl 
Exonuclease I Reaction Buffer 0.2 μl 10 μl 19.6 μl 
Exonuclease I (20 U/μl) 0.4 μl 20 μl 39.2 μl 
Total Volume 2 μl   
To each well on the PCR plate, 2 μl of the above master mix was added to the cDNA, making a final 
volume of 7 µl. The PCR plate was then vortexed and centrifuged and placed in the thermo cycler, 
as listed below.  
 
Condition    Temperature     Time 
Digest      37 °C      30 min 
Inactivate    80 °C      15 min 
Hold     4 °C    
The final products were diluted 5-fold by adding 18 μl DNA suspension buffer to the 7 µl of cDNA, 








Preparing Sample Pre-Mix and Samples for Gene Expression using Fluidigm Dynamic Arrays 
Component Volume per inlet (μl) Volume per inlet 
with overage (μl) 
 
   Pre-mix 
2X SsoFast EvaGreen 
Supermix with Low ROX 
2.5 μl 3 μl 
20X DNA Binding Dye 
Sample Loading Reagent 
0.25 μl 0.3 μl 
PreAmp and Exo I- treated sample 2.25 μl 2.7 μl 
Total Volume 5 μl  
3.3 μl of the Pre-xix for each sample was aliquoted and mixed with 2.7 μl of the PreAmp and Exo I 
treated cDNA on a 96 well plate. The plate was centrifuged and kept ready to be loaded onto the 
chip.  
 
Preparing the Assay Mix 
Component Volume per inlet (μl) Volume per inlet 
with overage (μl) 
 
   Assay mix 
2X Assay Loading Reagent 2.5 μl 3 μl 
1X DNA Suspension 
Buffer 
2.05 μl 2.46 μl 
100 μM each primer pair 0.45 μl 0.54 μl 
Total Volume 5 μl  
5.46 μl of the Assay Mix was aliquoted and mixed with 0.54 μl of each primer pair mix (100 μM), to 
make a total volume of 5 μl.  The plate was centrifuged and kept ready to be loaded onto the chip.  




2.2.3.4   Priming and Loading the Dynamic Array IFC 
To prime the Dynamic Array chip prior to use, a control line fluid was injected into each 
accumulator on opposite sides of the chip. The blue protective film was removed from the bottom of 
the chip, and the chip was placed in an integrated fluidic circuit (IFC) Controller (MX for the 48.48 
Dynamic Array or the HX for the 96.96 Dynamic Array) to be primed for the experiment. Following 
priming, 5 μl of each assay was loaded onto the left side of the chip, and 5 μl of each sample was 
loaded into the respective inlets on the right side of the chip. The Array was then returned to the 
respective IFC Controller to mix the samples and assays onto the chip. The chip was then run using 
the BioMark Gene Expression Data Collection software, following the given parameters for the 
96.96 dynamic arrays.  
 
Condition    Temperature  Time   Biomark HD   Biomark       
                    (°C)          (s)               Ramp Rate             Ramp Rate  
                          (°C /s)             (°C /s) 
Thermal Mix  70           2400         5.5        2   
   60    30                5.5                          2  
Hot Start   95    60         5.5            2  
PCR*    96     5         5.5                     2  
   60    20         5.5        2 
Melting Curve  60     3         1                     1  
   60-95      1°C /3s    1°C /3s 
* 40 cycles  
 
2.2.4 Histology 
2.2.4.1   Tissue cross-sections 
The small and large intestinal biopsies were fixed in 10 % formalin overnight at 4 °C and 
subsequently dehydrated in ethanol solutions of concentrations 50 %, 70 %, 80 %, 96 % and 100 
%, for 75 min each. This was followed by immersion in xylol for 2 x 75 min each. The biopsies 
were then immersed in liquid paraffin wax (56-58 °C) and then biopsies were embedded in paraffin 
blocks. Sections of 5 μm were cut from pre-chilled blocks using a microtome, and transferred to 
glass slides, and dried overnight at 37 °C and stored at room temperature.  




2.2.4.2    Hematoxylin and eosin staining  
Paraffin sections were stained with Hematoxylin and eosin (HE). The Hematoxylin dye stains 
acidic or basophilic structures, such as DNA and RNA to a purplish blue color, whereas Eosin dye 
stains acidophilic or basic structures such as cytoplasmic proteins, a red or pink color. The slides 
with the tissue sections were deparaffinated with xylol (3 x 7 min), and subsequently rehydrated 
with ethanol from 100 %, 96 %, 75 % and 60 % for 5 min each and washed with dH2O for 5 min. 
The tissues sections were then stained with Mayer’s hemalaum solution for 5 mins, rinsed for 10 
min and stained with eosin for 5 min. The slides were washed again and dehydrated with an 
increasing ethanol concentration, 60 %, 75 %, 96 % and 100 %, followed by isopropanol and xylol 
for 5 min each. The tissues were embedded with Roti-Histokitt.  
 
2.2.4.3   Immunohistochemistry 
The paraffin sections were stained with specific antibodies to detect proteins of interest. The 
sections were boiled in citrate buffer (3 x 5 min; 10mM, pH 6.0). On cooling, the tissues were 
blocked with IHC blocking solution (4 % BSA in PBS) for 1 hr at room temperature (RT). The 
primary antibody was diluted in PBS with 1 % BSA and incubated overnight at 4 °C. Following 
this, the tissue sections were incubated in 3 % H2O2 (30 %) in PBS at RT for 10 min to block 
endogenous peroxidases, and washed with PBS (3 x 5 min). Incubation with secondary biotin-
conjugated antibody for 1 hr at RT, followed by another round of washing (3 x 5 min) with PBS. 
The samples were incubated with HRP-streptavidin for 1 hr at RT and stained with DAB substrate 
solution (0.05 % DAB, 0.015 % H2O2, dissolved in PBS). The slides were than counterstained with 













2.2.5  Statistical Analysis 
2.2.5.1   Animal gene expression data analysis 
The dCt values were calculated as dCt is the CtGeomean(housekeeping genes) – Ct(genes of interest), where Geomean 
is the geometrical mean of the housekeeping genes Gapdh and Hprt. The gene expression data for 
mice and rats was tested for normality using the Shapiro-Wilk normality test. The data was not 
normally distributed, therefore the p-values were calculated for the dCt values using the Mann-
Whitney U-test on Prism Graphpad or SPSS. The data was corrected for multiple comparisons using 
Benjamin Hochberg’s false discover rate (FDR), and plotted as graphs using Prism Graphpad.  
 
2.2.5.2   Human gene expression data analysis 
The dCt was calculated as dCt is the CtGeomean(housekeeping genes) – Ct(genes of interest), where Geomean is the  
geometrical mean of the housekeeping genes, GAPDH and HPRT. The dCt values were transformed 
using Blom’s rank-based normalization on SPSS.  
 
2.2.5.3   EBMT Risk Score 
The EBMT risk score was calculated according to Gratwohl et al. (Gratwohl, 2012). The risk score 
is independent of the underlying disease. It comprises of the summation of different clinical factors 
that affect GvHD. The different factors are depicted in the Table 2.12. The score ranges from 0 to 
7, with 7 being the worst score. For example, male patients, above the age of 40 (score = 2), 
undergoing HSCT from an unrelated female donor (score = 1), after over a year of diagnosis of 
primary disease (score = 2) at a late stage (score = 2), would have a score of 7, which is the highest 










Risk factor Score points 
Table 2.12: EBMT risk score; adopted from 
(Gratwohl 2012). The EBMT risk score for five 
clinical risk factors.  *does not apply for aplastic 
anemia; **does not apply for patients transplanted in 
first complete remission (CR); *** does not apply 
for patients with autologous HSCT. In cases that are 
not applicable (NA), risk score = 0. 




    
Stage of disease* 
Early 0 
Intermediate 1 
 Late 2 
  





Donor Type***   
HLA-identical sibling donor 0 
Unrelated donor, other 1 
  
Donor recipient sex 
combination 
  
All other 0 
Female donor, male recipient 1 
 
2.2.5.4   Selection of covariates 
We modeled our multivariate analysis to compensate for several factors that affect the HSCT 
outcome, such as the EBMT score, age of donor, type of conditioning, source of stem cells. Based 
on the selected covariates, the gene expression patterns of the different outcomes such as aGvHD 
and TRM were determined.  
 
2.2.5.5   Step-wise regression model 
A step-wise regression model using R software (http://www.R- project.org) was generated to 
compensate for all the important covariates. The following covariates were selected for the final 
model: EBMT score, source of stem cell, type of conditioning regimen, blood group, steroid 
treatment, CMV status of the donor-recipient pairs, age of donor and time from transplant to date 
of biopsy taken. Based on the model, we assessed the change in gene expression for the selected 
variables. Two sample t-tests were performed and p-values and t values have been listed in the 




respective tables. Significant p-values (<0.05) and p-values that were near significance (<0.15) 
have been shown. The t-value represents the size of the difference relative to variation observed in 
the sample data, and positive (+) t-values depict upregulation and negative (-) t-values show 
downregulation.  
 
2.2.5.6   Hierarchical cluster heatmaps 
Hierarchical clustering of heatmaps was performed using R statistical packages. The hierarchical 
cluster was performed using ‘hclust’ on scaled data using ‘matrix’ and heatmap was generated using 









3.1   Animal aGvHD models 
3.1.1 aGvHD mouse model 
We studied the regulation of gene expression between aGvHD mice (n=17), where irradiated 
BALB/c mice were transplanted with BM and T cells from C57BL/6 mice, BM control mice (n=6), 
where irradiated BALB/c mice were transplanted with BM from C57BL/6 mice and compared the 
gene regulation with healthy control mice (n=15). The different in clinical scores between the 
transplant mouse groups is depicted in Figure 3.1. The aGvHD mice model is fully                    
MHC- mismatched, and the aGvHD mice, BM control and healthy control mice are of the same 
strain (BALB/c). We compared the gene expression between aGvHD mice and healthy controls to 
determine the overall gene regulation during aGvHD in the different target tissues (*red). To 
determine the effect of preconditioning and BM transplantation on the gene regulation, we 
compared the gene expression between BM control mice and healthy controls (*green). Finally, to 
isolate the genes that were differentially regulated as a result of aGvHD alone, we compared the 
gene expression between the aGvHD and BM control mice (*blue).   
  
 
3.1.2 aGvHD rat model 
In rats, the gene expression was studied between aGvHD rats (n=6), where PVG.1N
 
rats were 
irradiated and transplanted with BM and T cells from PVG.7B rats and control rats (n=6) where 
PVG rats were irradiated and transplanted with BM and T cells from PVG.7B rats. In the rat aGvHD 
model, we used MHC congenic rat strains of the same genetic background (PVG) that only differ in 















Figure 3.1: Clinical aGvHD score in mouse. 
The aGvHD mice had scores of 5.5 ± 0.41 and the BM 
controls had scores of 1 on day 6. The difference in scores 
was showing the extent of disease in the aGvHD mice in 





3.1.3 Gene expression profiling in different aGvHD tissues  
The fold-change of the gene expression and the respective p-values have been specified for the 
genes that were significantly regulated, as (Fold change; p-value). In the supplement, the table with 
the entire gene expression results is given (Section 7). All the graphs have been plotted with the 
relative gene expression (dCt) on the y-axis and target organs on the x-axis.  
We have studied the regulation patterns of several selected genes in different mouse aGvHD tissues, 
rat aGvHD tissues and compared these expression patterns to human GI biopsies in patients that 
have undergone HSCT.  Several genes encoding inflammatory cytokines and chemokines have been 
studied in different aGvHD tissues. We wanted to validate the expression of several previously 
known genes and compare their regulation patterns in the different tissues simultaneously and in the 
different species. Furthermore, we also validated the regulation patterns of previously identified 
candidate genes that were found to be regulated in rat and human skin biopsies, in the different 
aGvHD tissues in the different species. In addition, based on our results for the MICA-129 
polymorphism, we also studied the regulation patterns of the activating NK receptor, KLRK1 
(NKG2D) and its ligands, as well as another important activating NK receptor, CD226 (DNAM-1) 
and its ligands in the different aGvHD tissues in the two animal models and compared their 
expression patterns to human GI biopsies from HSCT patients.  
 
3.2   Important genes regulated in different mouse tissues due to 
preconditioning and aGvHD 
 
Several genes that are expected to be regulated during aGvHD were selected for our study. In 
addition, we included other genes that are important in adaptive immune responses that we 
expected to be important during aGvHD. Here we show the gene expression data in different 
mouse tissues as a result of preconditioning and aGvHD for genes associated with Th1, Th2, Th17 
and Treg responses. In addition, several genes important during aGvHD immune responses were 
also studied.  
In this section, results show the regulation of genes as a result of overall aGvHD between mouse 
tissues affected by aGvHD and healthy controls, as well as the effect of preconditioning on the 
regulation patterns of these genes in the different mouse tissues. Moreover, we also show the 
alterations in gene expression patterns between aGvHD affected mouse tissues and BM control 
mice that have been irradiated and transplanted with BM alone. This model allows us to determine 
genes that are regulated solely due to aGvHD occurrence and not as a result of preconditioning or 





3.2.1 Expression of cytokines associated with Th1 responses in mice 
The most important cytokines involved in the inflammatory response during aGvHD are IL-2 and 
IFN-γ, and are produced by Th1 cells. IFN-γ and IL-12 drive the differentiation of Th1 cells. Th1 
cells are known to be the initial drivers of aGvHD (Ferrara et al., 2009). Here we studied the gene 
expression of Ifng, Il12a, Il2 and Tnf. 
 
Except in the liver, the overall mRNA expression of Ifng was increased in mice with aGvHD 
compared to health controls, in the lung (33.76; p = 0.008), skin (3 x 10
6
; p = 0.008), spleen (5.63; 
p = 0.008), small intestine (1.16 x 10
8
; p = 0.008), and large intestine (43.6; p = 0.008). In the lung 
and spleen, the expression of Ifng was increased primarily as a result of preconditioning in the BM 
control mice in comparison with healthy controls (6.25; p = 0.004 and 7.23; p = 0.004), and further 
increased as a result of aGvHD in the lung (5.41; p = 0.008), small intestine (235.18; p = 0.008) 
and large intestine (95.52; p = 0.008) respectively, compared to BM control mice (Figure 3.2A). 
 
The expression of Il12a was downregulated in the spleen alone, due to preconditioning (0.1; p = 
0.004) and in aGvHD mice compared to healthy controls (0.11; p = 0.008) (Figure 3.2B). Il2, on 
the other hand, showed a mixed expression pattern, whereby it was significantly reduced in the 
spleen of aGvHD mice compared to BM control mice and compared to healthy controls (0.65; p = 
0.004), and in the liver of aGvHD mice compared to BM controls (0.03; p = 0.004), and 
significantly increased in the lung as a result of preconditioning in BM control mice compared to 
healthy controls (3.19; p = 0.04) and further upregulated in the lung (5.4; p = 0.004) and large 
intestine (3.31; p = 0.004) of aGvHD mice compared to healthy controls (Figure 3.2C). The 
proinflammatory cytokine Tnf was significantly reduced in the spleen during preconditioning 
(0.34; p = 0.004) and further reduced in aGvHD mice compared to BM controls (0.41; p = 0.004) 
as well as healthy controls (0.14; p = 0.008). In the lung and large intestine, the expression of Tnf 
was strongly upregulated in aGvHD mice compared to BM control mice (2.93; p = 0.004 and 5.63; 
p = 0.004), and compared to healthy control mice respectively (2.06; p = 0.004 and 3.15; p = 
0.004) (Figure 3.2D). 
 
Overall, the observed increase in the expression of Ifng and Tnf is consistent with severe 














Figure 3.2: mRNA expression of cytokines associated with Th1 responses in different tissues 
in mice.                                              
Relative mRNA expression of cytokines associated with Th1 responses, in aGvHD mice (n = 17) in 
comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice (n = 6) 
(blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-axis 
shows relative expression (dCt), and x axis shows different mice groups in each tissue type. The p-values 
were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg correction.               
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)                          
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)                                          
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3.2.2 Expression of cytokines associated with Th2 responses in mice 
Th2 cells are characterized by the production of cytokines IL-4, IL-5, IL-13 and IL-33. IL-13 
requires IL-4Rα for regulating Th2 responses (Barner et al., 1998). We observed an overall 
increased regulation of the Th2 cytokines in the different tissues in mice. Il4 was significantly 
increased in the aGvHD mice compared to healthy controls in the liver (133.21; p = 0.02), skin 
(59.98; p = 0.007), spleen (2.2 x 10
2
; p = 0.004), small (2.84; p = 0.029) and large intestines (5.48; 
p = 0.001). The expression of Il4 was significantly increased in the liver also as a result of 
preconditioning in the BM control mice compared to the healthy controls (56.92; p = 0.001), and in 
the large intestine between aGvHD mice and BM control mice (2.76; p = 0.008) (Figure 3.3A). 
 
The expression of Il5 was also significantly increased in the large intestine in aGvHD mice 
compared to healthy controls (684.19; p = 0.008), but was significantly downregulated in the lung 
(0.29; p = 0.016) (Figure 3.3B). Il13 mRNA was significantly upregulated in the lung (1.52; p = 
0.016) and large intestine (6.85; p = 0.008)  in aGvHD mice compared to healthy controls (Figure 
3.3C). Il4ra was significantly increased in the lung (19.28; p = 0.019), small (3.23; p = 0.001) and 
large intestine (4.91; p = 0.001) in aGvHD mice compared to healthy controls. In the lung (27.39; 
p = 0.001) and large intestine (2.54; p = 0.007), the increase in the expression of Il4ra was also in 
part due to preconditioning, and in the small intestine, Il4ra was strongly increased in the aGvHD 
mice in comparison with the BM controls (2.18; p = 0.008) (Figure 3.3D). Similarly, Il33 was also 
strongly upregulated in aGvHD mice in the skin (3.44; p = 0.007) and large intestine (4.78; p = 
0.007), compared to healthy controls and in the small intestine (3.55; p = 0.008) compared to BM 
control mice (Figure 3.3E). IL-33 is highly expressed on Th2 cells and serves as a ligand for the 
IL-33R (IL-1RL1 or ST2) (Yagami et al., 2010) and has been shown previously to worsen 
experimental GvHD via its interaction with its receptor IL-1RL1 on alloreactive cells (Reichenbach 
et al., 2015). 
 
Taken together, we observed a strong increase in the expression of Th2 cytokines, mainly between 
aGvHD mice and healthy controls. The Th2 response was also most significant in the intestine. 
Preconditioning alone did not significantly alter the expression of these cytokines, suggesting that 

















Figure 3.3: mRNA expression of cytokines associated with Th2 responses in different tissues 
in mice.                  
Relative mRNA expression of cytokines associated with Th2 responses, in aGvHD mice (n = 17) in 
comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice (n = 6) 
(blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-axis 
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were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg correction.             
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            




3.2.3 Expression of cytokines associated with Th17 responses in mice 
Th17 cells require TGF-β and IL-6 to differentiate (Bettelli et al., 2006), and they are characterized 
by the production of IL-17A, IL-21 and  IL-22 (Korn et al., 2009; Park et al., 2005; Weaver et al., 
2007). IL-23 is required for the stabilization of Th17 cells, along with TNF-α and IL-1β (Aggarwal 
et al., 2002). In mice, cutaneous aGvHD is suggested to be predominantly driven by Th17 
responses (Carlson et al., 2009). An augmented damage to the lung and skin tissue has been 
associated with Th17 cells (Yi et al., 2009). Moreover, it was suggested that Th17 cells were 
sufficient but not necessary to induce aGvHD (Iclozan et al., 2010). To study the regulation of 
Th17 responses in our study, here we show the regulation of the Th17 cytokine genes, Il6, Il17a, 
Il22 and Il23a.  
 
As expected, we observed a significant increase in the expression of these cytokines in the different 
tissues during aGvHD. The expression of Il17a was significantly increased in the spleen and large 
intestine in aGvHD mice compared to healthy controls (17.88; p = 0.032 and 14.56; p = 0.008) 
respectively (Figure 3.4A). The expression of Il6 was significantly increased in the lung (1.41; p = 
0.03), spleen (5.43; p = 0.004) and large intestine (1.2 x 10
2
; p = 0.004) as a result of 
preconditioning in BM control mice compared to healthy controls. The gene expression was further 
augmented in the aGvHD mice compared to healthy control mice in the lung (4.57; p = 0.008), 
small (791.68; p = 0.008) and large intestines (3.2 x 10
2
; p = 0.008). The Il6 expression was also 
significantly increased in the aGvHD mice compared to the BM control mice in the lung (3.25; p = 
0.004) and small intestine (3.37; p = 0.004) (Figure 3.4B). Similarly, Il22 was significantly 
increased in the lung due to preconditioning in BM control mice (1.04 x 10
4
; p = 0.004), and was 
further increased in aGvHD mice compared to healthy controls in the lung (6.4 x 10
4
; p = 0.008) 
and large intestine (1.4 x 10
2
; p = 0.008) (Figure 3.4C). Il23a was significantly increased in the 
aGvHD large intestine compared to BM control mice (3.8 x 10
2
; p = 0.004) as well as healthy 
controls (4.9 x 10
3
; p = 0.008), but reduced in the lung as a result of preconditioning (0.7 x 10
-3
; p 






The Th17 response was also strongest in the intestine, followed by the lung. Th17 cytokines are 
mainly associated with cutaneous aGvHD in mice, however in this study, these cytokines were not 





Figure 3.4: mRNA expression of cytokines associated with Th17 responses in different tissues 
in mice.             
Relative mRNA expression of cytokines associated with Th2 responses, in aGvHD mice (n = 17) in 
comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice (n = 6) 
(blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-axis 
shows relative expression (dCt), and x axis shows different mice groups in each tissue type. The p-values 
were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg correction.             
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
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3.2.4 Expression of genes associated with Tregs in mice 
Another important subset of T cells, are the Tregs. Here, we observed an increased gene expression 
pattern for genes that have previously been associated with the expression, regulation or function of 
Tregs.  
 
The expression of Foxp3 and Il2ra (CD25) is characteristic of nTregs. The gene expression of 
Foxp3, which is a transcription factor that is critical for the development and function of Tregs, 
was significantly increased in aGvHD mice compared to the BM controls (8.89; p = 0.0079) in the 
large intestine (Figure 3.5A). On the other hand, Il2ra was significantly increased in almost all the 
tissues of aGvHD mice compared to BM control mice, in the liver (4.07; p = 0.004), lung (4.33; p 
= 0.004), skin (10.12; p = 0.009), small (8.77; p = 0.004) and large intestines (10.08; p = 0.004). 
Moreover, in the lung and spleen, Il2ra was significantly increased as a result of preconditioning in 
BM control mice (1.73; p = 0.017 and 1.01; p = 0.004) and in aGvHD mice compared to healthy 
controls in the lung (7.49; p = 0.008) and large intestine (10.21; p = 0.008), however the Il2ra 
expression was decreased in the spleen (0.69; p = 0.008) (Figure 3.5B). Il2ra is expressed not only 
by Tregs, but on activated T cells too, suggesting there is an infiltration of activated alloreactive T 
cells as well as Tregs in the different target tissues. IL-10 is a Th2 cytokine, but is also produced by 
Tregs, and both IL-10 and TGF-β are important in Treg regulation to reduce immunity and 
autoimmunity (Carrier et al., 2007; Erhardt et al., 2007). The overall expression of Il10 was not 
regulated in the tissues, except in the large intestine, where Il10 was strongly upregulated in 
aGvHD mice compared to healthy controls (63.27; p = 0.008) (Figure 3.5C). Tgfb1 and Tgfbr1 
mRNA were both strongly increased in the lung due to preconditioning (7.42; p = 0.002 and 12.06; 
p = 0.012) (Figure 3.5D and 3.5E). While the Tgfbr1 expression was not altered in any other tissues 
with aGvHD, Tgfb1 mRNA was significantly increased in the liver (1.76; p = 0.022), skin (2.15; p 
= 0.012) and large intestine (2.01; p = 0.004) in mice with aGvHD compared to healthy controls, 
and in aGvHD small and large intestines compared to BM control mice (1.97; p = 0.008 and 2.03; 
p = 0.008). In contrast, Tgfb2 was mostly downregulated due to preconditioning in BM control 
mice compared to healthy controls in the liver (0.37; p = 0.001), spleen (0.41; p = 0.001) and large 
intestine (0.33; p = 0.001). However, the mRNA expression of Tgfb2 increased significantly in 
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Figure 3.5: mRNA expression of cytokines associated with Tregs responses in different tissues 
in mice.                      
Relative mRNA expression of cytokines associated with Tregs responses, in aGvHD mice (n = 17) in 
comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice (n = 6) 
(blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-axis 
shows relative expression (dCt), and x axis shows different mice groups in each tissue type. The p-values 
were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg correction.             
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)             
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in BM control mice due 
to preconditioning) 
 
Similarly, we observed an upregulation of Ido mRNA. IDO1 is strongly linked to the 
differentiation of Tregs and contributes to their suppressive capacity. The overall expression of 
Ido1 was upregulated in aGvHD lung (36.57; p = 0.008), small (93.18; p = 0.008) and large 
intestine (30.82; p = 0.008) compared to healthy controls. The expression of Ido1 was increased in 
both small and large intestines as a result of preconditioning in BM control mice compared to 
healthy controls (7.75; p = 0.004 and 11.19; p = 0.004), and further increased in the small intestine 
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3.5G). In addition to IDO, another metabolic enzyme induced by inflammation is Arginase-1 
(ARG1) (Rodriguez et al., 2004), that is important in Treg function. Activation of ARG1, reduces 
arginine, which in turn reduces T cell responses (Highfill et al., 2010; Rodriguez et al., 2004). We 
observed a significant upregulation in the expression of Arg1 in the aGvHD liver (9.5; p = 0.008), 
lung (22.69; p = 0.008), small (7.29; p = 0.008) and large intestine (59.31; p = 0.008) compared to 
healthy controls and in the liver (1.48; p = 0.009), small (9.92; p = 0.004) and large (24.64; p = 
0.004) intestines compared to BM control (Figure 3.5H). The Interleukin-1 receptor-like 2 
precursor (IL-1RL2) has been shown to be expressed on human Tregs (Pfoertner et al. 2006). The 
expression of Il1rl2 was significantly increased in the liver (6.03; p = 0.019) and the lung (11.62; p 
= 0.001) as a result of preconditioning in the BM control mice compared to healthy controls. This 
expression was further augmented due to aGvHD in the mice compared to healthy controls in the 
liver (7.22; p = 0.012) and lung (15.08; p = 0.019) respectively (Figure 3.5I). Galacten-3 
(LGALS3) was also reported to be expressed on human Treg subsets (Pfoertner et al. 2006). An 
important role of LGALS3 is limiting TCR mobility causing a restricted TCR-mediated signaling 
on T cells, subsequently resulting in a change of the cytokine profile of T cells, thereby regulating 
the effector cells and homeostasis of immune cells (Demetriou et al., 2001). The expression of 
Lglas3 was significantly increased in the BM control liver (4.87; p = 0.019), lung (9.3; p = 0.019) 
and spleen (3.29; p = 0.007) compared to healthy controls due to preconditioning, and it was 
further increased in aGvHD liver compared to healthy control liver (7.63; p = 0.007), and in 
aGvHD large intestine (1.63; p = 0.016), compared to BM control mice (Figure 3.5J).  
Tregs are generally present in the peripheral lymphoid organs in the presence of TGF-β, which is 
consistent with our findings in the large intestine where we observed an increased expression of all 
the genes associated with Tregs except Tgfb2, suggesting an increase in Treg population in the 
different tissues, but mainly the intestine.  
 
3.2.5 Expression of IFN-γ inducible chemokine receptor Cxcr3 and its ligands 
Cxcl9, Cxcl10 and Cxcl11 in mice 
In general, we observed an increased expression pattern of the IFN-γ inducible Th1 chemokines 
Cxcl9, Cxcl10, Cxcl11 and their receptor Cxcr3. However, these chemokines showed a mixed 
expression pattern in the liver, compared to the other tissues.  
 
The mRNA expression of Cxcr3 was significantly upregulated in the aGvHD mice compared to 
healthy controls in the lung (21.16; 0.008), skin (1.9 x 10
6
; 0.008), small (12.59; 0.008) and large 
(4.4 x 10
10
; 0.008) intestines, whereas it was significantly reduced in the liver (0.41; 0.008). Our 





(0.2; p = 0.008), and due to aGvHD in the lung (49.15; p = 0.004). On the other hand, the 
expression of Cxcr3 was increased in the skin (2.1 x 10
4
; p = 0.004) and large intestine (1.9 x 10
6
; 
p = 0.004) of the BM control mice compared to healthy controls as a result of preconditioning, and 
further increased in the aGvHD mice skin (92.4; p = 0.004), small (51.31; p = 0.004) and large (2.2 
x 10
4
; p = 0.004) intestines compared to BM control mice (Figure 3.6A).  
 
Cxcl9 mRNA was significantly increased in the liver (48.67; p = 0.002) and lung (7.83; p = 0.018) 
as a result of preconditioning in BM control mice compared to healthy controls, and its expression 
was strongly increased in aGvHD mice compared to healthy controls in the liver (10.54; p = 
0.007), lung (9.07; p = 0.01), small (3.18; p = 0.001) and large (10.54; p = 0.007) intestines (Figure 
3.6B). Similarly, Cxcl10 mRNA was significantly increased in the BM control lung (18.44; p = 
0.004) due to preconditioning further increased in aGvHD lung (47.87; p = 0.008) compared to 
healthy controls, and in aGvHD skin (21.77; p = 0.008), small (10.46; p = 0.008) and large (21.32; 
p = 0.008) intestines compared to healthy controls. However, in the liver and spleen, the expression 
of Cxcl10 was increased as a result of preconditioning (13.08; p = 0.004 and 8.03; p = 0.004) in the 
BM control mice compared to healthy controls  and reduced significantly in aGvHD mice (0.17; p 
= 0.004 and 0.12; p = 0.004) compared to BM controls, respectively (Figure 3.6C). Cxcl11 mRNA 
showed an increased expression in the BM control lung (19.99; p = 0.004) due to preconditioning 
and aGvHD lung (65.71; p = 0.008) compared to healthy control mice. The expression of Cxcl11 
was also significantly increased in the aGvHD large intestine compared to healthy controls (64.82; 
p = 0.008) as well as BM controls (31.09; p = 0.004) (Figure 3.6D). 
  
Overall, the expression of Cxcr3 and its ligands Cxcl9, Cxcl10 and Cxcl11 might have contributed 


















Figure 3.6: mRNA expression of chemokines induced by IFN-γ in different tissues in mice.  
Relative mRNA expression of chemokine receptor A. Cxcr3 and its ligands B. Cxcl9 (Mig), C. Cxcl10 (IP-
10) and D. Cxcl11 (IP-9), in aGvHD mice (n = 17) in comparison with normal healthy controls (n=15) (red), 
in aGvHD mice compared to BM control mice (n = 6) (blue) and preconditioning alone by comparing BM 
control mice to healthy controls (green). The y-axis shows relative expression (dCt), and x axis shows 
different mice groups in each tissue type. The p-values were calculated by Mann-Whitney U-test, and were 
corrected for FDR by Benjamin Hochberg correction.                    
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
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3.2.6 Expression of the chemokine receptors Ccr1, Ccr4, Ccr5 and their 
ligands Ccl9, Ccl5 and Ccl4 in mice 
Here, we studied the mRNA expression of Ccl9 and its receptor Ccr1, Ccl4 and its receptor Ccr5, 
and Ccl5 and its receptor Ccr4. Overall, the gene expression of the chemokine Ccl4 was 
significantly increased in all the tissues during aGvHD. Ccl4 was significantly increased in the 
aGvHD mice compared to the BM controls in the liver (3.23; p = 0.004), lung (4.09; p = 0.004), 
small (11.97; p = 0.004) and large (14.42; p = 0.004) intestines, and its expression was further 
increased in the lung (8.02; p = 0.004), spleen (2.05; p = 0.008), small (16.93; p = 0.008) and large 
(11.87; p = 0.008) intestines in the aGvHD mice compared to healthy controls. Furthermore, Ccl4 
was also significantly increased due to preconditioning in the BM control skin (3.3 x 10
5
; p = 
0.004) and further increased in aGvHD skin (8.5 x 10
7
; p = 0.008) compared to the healthy controls 
(Figure 3.7A). Ccl5, on the other hand exhibited a more complex expression pattern in the different 
mice tissues. Overall, the expression of Ccl5 was downregulated in the liver (0.23; p = 0.004), lung 
(0.27; p = 0.017), skin (0.12; p = 0.009), spleen (0.31; p = 0.004) and large (0.06; p = 0.004) 
intestines in BM control mice compared to healthy controls as a result of preconditioning. Ccl5 was 
further downregulated in the spleen of aGvHD mice compared to BM control mice (0.46; p = 
0.009), as well as healthy controls (0.14; p = 0.008). Additionally, in the large intestine, Ccl5 
expression was reduced during aGvHD compared to healthy controls (0.37; p = 0.008). However, 
the expression of Ccl5 was significantly increased in aGvHD mice compared to BM controls in the 
liver (2.81; p = 0.004), skin (8.78; p = 0.009) and large intestine (6.27; p = 0.009) (Figure 3.7B). 
 
On the other hand, except for the liver, Ccl9 was significant upregulated in all the tissues during 
aGvHD. In aGvHD mice, Ccl9 was strongly increased in the lung (31.98; p = 0.019), skin (29.18; 
p = 0.004), spleen (5.96; p = 0.001), small (3.78; p = 0.001) and large (11.61; p = 0.001) intestines. 
Moreover, in the large intestine, a significant upregulation of Ccl9 was also observed in the aGvHD 
mice compared to the BM controls (9.26; p = 0.008) (Figure 3.7C). Similarly Ccr1 was 
significantly increased in the aGvHD liver (17.84; p = 0.012), skin (47.37; p = 0.029), spleen 
(4.64; p = 0.001), small (4.5; p = 0.001) and large (6.62; p = 0.002) intestines compared to healthy 
controls, and in the spleen (2.64; p = 0.008), small (5.31; p = 0.008) and large (2.57; p = 0.016) 
intestines compared to BM control mice (Figure 3.7D).  
 
In contrast, the gene expression of Ccr4 was significantly reduced in the different tissues during 
aGvHD. In the lung (0.37; p = 0.004), skin (0.19; p = 0.004) and small intestine (0.32; p = 0.004) 
Ccr4 is reduced due to preconditioning in BM control mice compared to healthy controls. The 
regulation is further reduced in the aGvHD lung (0.35; p = 0.008), spleen (0.05; p = 0.008) and 





healthy controls, and in the aGvHD spleen compared to BM controls (0.11; p = 0.004)            
(Figure 3.7E). The overall expression of Ccr5 was significantly increased in the liver (3.01; p = 
0.004), spleen (1.56; p = 0.004), small (3.82; p = 0.004) and large (3.15; p = 0.004) intestines in 
aGvHD mice compared to healthy controls. In addition, Ccr5 is significantly increased in the BM 
control liver (2.81; p = 0.001) compared to healthy controls due to preconditioning, whereas in the 
small and large intestines, the expression of Ccr5 was significantly increased in the aGvHD mice 
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Figure 3.7: mRNA expression of chemokine receptors Ccr1, Ccr4, Ccr5 and ligands Ccl4, Ccl5 
and Ccl9 in different tissues in mice.            
Relative mRNA expression of chemokines A. Ccl4 B. Ccl5 C. Ccl9 and chemokine receptors D. Ccr1 E. 
Ccr4 F. Ccr5 in aGvHD mice (n = 17) in comparison with normal healthy controls (n=15) (red), in aGvHD 
mice compared to BM control mice (n = 6) (blue) and preconditioning alone by comparing BM control mice 
to healthy controls (green). The y-axis shows relative expression (dCt), and x axis shows different mice 
groups in each tissue type. The p-values were calculated by Mann-Whitney U-test, and were corrected for 
FDR by Benjamin Hochberg correction.                                                            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            




3.2.7 Expression of Cxcl15, Cxcl16 and chemokine receptor Cxcr4 in mice 
In addition we studied the expression profile of the other chemokines, Cxcl15 or Il8, Cxcl16 and 
the chemokine receptor Cxcr4. 
 
Cxcl15 showed a mixed expression across the different aGvHD tissues, although it was mostly 
downregulated during aGvHD. Cxcl15 mRNA expression was significantly reduced in the liver 
(0.17; p = 0.004), lung (0.51; p = 0.004), spleen (0.26; p = 0.004) and large intestine (0.47; p = 
0.009) in aGvHD mice compared to BM controls. In the the liver (0.07; p = 0.008), lung (0.3; p = 
0.008) and spleen (0.19; p = 0.008), Cxcl15 was further reduced in aGvHD mice compared to 
healthy controls. In contrast, Cxcl15 mRNA was significantly increased in the small intestine 
(2.57; p = 0.016) (Figure 3.8A). On the other hand, Cxcl16 expression was strongly increased in 
the liver (2.97; p = 0.007), skin (4.52; p = 0.002), small (2.17; p = 0.001) and large (5.66; p = 
0.001) intestines of aGvHD mice compared to healthy controls. Furthermore, in the BM control 
skin, the expression of Cxcl16 was significantly increased due to preconditioning (2.02; p = 0.007) 
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(3.09; p = 0.008) intestines, in aGvHD mice compared to BM controls (Figure 3.8B). Cxcr4 was 
strongly downregulated in BM control mice compared to healthy controls due to preconditioning in 
the lung (0.4; p = 0.004), small (0.05; p = 0.004)  and large (0.13; p = 0.004) intestines and its 
expression was further reduced in aGvHD mice in the lung (0.27; p = 0.008), small (0.07; p = 





Figure 3.8: mRNA expression of chemokines Cxcl15, Cxcl16 and chemokine receptor Cxcr4 
in different tissues in mice.                
Relative mRNA expression chemokines of A. Cxcl15, B. Cxcl16  and chemokine receptor C. Cxcr4 in 
aGvHD mice (n = 17) in comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to 
BM control mice (n = 6) (blue) and preconditioning alone by comparing BM control mice to healthy controls 
(green). The y-axis shows relative expression (dCt), and x axis shows different mice groups in each tissue 
type. The p-values were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin 
Hochberg correction.                      
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
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*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in BM control mice due 
to preconditioning) 
 
3.2.8 Expression of the chemokine receptor Cx3cr1 and its ligand Cx3cl1 in 
mice 
We observed a strong upregulation of Cx3cr1 mRNA in aGvHD mice compared to healthy controls 
in the spleen (13.34; p = 0.016), small (49.71; p = 0.008) and large (265.77; p = 0.008) intestines 
(Figure 3.9A), whereas its ligand, Cx3cl1 was strongly downregulated in the aGvHD lung (0.47; p 
= 0.008) and large intestine (0.36; p = 0.008) compared to healthy controls. Furthermore, Cx3cl1 





Figure 3.9: mRNA expression of chemokine receptor Cx3cr1 and its ligand Cx3cl1 in 
different tissues in mice.             
Relative mRNA expression of chemokine receptor A. Cx3cr1 and its ligand B. Cx3cl1, in aGvHD mice (n = 
17) in comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice 
(n = 6) (blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-
axis shows relative expression (dCt), and x axis shows different mice groups in each tissue type. The p-
values were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg 
correction.              
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
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3.2.9 Expression of other genes 
IL-15 is a critical mediator for T cell function during aGvHD (Blaser et al., 2005). Il15 mRNA was 
not differentially regulated in any of the tissues, except it was significantly reduced in the large 
intestine (0.44; p = 0.029) in aGvHD mice compared to healthy controls (Figure 3.10A). We found 
Interleukin-1 receptor-1 (Ilr1) mRNA to be significantly upregulated in the small intestine in mice 
with aGvHD (5.40; p = 0.008) compared to BM controls. The expression of Il1r1 was also 
increased in the liver (6.64; p = 0.001) and small intestine (2.33; p = 0.007) of aGvHD mice 
compared to healthy controls (Figure 3.10B). Bone morphogenetic protein receptor type-1A 
(Bmp1ra) mRNA was significantly increased as a result of preconditioning in the liver (2.76; p = 
0.001) and lung (7.99; p = 0.002) in BM control mice compared to healthy controls, and its 
expression was further augmented in aGvHD mice in the liver (3.15; p = 0.001) and lung (7.94; p = 
0.019) compared to healthy controls (Figure 3.10C). BMPR1A is a receptor that belongs to a 
family of  transmembrane serine-threonine kinases, its ligands are members of the TGF-β 
superfamily. Ectonucleotide pyrophosphatase/ phosphodiesterase 1 (Enpp1) mRNA was increased 
as a result of preconditioning in the large intestine (2.55; p = 0.007) in BM controls compared to 
healthy controls, and in aGvHD small intestine (3; p = 0.042) compared to healthy controls. On the 
other hand, the expression of Enpp1 was significantly decreased in the aGvHD liver (0.07; p = 
0.042) and lung (0.17; p = 0.042) compared to healthy controls (Figure 3.10D). ENPP1 has a broad 
specificity and cleaves a number of substrates such as phosphodiester bonds of nucleic acids. Fc 
fragment of immunoglobulin epsilon receptor subunit gamma (FCER1G) is involved in 
transmembrane signalling receptor activity and binding of IgE. Fcer1g mRNA was significantly 
increased in the spleen (2.46; p = 0.004) as due to preconditioning in BM controls and in aGvHD 
liver (2.31; p = 0.012), skin (6.92; p = 0.002) and large intestine (2.15; p = 0.001) compared to 
healthy controls (Figure 3.10E). Low affinity immunoglobulin gamma Fc region receptor III 
(FCGR3) is required for NK cell-mediated antibody-dependent cytotoxicity and phagocytosis by 
macrophages. On the other hand, we observed no change in expression patterns of Fcgr3 in any of 
the tissues (Figure 3.10F). The Intercellular adhesion molecule 1 (ICAM-1) is expressed on 
endothelial cells and is critical for the migration of leukocytes to tissues during inflammation (Ren 
et al., 2010). Icam1 mRNA was significantly increased in the liver (5.66; p = 0.001), skin (10.13; p 
= 0.001), small (4.13; p = 0.001) and large (10.55; p = 0.001) intestines of aGvHD mice compared 
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Figure 3.10: mRNA expression other genes involved in immune responses in different tissues 
in mice.                 
Relative mRNA expression of other genes involved in immune responses, in aGvHD mice (n = 17) in 
comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice (n = 6) 
(blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-axis 
shows relative expression (dCt), and x axis shows different mice groups in each tissue type. The p-values 
were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg correction.             
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in BM control mice due 
to preconditioning) 
 
In summary, we observed an observed upregulation of the Th1, Th2 and Th17 cytokines, genes 
associated with Tregs, as well as the adhesion molecule Icam1, and several other chemokines 
including chemokine receptor Cxcr3 and its ligands Cxcl9, Cxcl10 and Cxcl11, chemokine 
receptors Ccr1, Ccr5, Cx3cr1 and chemokines Ccl9 and Cxcl16 in the different tissues in aGvHD 
mice compared to the healthy control mice. This is possibly due to activation of alloreactive T cells 
in the target organs or T cell infiltration in sites of inflammation. Other chemokines, Cxcl15, 
Cx3cl1, Ccl4, chemokine receptors Ccr4, Cxcr4 and the cytokine Il15 were significantly 
downregulated. Overall, the genes were differentially expressed across the different target organs, 
















Liver       Lung       Skin    Spleen     Small        Large 









3.3   Gene expression of previously identified candidate genes in mice and rat 
aGvHD 
3.3.1 Expression of genes regulated by IFN-γ  
Of the candidate genes previously identified by Novota and colleagues, several genes are regulated 
by the IFN-γ, suggesting their role in inflammation during aGvHD pathogenesis.  
 
3.3.1.1 Mice 
Interestingly, Lilra5 was significantly increased during aGvHD in all the tissues. Leukocyte 
immunoglobulin-like receptor subfamily A member 5 (LILRA5) is an activating Ig-like receptor, 
expressed by immune cells and is associated with the release of pro-inflammatory cytokines 
(Brown et al., 2004). In aGvHD mice compared to healthy controls, Lilra5 was significantly 
upregulated in the liver (6.84; p = 0.0001), lung (4.01; p = 0.007), skin (128.6; p = 0.02), spleen 
(8.58; p = 0.001), small (9.8 x 10
2
; p = 0.0001) and large (168.91; p = 0.002) intestines. Moreover, 
the expression of Lilra5 was also significantly increased in the BM control spleen due to 
preconditioning (8.1; p = 0.005) and in aGvHD small intestine (134.34; p = 0.015) compared to 
BM controls (Figure 3.11A). Similarly, Lst1 was significant increased in aGvHD mice lung (9.63; 
p = 0.002), skin (8.38; p = 0.007), spleen (65.59; p = 0.0001), small (734.91; p = 0.0001) and large 
(37.68; p = 0.016) intestines compared to healthy controls. Furthermore, the expression of Lst1 was 
upregulated in the BM control spleen due to preconditioning (41.07; p = 0.0001) compared to 
healthy controls, and between aGvHD and BM control mice, in both the small (5.48; p = 0.02) and 
large (3.2; p = 0.013) intestines (Figure 3.11B). Leukocyte-specific transcript 1 (LST1) is encoded 
within class III region of the MHC, (de Baey et al., 1997) and has been implicated in inflammatory 
and infectious diseases (Mulcahy et al., 2006). 
 
It has previously been reported that MSR1 is involved in the regulation of anti-inflammatory 
responses (Fulton et al., 2006). Msr1 mRNA was also increased in all tissues except the liver. In 
aGvHD mice compared to healthy controls, Msr1 was strongly upregulated in the lung (5.29; p = 
0.018), skin (106.48; p = 0.0001), spleen (9.34; p = 0.0001), small (9.65; p = 0.0001) and large 
(13.69; p = 0.001) intestines. In addition, Msr1 was also increased in the spleen (8.13; p = 0.003) 
of BM control mice compared to healthy controls as a result of preconditioning (Figure 3.11C). We 
observed an increased expression of Ptger2 mRNA in the large intestine (3.2; p = 0.013) in mice 
with aGvHD compared to BM controls. Prostaglandin E receptor 2 (PTGER2) or Prostaglandin E2 
can modulate cytokine responses by CD4
+





and decreased IFN-γ production by acting on T cells directly (Napolitani et al., 2009) and inhibit T 
cell responses by blocking the proliferation of T cells (Harris et al., 2002). In addition, PTGER2 
was also associated with an enhanced secretion of IL-23 by DCs (Weaver et al., 2007). 
Furthermore, Ptger2 mRNA was significantly increased in aGvHD small (1.78; p = 0.02) and large 
(1.91; p = 0.025) intestines and reduced in spleen (0.39; p = 0.004) compared to healthy control 
mice (Figure 3.11D).  
 
We observed an increased expression of Tap1 in BM control mice due to preconditioning in the 
lung (603.45; p = 0.003) and liver (129.22; p = 0.005) compared to healthy controls, whereas its 
expression was significantly reduced in aGvHD liver (0.001; p = 0.002) compared to BM controls 
and in aGvHD spleen compared to healthy controls (0.01; p = 0.004) (Figure 3.11E).  
Trem2 was significantly downregulation in aGvHD lung (0.10; p = 0.001), spleen (0.07; p = 0.001) 
and small intestine (0.1 x 10
-4
; p = 0.001) compared to healthy controls, and in aGvHD liver (0.04; 
p = 0.013) compared to BM controls. In contrast, preconditioning in the BM control liver (393.05; 
p = 0.005) as well as aGvHD liver (16.48; p = 0.008), showed a strong increase expression of 
Trem2 compared to healthy controls (Figure 3.11F). TREM2 is downregulated by IFN-γ (Zhao and 
Ivashkiv, 2011).   
 
The gene expression of Ubd was strongly increased in all the target tissues of aGvHD, in the liver 
(2.17; p = 0.0001), lung (10.32; p = 0.0001), skin (59.3; p = 0.0001), spleen (59.3; p = 0.001), 
small (11.25; p = 0.0001) and large intestines (7.55; p = 0.0001) and in aGvHD mice compared to 
BM controls in the liver (2.17; p = 0.004), lung (10.32; p = 0.016), skin (59.3; p = 0.0001), small 
(11.25; p = 0.001) and large intestines (7.55; p = 0.0001). Moreover, Ubd was also highly 
increased in the liver (28.71; p = 0.0001) and lung (10.65; p = 0.014) of BM control mice 
compared to healthy controls due to preconditioning (Figure 3.11G). UBD is a downstream 
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Figure 3.11: mRNA expression of candidate genes regulated by IFN-γ in different tissues in 
mice.               
Relative mRNA expression of candidate genes regulated by IFNγ, in aGvHD mice (n = 17) in comparison 
with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice (n = 6) (blue) and 
preconditioning alone by comparing BM control mice to healthy controls (green). The y-axis shows relative 
expression (dCt), and x axis shows different mice groups in each tissue type. The p-values were calculated by 
Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg correction.                
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            




In the aGvHD rats, these genes were not as differentially expressed. Lilra5, Msr1, Lst1 and Trem2 
were not regulated in aGvHD mice compared to syngeneic control mice. The expression of Lilra5 
(Figure 3.12A) and Lst1 (Figure 3.12B) showed a trend of upregulation in the liver, lung and small 
intestine, same as in mice. In addition, we observed a trend of upregulation of Msr1 (Figure 3.12C) 
and Trem2 (Figure 3.12F) in the rat liver, in line with their regulation in mice, but their expression 
trends in the other tissues were different. On the other hand, Ptger2 was increased significantly in 
aGvHD liver alone (6.98; p = 0.007) (Figure 3.12D). Similarly, the expression of Tap1 mRNA was 
significantly increased in the liver (2.98; p = 0.0069), as seen in aGvHD mice as well (Figure 
3.12E). Moreover, Ubd was strongly upregulated in the lung (58.58; p = 0.0001) and the small 
intestine (30.85; p = 0.0036) in aGvHD rat compared to the syngeneic controls (Figure 3.12G). 
Moreover, Ubd showed an upregulated trend of expression in the liver and skin as well, similar to 
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Figure 3.12: mRNA expression of genes regulated by IFN-γ in different tissues in rats.    
Relative mRNA expression of genes regulated by IFN-γ in rats with aGvHD (n = 6), compared to syngeneic 
controls (n = 6). The y-axis shows relative expression (dCt), and x-axis shows control rat and aGvHD 
expression in different tissues. The p-values were calculated by Mann-Whitney U-test, and were corrected 
for FDR by Benjamin Hochberg correction.                                      
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
 
3.3.2 Expression of genes regulated by B and T cell activation  
3.3.2.1  Mice 
Capsase recruitment domain 11 (CARD11) is critical for antigen receptor signalling (Pomerantz et 
al., 2002). Card11 mRNA was significantly decreased in the spleen (0.38; p = 0.012) due to 
preconditioning in BM control mice, and was further reduced as a result of aGvHD in the spleen 
(0.33; p = 0.0001) and small intestine (0.52; p = 0.007) compared to BM controls. Moreover, the 
overall expression of Card11 was also significantly decreased in aGvHD mice compared to healthy 
controls in the spleen (0.2 x 10
-3
; p = 0.0001), small (0.23; p = 0.0001) and large (0.31; p = 0.0001) 
intestines (Figure 3.13A). The lack of Hematopoietic cell-specific Lyn substrate 1 (HCLS1) on B 
and T cells causes a defect in proliferation and antigen receptor induced apoptosis (Fukuda et al., 
1995). Hcls1 mRNA was significantly increased in the liver (3.95; p = 0.0001), lung (8.61; p = 
0.001), skin (44.29; p = 0.0001) and large intestine (3.18; p = 0.001) in aGvHD mice compared to 
healthy controls (Figure 3.13B). Moreover, preconditioning significantly increased the expression 
of Hcls1 in the liver (1.82; p = 0.011) and lung (9.9; p = 0.006) in BM control mice compared to 
healthy mice, as well as in aGvHD small (3.28; p = 0.002) and large (2.47; p = 0.018) intestines 
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Figure 3.13: mRNA expression of candidate genes regulated by activation of B and T cells in 
different tissues in mice.              
Relative mRNA expression of candidate genes regulated by activation of B and T cells, in aGvHD mice (n = 
17) in comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice 
(n = 6) (blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-
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values were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg 
correction.              
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in BM control mice due 
to preconditioning) 
 
Phosphoinositde-3-kinase adaptor protein 1 (PIK3AP1) is involved in the development of B cells 
(Yamazaki and Kurosaki, 2003) and activation of NK cells (Ni et al., 2012). Pik3ap1 was not 
regulated in many of the aGvHD target tissues, but was significantly decreased in the aGvHD 
spleen (0.36; p = 0.0001) compared to BM controls and increased in the aGvHD lung (4.04; p = 
0.016) compared to healthy controls (Figure 3.13C). On the other hand, Proline serine threonine 
phosphatase interacting protein 1 (Pstpip1) was significantly increased in all the aGvHD target 
tissues. In aGvHD mice compared to BM controls, Pstpip1 was significantly increased in the liver 
(10.73; p = 0.0001), small (5.66; p = 0.0001) and large intestine (5.13; p = 0.0001). Pstpip1 was 
further upregulated in aGvHD mice compared to healthy controls in the liver (9.47; p = 0.0001), 
lung (1.66; p = 0.005), skin (1.15; p = 0.013), small (2.12; p = 0.038) and large (4.34; p = 0.0001) 
intestines (Figure 3.13D). PSTPIP1 is involved in the downregulation of CD2-triggered adhesion 
and activation of T cells (Li et al., 1998). Similarly, Protein tyrosine phosphatase non-receptor type 
7 (Ptpn7) was significantly upregulated in the liver (10.73; p = 0.0001), small (5.66; p = 0.0001) 
and large intestine (5.13; p = 0.0001) in aGvHD mice compared to BM controls. Its expression was 
further increased in aGvHD mice compared to healthy controls in the liver (8.14; p = 0.0001), lung 
(1.19; p = 0.027) and large intestine (4.09; p = 0.0001) (Figure 3.13E). PTPN7 is involved in T and 
B lymphocyte development and signal transduction (Saxena et al., 1998). 
 
3.3.2.2 Rats 
In rat aGvHD liver, we observed an increase in the expression of Hcls1 (5.28; p = 0.0069) (Figure 
3.14A) and Ptpn7 compared to (3.67; p = 0.004) (Figure 3.14D) gene expression was observed in 
rats with aGvHD. The mRNA expression of Pik3ap1and Pstpip1 was not differentially regulated in 
the rat. However, a similar trend of upregulation to mice was observed for Pik3ap1 (Figure 3.4B) 












    
Figure 3.14: mRNA expression of genes regulated by B and T cell activation in different 
tissues in rats.                            
Relative mRNA expression of genes regulated by B and T cell activation in rats with aGvHD, (n = 6) on 
comparison with syngeneic controls (n = 6). The y-axis shows relative expression (dCt), and x-axis shows 
control rat and aGvHD expression in different tissues. The P values were calculated by Mann-Whitney U-test, 
and were corrected for FDR by Benjamin Hochberg correction.               
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3.3.3 Expression of genes regulated by innate immune responses  
3.3.3.1 Mice 
No significant changes in the expression of Acidic Nuclear Phosphoprotein 32 Family, Member A 
(Anp32a) mRNA was observed in the mice during aGvHD. ANP32A is protein coding gene 
involved in several cellular processes including proliferation, differentiation and apoptosis. It is 
also implicated in tumor suppression, by stimulating apoptosis (Pan et al., 2009). Anp32a mRNA 
was decreased in the liver due to preconditioning (0.06; p = 0.014), but remained unchanged in the 
other tissues (Figure 3.15A).  
 
C1q and Tumor Necrosis Factor Related Protein 7 (C1QTNF7) is a protein coding gene that is 
indirectly impacted by NR3C1 protein (Lu et al., 2007), the glucocorticoid receptor gene is 
involved in cellular proliferation and inflammatory responses (Ray and Prefontaine, 1994). The 
mRNA expression of C1qtnf7 was strongly increased in the skin (2.7; p = 0.008), but reduced in 
the spleen (0.01; p = 0.0001) and large intestine (0.3 x 10
-3
; p = 0.002) in aGvHD mice compared 
to healthy controls. In the spleen, C1qtnf7 was further reduced in aGvHD mice (0.11; p = 0.008) 
compared to BM controls. No change in C1qtnf7 expression was observed in the aGvHD liver, 
however it was strongly reduced in the BM control liver as a result of preconditioning (0.001; p = 
0.0001) compared to BM controls (Figure 3.15B).  
 
Induction of High-Temperature Requirement A Serine Peptidase 1 (HTRA1) in the presence of 
LPS, increases the incidence of collagen-induced arthritis in mice (Hou et al., 2013). Moreover 
TLR-4 ligands induce the expression of HTRA1 in macrophages and fibroblasts (Hou et al., 2013). 
Htra1 was significantly reduced in the aGvHD spleen (0.49; p = 0.001) compared to healthy 
controls and decreased in the aGvHD spleen (0.33; p = 0.0001) and small intestine (2.64; p = 
0.0001) but increased in the large intestine (1.71; p = 0.018) compared to BM controls. In the liver 
however, Htra1 was downregulated in BM control mice due to preconditioning (0.4; p = 0.0001), 



















Figure 3.15: mRNA expression of candidate genes regulated by innate immune responses in 
different tissues in mice.               
Relative mRNA expression of candidate genes regulated by innate immune responses, in aGvHD mice (n = 
17) in comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice 
(n = 6) (blue) and preconditioning alone by comparing BM control mice to healthy controls (green). The y-
axis shows relative expression (dCt), and x axis shows different mice groups in each tissue type. The P 
values were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg 
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*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in BM control mice due 
to preconditioning) 
 
The expression of Galectin-7 (Lgals7) mRNA was significantly reduced in the lung (0.01; p = 
0.001) in BM control mice due to preconditioning and in aGvHD mice (0.01; p = 0.0001), 
compared to healthy controls. In contrast, we observed a significant upregulation of Lgals7 in the 
BM control small intestine (107.564; p = 0.02) as well as in the aGvHD small intestine (6.4 x 10
2
; 
p = 0.038) compared to healthy controls (Figure 3.15D). LGALS7 is involved in modulating 
apoptosis and tumor growth (St-Pierre et al., 2012). 
Interestingly, Transglutaminase 2 (Tgm2) was significantly upregulated in all the tissues, in 
aGvHD mice compared to healthy controls, i.e., liver (5.05; p = 0.0001), lung (26.28; p = 0.0001), 
skin (3.07; p = 0.002), spleen (3.22; p = 0.0001), small (9.91; p = 0.0001) and large (8.76; p = 
0.0001) intestines (Figure 3.15E). In the river (3.71; p = 0.0001), lung (30.82; p = 0.005) and 
spleen (5.02; p = 0.0001), the increased Tgm2 expression was in part due to preconditioning in the 
BM control compared to healthy controls. In addition, Tgm2 was also increased in aGvHD small 
intestine (3.44; p = 0.0001) and large intestine (3.94; p = 0.0001) compared to BM controls. TGM2 
is induced by retinoic acid and is involved in apoptosis (Rébé et al., 2009), inflammation and tumor 
biology (Griffin et al., 2002). 
 
3.3.3.2 Rats 
No significant change in gene expression was observed in C1qtnf7, Lgals7 or Tgm2 whereas a 
downregulation, similar to that in mice, was observed in the expression of Htra1 in the lung (0.53; 
p = 0.0041) (Figure 3.16B). However, the trend of the regulation pattern of C1qtnf7 in rat aGvHD 
was similar in the lung, skin and small intestine compared to mice aGvHD (Figure 3.16A). 
Furthermore, Lglas7 showed a similar expression pattern in the rat aGvHD in the liver and small 
intestine (Figure 3.16C), whereas the expression pattern of Tgm2 showed a trend of upregulation in 














Figure 3.16: mRNA expression of genes regulated by innate immune responses in different 
tissues in rats.               
Relative mRNA expression of genes regulated by innate immune responses in rats with aGvHD, (n = 6) on 
comparison with syngeneic controls (n = 6). The y-axis shows relative expression (dCt), and x-axis shows 
control rat and aGvHD expression in different tissues. The P values were calculated by Mann-Whitney U-
test, and were corrected for FDR by Benjamin Hochberg correction.               
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
 
In summary, several candidate genes showed a mixed expression pattern in the different target 
tissues. However, most of the genes regulated by IFN-γ were upregulated significantly in the mice, 
and showed a similar trend in the rats. Several other genes were also increased in the aGvHD mice 
and rats, however, we observed a downregulation in genes such as Tap1, Trem2 in the mice, and 
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3.3.4 Gene expression of Klrk1 and its ligands in different tissues  
3.3.4.1 Mice 
In aGvHD mice compared to healthy controls, an increased expression pattern of Klrk1, encoding 
NKG2D was observed in all the aGvHD target tissues; liver (2.32; p = 0.001), lung (15.55; p = 
0.001), skin (7.2; p < 0.0001), small (4.29; p < 0.0001) and large (3.12; p < 0.0001) intestines 
(Figure 3.17A). In both the liver (2.97; p = 0.002) and lung (7.27; p = 0.023), Klrk1 mRNA was 
also increased in BM control mice compare to healthy controls due to preconditioning alone. 
Moreover, Klrk1 was increased in aGvHD skin (6.42; p = 0.013), small (4.64; p < 0.0001) and 
large (3.67; p < 0.0001) compared to BM controls.  
 
On the other hand, the expression pattern of Rae1 showed a strong downregulation in aGvHD liver 
(0.05; p = 0.005), lung (0.02; p = 0.004), small (0.09; p < 0.0001) and large (0.1; p < 0.0001) 
intestines compared to healthy controls. This downregulation was in part, a result of 
preconditioning in the BM control liver (0.10; p = 0.006), lung (0.02; p < 0.0001), small (0.001; p 
< 0.0001) and large (0.05; p = 0.011) intestines compared to healthy controls. Interestingly, the 
expression of Rae1 was increased in the aGvHD small intestine (20.05; p = 0.048) compared to the 
BM controls (Figure 3.17B). In contrast, H60a showed a more complex expression pattern across 
the different mouse tissues. In aGvHD liver (3.7; p = 0.048), skin (2.94; p = 0.048) and large 
intestine (3.46; p = 0.048), the expression of H60a was significantly increased, in contrast to the 
lung (0.17; p = 0.048) and spleen (0.87; p = 0.048), where it was downregulated in comparison to 
healthy controls. However, preconditioning in BM control mice resulted in a significant increase in 
the expression of H60a in the liver (5.26; p = 0.003) but a downregulation in the lung (0.30; p = 
0.036) and small intestine (0.32; p = 0.05) (Figure 3.17C). 
 
Ulbp1 encoding MULT-1, showed a clear upregulation across all the tissues during aGvHD. The 
overall expression in aGvHD mice compared to healthy controls showed a significant increase in 
the regulation of Ulbp1 in the liver (4.46; p < 0.0001), lung (4.82; p < 0.0001) and spleen (1.87; p 
= 0.012) compared to healthy controls, and in aGvHD liver (2.14; p < 0.0001), skin (1.99; p = 
0.044), spleen (1.36; p = 0.04), small intestine (2.32; p = 0.037) and large intestine (1.39; p = 0.05) 
compared to BM controls. Moreover, the upregulation of Ulbp1 was also a result of 
preconditioning in BM control liver (2.08; p = 0.008) and lung (6.53; p = 0.008) compared to 










Figure 3.17: mRNA expression of Klrk1 and its ligands in different tissues in mice.             
Relative mRNA expression of A. Klrk1, B. Rae1 C. H60 D. Ulbp1, in aGvHD mice (n = 17) in comparison 
with normal healthy controls (n=15) (red), in aGvHD mice compared to BM control mice (n = 6) (blue) and 
preconditioning alone by comparing BM control mice to healthy controls (green). The y-axis shows relative 
expression (dCt), and x axis shows different mice groups in each tissue type. The P values were calculated by 
Mann-Whitney U-test, and were corrected for FDR by Benjamin Hochberg correction.                                  
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
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Gene expression of Klrk1 was not significantly regulated in any of the tissues in rats with aGvHD. 
However, a similar trend of increased pattern of Klrk1 mRNA expression was observed in the liver 
and skin, as was observed in mice (Figure 3.18A). Rrlt mRNA was also not regulated in any of the 
tissues (Figure 3.18C). However, Rae1l mRNA was upregulated significantly in the liver (185.78; 






Figure 3.18: mRNA expression of Klrk1 and its ligands in different tissues in rat.        
Relative mRNA expression of A. Klrk1 and its ligands, B. Rae1l and C. Rrlt in rats with aGvHD, (n = 6) on 
comparison with syngeneic controls (n = 6). The y-axis shows relative expression (dCt), and x-axis shows 
control rat and aGvHD expression in different tissues. The P-values were calculated by Mann-Whitney U-
test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
 
Overall, the Klrk1 mRNA was upregulated in all the tissues in the mice, but was not significant in 
the spleen. In the rats, the Klrk1 gene regulation was not statistically significant, however it showed 
a similar trend of upregulation as in the rat. The NKG2D ligands, Rae1 was significantly decreased 
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upregulated in all aGvHD mice tissues when compared to healthy controls or BM control mice. On 
the other hand, H60a had a mixed expression pattern in the different mice tissues, however, it was 
significantly regulated in all the mice aGvHD tissues. In the rat, Rae1l showed a mixed expression 
pattern in the different tissues, whereas the expression of Rrlt remained unchanged.  
 
3.3.5 Gene expression of Cd226 and its ligands in different tissues  
 
3.3.5.1 Mice 
The expression of Cd226 encoding DNAM-1 was also significantly upregulated in all the aGvHD 
mice tissues, liver (1; p = 0.003), lung (4.25; p = 0.006), skin (10.54; p < 0.0001), small (10.66; p 
< 0.0001) and large (4.89; p < 0.0001) intestines compared to healthy controls. We also observed a 
significant increase in the expression of Cd226 between aGvHD liver (1.44; p = 0.016), skin (9.16; 
p = 0.003), spleen (1.61; p = 0.027), small intestine (8.52; p < 0.0001) and large intestine (10.8; p 
< 0.0001) compared to BM controls (Figure 3.19A). Similarly, the DNAM-1 ligand, Pvrl2, 
encoding CD112, was also significantly upregulated in aGvHD liver (2.23; p < 0.0001), lung 
(2.43; p = 0.03), spleen (2.39; p = 0.001), small (2.83; p < 0.0001) and large (1.92; p = 0.003) 
intestines (Figure 3.19B). The increased expression of Pvrl2 was in part due to preconditioning in 
the BM control liver (1.79; p = 0.001), lung (3.84; p = 0.036) and spleen (4.65; p < 0.0001) 
compared to healthy controls. Furthermore, in the small intestine, we also observed a significant 
increase in the expression of Pvrl2 between the aGvHD mice and BM control mice (1.82; p = 
0.048). The expression of the other ligand Pvr encoding CD155, was also strongly upregulated in 
the aGvHD skin (2.56; p = 0.048), small (3.38; p = 0.048) and large intestine (1.41; p = 0.048) 
compared to healthy controls, as well as in the skin (8.32; p = 0.006) and large intestine (5.89; p = 



















Figure 3.19: mRNA expression of Cd226 and its ligands in different tissues in mice.     
Relative mRNA expression of A. Cd226, and its ligands B. Pvrl2 (CD112) and C. Pvr (CD155), in aGvHD 
mice (n = 17) in comparison with normal healthy controls (n=15) (red), in aGvHD mice compared to BM 
control mice (n = 6) (blue) and preconditioning alone by comparing BM control mice to healthy controls 
(green). The y-axis shows relative expression (dCt), and x axis shows different mice groups in each tissue 
type. The P values were calculated by Mann-Whitney U-test, and were corrected for FDR by Benjamin 
Hochberg correction.                                   
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to healthy controls)            
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (significantly regulated genes in aGvHD mice 
compared to BM controls)            
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Cd226 mRNA was not significantly regulated in any of the tissues, however a trend of increased 
expression of Cd226 was observed in the liver and skin, similar to that in mice (Figure 3.20A). 
Pvrl2 was significantly increased in the small intestine (2.87; p = 0.0077), however a trend of 
upregulation was observed in the liver, lung and skin as well (Figure 3.20B). No change in gene 
expression was observed in Pvr, in any of the rat aGvHD tissues, although a trend of upregulation 
was observed in all tissues similar to that in mice, except the liver (Figure 3.20C). 





Figure 3.20: mRNA expression of Cd226 and its ligands in different tissues in rats.          
Relative mRNA expression of A. Dnam-1 and its ligands, B. Pvrl2 and C. Pvr in rats with aGvHD, (n = 6) on 
comparison with syngeneic controls (n = 6). The y-axis shows relative expression (dCt), and x-axis shows 
control rat and aGvHD expression in different tissues. The P values were calculated by Mann-Whitney U-
test, and were corrected for FDR by Benjamin Hochberg correction.               
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 
 
In summary, we observed an upregulation of Cd226 and its ligands Pvrl2 and Pvr in the different 
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significantly upregulated in all the tissues except the skin, and Pvr was upregulated in three tissues. 
Similarly, in the rat aGvHD as well Cd226 and its ligands showed a trend of upregulation in all the 
tissues, however Pvrl2 was only significant in the small intestine.  
 
3.4 T cell infiltration in the small and large intestines during aGvHD 
On IHC staining, we observed infiltrating cells expressing CD3 in the small (Figure 3.21A) and 
large intestine (Figure 3.21B) biopsies during aGvHD. In the large intestine, we also observed 
substantial number of infiltrating T cells in the BM control, as a result of preconditioning. 
Moreover, the infiltrating T cells could explain the upregulation of several of our focus genes that 
are associated with T cell activation and cytokines and chemokines that are induced as a result of 
activation of T cells.   
In addition to T cell infiltration, we observed loss of crypts, and necrosis, both symptoms of severe 
aGvHD. The histological observations of the intestines are consistent with severe aGvHD in the 
intestines, which could also explain a more predominant expression of several genes in the 











Figure 3.21: CD3 staining of small and large intestines in mice.                 
A. CD3 immunohistological staining of healthy, bone marrow control and aGvHD small intestine in mice. B. 
CD3 immunohistological staining of healthy, bone marrow control and aGvHD small intestine in mice. The 
arrows show CD3 stained infiltrating cells in the tissues. 
 
3.5 Human aGvHD GI biopsies  
We studied gene expression of all the selected genes in human gastrointestinal biopsies (n=186). 
 
3.5.1 Patient Cohort 
The patient biopsies from different parts of the gastrointestinal tract (GI) were obtained from 
University Klinik Regensburg from Prof. Ernst Holler’s group. Patients underwent transplantation 
from Match 2009 till October 2013.  
Table 3.1: Patient characteristics 
Characteristics                  Values 
Recipients (n=186) 
 Median age, y 52 
Younger than 20 y, n (%) 4 (2.2) 
20 to 40 y, n (%) 32 (17.2) 
Older than 40 y, n (%) 150 (80.6) 
Male, n (%) 118 (63.4) 
Female, n (%) 68 (36.6) 






 Acute Myeloid Leukemia (AML), n (%) 78 (41.9) 
Acute Lymphoblastic Leukemia (ALL), n (%) 21 (11.3) 
Chronic Myeloid Leukemia (CML), n (%) 7 (3.8) 
Chronic Lympholytic Leukemia (CLL), n (%) 13 (7) 
Aplastic Anemia (AA), n (%) 6 (3.2) 
Myelodysplastic Syndrome (MDS), n (%) 24 (12.9) 
Non-Hodgkin's Lymphoma (NHL), n (%) 17 (9.1) 
Hodgkin Lymphoma (HL), n (%) 3 (1.6) 
Plasmocytoma (PC), n (%) 8 (4.3) 
Other diagnoses, n (%) 4 (2.2) 
Disease status for malignant disorders 
 Early, n (%) 46 (24.7) 
Intermediate, n (%) 64 (34.4) 
Advanced, n (%) 68 (36.6) 
ND, n (%) 8 (4.3) 
Donors (n = 186) 
 Median age, y 41 
Younger than 20 y, n (%) 7 (3.8) 
20 to 40 y, n (%) 70 (37.6) 
Older than 40 y, n (%) 109 (58.6) 
Male, n (%) 139 (74.7) 
Female, n (%) 47 (25.3) 
CMV-donor to CMV+ recipient, n (%) 36 (19.4) 
CMV+donor to CMV- recipient, n (%) 19 (10.2) 
Female donor to male recipient, n (%) 13 (16.7) 
HLA-matched unrelated donor, n (%) 127 (68.3) 
Related donor, n (%) 59 (31.7) 
Transplantation 
 Source of stem cells 
 Peripheral blood, n (%) 164 (88.2) 
Bone marrow, n (%) 21 (11.3) 
Cord blood, n (%) 1 (0.5) 
Conditioning 





Reduced intensity conditioning, n (%) 140 (75.3) 
ND, n (%) 11 (5.9) 
Treatment 
 Steroid > 20mg, n (%) 68 (36.6) 
ND, n (%) 49 (26.3) 
Outcome 
 No GvHD, n (%) 71 (38.2) 
Grade I to II, n (%) 75 (40.3) 
Grade III to IV n (%) 12 (6.4) 
ND, n (%) 28 (15.1) 
Transplant related mortality, n (%) 75 (40.3) 
 
3.5.2 Gene expression analysis during GI aGvHD in all patients 
We designed a step-wise regression model on R, to select covariates that affect the expression of 
the selected genes listed in Table 3.2. The regulation of genes was assessed for a number of 
variables such as GvHD incidence, TRM using a two-sample t-test for the multivariate analyses. 
Only the statistically significant p-values (p<0.05) for expression of genes have been shown and 
regulation of genes that are near significance (p<0.15). The size of the relative difference to the 
variation of the sample data is shown by t-values, where a t-value > 0 shows an upregulation of the 
gene and a t-value > 0 shows a downregulation of the gene.  
  
Table 3.2: Genes selected for gene expression study in human GI aGvHD. 
 Genes Selected Covariates (p < 0.05) Potential Covariates (p > 0.05) 
IL2   Type of conditioning Steroid treatment 
IL4  Stem cell source EBMT risk score 
IL4R   CMV risk   
IL5  Steroid treatment 
 
IL13   CMV risk Stem cell source 
IL33 Donor age EBMT risk score  
IL6 Type of conditioning Days after transplant CMV risk 
IL15 Stem cell source Days after transplant  
IL1R1 Type of conditioning     
  Stem cell source     
  Blood group     
IL1R2  Days after transplant Blood group 
TGFB1   Donor age   





TGFB2   CMV risk   
IL2RA Stem cell source Type of conditioning 
 
CCL4   EBMT risk score Stem cell source 
CCL5  Steroid treatment Donor age 
CCR1 Stem cell source     
CCR4  Stem cell source 
 
CCR5   CMV risk 
Type of 
conditioning 
CX3CR1 Steroid treatment   
CXCL10   Steroid treatment   
CXCL11  Days after transplant  
CXCL16   Steroid treatment   
CXCL8  Steroid treatment 
 
CXCL9       
CXCR3    
CXCR4   Steroid treatment   
ENPP1  Type of conditioning 
 




ICAM1 Stem cell source     
VCAM1 Steroid treatment 
 
 
ANP32A CMV risk Type of conditioning   
BMP1RA  EBMT risk score CMV risk 
C1QTNF7   Steroid treatment   
CARD11  EBMT risk score Donor age 
HCLS1   Steroid treatment Donor age 
HTRA1  Stem cell source Blood group 
LGALS7 Steroid treatment Days after transplant EBMT risk score 
LILRA5 EBMT risk score   
LST1   CMV risk   
MSR1 
 
Stem cell source 
Days after 
transplant 
PIK3AP1   Steroid treatment Stem cell source 
PSTPIP1  Donor age Stem cell source 
PTGER2   Type of conditioning EBMT risk score 
PTPN7 EBMT risk score   
  Blood group     
TAP1 Type of conditioning 
  
  Stem cell source     
TGM2 Type of conditioning Blood group  
TREM2   Steroid treatment   
UBD  Donor age  
KLRK1 EBMT risk score Days after transplant Blood group 
MICA EBMT risk score CMV risk 
 
MICB   Stem cell source   
ULBP1 CMV risk Blood group  
ULBP2       
ULBP3  Days after transplant 
 
CD226 Type of conditioning Days after transplant Steroid treatment 





PVRL2   Days after transplant   
Listed are genes and selected covariates that affect their expression during GI aGvHD in human biopsies.  
Steroid treatment - patients that received steroid vs. patients that received < 20mg/Kg or no steroids;                     
EBMT risk score – described in section 2.2.5.3, in Table 2.12;       
CMV risk – CMV- donor to CMV+ recipient (score = 2), CMV+ donor to CMV- recipient (score=1), both 
donor and recipient with same CMV status (score = 0).     
The selected covariates are statistically significant covariates that affect the expression of the 
specified gene. Based on the model specified, we calculated the gene expression for different 
specified variables. Interestingly, the expression of several genes from the previously identified 
candidate genes and Klrk1 and its ligands were affected by EBMT score. Other covariates that were 
found to be important were the type of conditioning, CMV risk, steroid treatment, type of 
conditioning regimen and source of stem cell. The days after transplant could be a potential 
covariate affecting the expression of several genes, however it was not selected as one of the more 
important ones. Our gene expression data has been analyzed with a multivariate analysis to 
compensate for all the selected covariates. 
 
3.5.2.1 Effect of clinical GI GvHD grade on gene expression patterns of the 
selected genes 
The patients were graded in the clinic based on symptoms exhibited by the patients such as rash on 
skin, blood in stool, diarrhea, etc. Here, we analyzed the gene expression in two patient groups,  
those that did not exhibit any clinical symptoms of aGvHD (grade 0) and patients with clinical 
aGvHD symptoms (grade 1 to 4). The gene expression was assessed based on the model described 
in section 2.2.5.2. The significant (p < 0.05) genes and nearly significant genes (p < 0.15) that show 












Table 3.3: Genes regulated in severe 
clinical aGvHD (grade 1-4) versus no 
aGvHD (grade 0) in patients. Genes 
significantly regulated (p < 0.05) based on 
clinical aGvHD in human GI biopsies. 
Additionally, genes that show a trend of 
significance ( p < 0.15; n.s.) are listed. t-values 
represent the size of the relative difference to 
variation of the sample data; t > 0 shows 

















32.8 % of the patients did not develop clinical aGvHD symptoms, whereas 46.7 % of the patients 
exhibited grade 1-4 aGvHD. Several genes were significantly upregulated in clinical GI aGvHD 
compared to patients without aGvHD, including the adhesion molecule, VCAM1 and the cytokines 
IL2 and IL6. However, we observed a more significant pattern in the expression of chemokines 
receptors, CCR1, CCR4, CCR5, CXCR3 and CXCR4 and the chemokine ligand CCL4. 
It could be that the clinical symptoms are associated with a more dominant tissue-mediated 
chemokine response, due to tissue injury in the gut, in addition to infiltrating immune cells. In 
addition several genes associated with B and T cell activation, HCLS1, CARD11, PIK3AP1, LST1, 
FCER1G and FCGR3 were significantly increased, suggesting an infiltration of B and T cells in the 
gut and an activation of alloreactive cells during aGvHD. Interestingly, TGFB1 was increased 
significantly. It has been shown previously that Treg expression is induced in the gut in the presence 
Genes t-value p-value ( < 0.05) 
HCLS1 4.101 0.00008 
IL2 3.04 0.002 
CCR5 3.007 0.003 
FCGR3 2.886 0.004 
CXCR3 2.815 0.005 
CCR4 2.789 0.006 
TGFB1 2.672 0.008 
CCR1 2.652 0.009 
IL6 2.496 0.014 
C1QTNF7 2.44 0.014 
CXCR4 2.374 0.016 
CCL4 2.322 0.019 
VCAM1 2.280 0.022 
FCER1G 2.277 0.024 
CARD11 2.225 0.028 
PIK3AP1 2.1 0.038 
LST1 2.055 0.042 
    
p-value  
(<0.15; n.s.) 
PTGER2 1.925 0.057 
IL2RA 1.908 0.059 
IL1R1 -1.844 0.062 
HTRA1 -1.836 0.076 
MSR1 -1.786 0.091 
PSTPIP1 1.55 0.124 
MICB 1.503 0.135 





of  TGF-β (Cobbold et al., 2004). We also found an increase IL2RA (n.s) in the intestinal biopsies, 
suggesting the expansion of iTregs during aGvHD in the gut.  
 
3.5.2.2   Effect of histological aGvHD score on gene expression patterns of the 
selected genes 
Clinical scoring of patients that experience GI GvHD is not absolutely reliable for determining the 
extent of aGvHD in the gut, since the clinical scoring involves scoring of other organs such as rash 
on the skin, and other immeasurable symptoms such as blood in stool, vomiting and diarrhea. 
Therefore, the biopsies are further graded histologically in the clinic, from grade 0 to 4, representing 
a more accurate extent of aGvHD in the gut. It is important to note, therefore that the clinical and 
histological scoring defers greatly (p=0.959, R
2
=0.004), however, both scoring systems are equally 
important. The gene expression was assessed based on the model described in section 3.5.1. Genes 
regulated during histological aGvHD are listed in Tables 3.4 and 3.5. 
 
3.5.2.2.1 Histological aGvHD grades 1-4 versus no aGvHD 
The genes regulated between histological aGvHD grades 1-4 versus no aGvHD (grade 0) were 
assessed.  
 
Table 3.4: Genes regulated in histological 
GI aGvHD (grade 1-4) versus no aGvHD 
in patients. Genes significantly regulated (p < 
0.05) based on histological aGvHD in human GI 
biopsies. Additionally, genes that show a trend 
of significance ( p < 0.15; n.s.) are listed. t-
values represent the size of the relative 
difference to variation of the sample data; t 




The gene expression during aGvHD (histologically scored) was biased towards genes regulated by T 
and B cells. A significant downregulation in the IL2RA (CD25) was observed. CD25 is present on a 
number of immune cells, including Tregs. Moreover, we observed a downregulation of other genes 
 
 
t-value p-value ( < 0.05) 





CCL4 -1.977 0.051 
CXCR4 -1.957 0.053 
CARD11 1.914 0.059 
FCGR3 -1.745 0.084 
ANP32A 1.635 0.105 
PSTPIP1 -1.63 0.106 
CCR4 -1.629 0.107 





associated with T and B cells, CCL4, CCR4, PSTPIP1 and CARD11, whereas genes associated with 
innate immune responses, ANP32A and LGALS7 were increased.  
 
3.5.2.2.2 Histological aGvHD grades 2-4 versus no or low aGvHD (grades 0-1) 
The genes regulated between histological aGvHD grades 2-4 versus no or low aGvHD (grade 0-1) 
were assessed.  
Table 3.5: Genes regulated in severe 
histological GI aGvHD (grade 2-4) versus 
no or low aGvHD (grade 0-1) in patients.   
Genes significantly regulated (p < 0.05) based on 
histological aGvHD in human GI biopsies. 
Additionally, genes that show a trend of 
significance ( p < 0.15; n.s.) are listed. t-values 
represent the size of the relative difference to 
variation of the sample data; t > 0 shows 
upregulation and t < 0 shows downregulation. 
 
 
Severe aGvHD was associated with a decrease in the gene expression of the chemokines CXCL8 and 
CCL4 were significantly decreased, but an increase in the expression of chemokine receptor, 
CX3CR1 and CXCL16 mRNA were significantly increased.  Moreover, the NKG2D ligand, ULBP3 
was significantly upregulated.  
Taken together, we observed that overall aGvHD (grades 1-4) was associated with an increase in 
genes associated with B and T cell activation, whereas severe aGvHD compared to a low aGvHD 
grade represents a gene regulation pattern associated with innate immune responses, possibly as a 




Genes t-value p-value ( < 0.05) 
CXCL8 -3.144 0.002 
CCL4 -3.047 0.003 
CX3CR1 2.453 0.016 
CXCL16 2.275 0.025 
ULBP3 2.111 0.037 
ENPP1 -1.985 0.05 





PSTPIP1 -1.862 0.066 
CXCL9 -1.76 0.082 
IL2RA -1.709 0.091 
TAP1 -1.677 0.097 





3.5.2.3 Effect of gene regulation on transplant related mortality (TRM) in 
HSCT patients 
The effect of gene regulation on transplant related mortality was studied. We compared patients who 
died due to transplant related causes to patients who were still alive or died due to unrelated causes 
such as relapse (Table 3.6). Since 40.3 % of the patients died due transplant related causes, it is 
possible that they exhibit a different pattern in the expression of certain genes that could be 
associated with risk of death.  
 
Table 3.6: Effect of gene regulation on 
TRM in HSCT patients. Genes significantly 
regulated (p < 0.05) in patients that died due to 
transplant and patients who died due to other 
causes and patients who are still alive. 
Additionally, genes that show a trend of 
significance ( p < 0.15; n.s.) are listed. t-values 
represent the size of the relative difference to 
variation of the sample data; t > 0 shows 
upregulation and t < 0 shows downregulation. 
 
The mRNA expression of the chemokine receptor, CX3CR1 was significantly higher in patients that 
died due to TRM, compared to patients that died due to other causes or were still alive. Furthermore, 
CXCL8, IL1R1, LGALS7 and the DNAM-1 ligand, PVRL2 were also increased in those patients, 
though they did not reach statistical significance (Table 3.6). Interestingly, the expression of 
CX3CR1was increased in severe aGvHD as well, suggesting a correlation between extent of disease 
and death, however the expression of CXCL8 was contrary to that, whereby an increased expression 
was associated with death, however the aGvHD severity was associated with a reduced mRNA 
expression. 
  
3.5.2.4   Effect of time period after transplant (< 100 days and > 100 days) on 
gene expression patterns of the selected genes 
Here we studied the gene expression patterns in biopsies that were taken at a later time point after 
transplant (>100 days) compared to biopsies that were taken <100 days after transplant. The time 
period between transplant and day the biopsy was taken could be considered to be correlated with 
Genes t-value p-value ( < 0.05) 
CX3CR1 1.998 0.048 
    p-value (<0.15) 
PVRL2 1.844 0.068 
CXCL10 -1.798 0.075 
CXCL8 1.716 0.089 
IL1R1 1.466 0.146 





either severity of the disease, or delayed aGvHD onset. It would be interesting to determine the 
expression patterns of genes that could be associated with this delayed onset. 
 
Table 3.7: Gene regulation based on time 
of biopsy taken post transplant.                       
Genes significantly regulated (p < 0.05) in 
biopsies taken < day 100 post transplant and 
biopsies taken > 100 days. Additionally, genes 
that show a trend of significance ( p < 0.15; n.s.) 
are listed. t-values represent the size of the 
relative difference to variation of the sample 
data; t > 0 shows upregulation and t < 0 shows 
downregulation. 
 
The time of biopsy after transplant did not affect the gene expression patterns strongly. Most genes 
were not regulated, however we observed a downregulation of the Th2 cytokine IL33 in biopsies 
that were taken at a later time point. In addition, HCLS1 and the NK receptor CD226 were also 
reduced but were not significant.  
 
3.5.3 Gene expression in patients with no steroid* treatment  
In order to eliminate the effects of steroid treatment on the gene regulation in the patient biopsies, 
we separated the patients that were not treated with steroids or those who were treated with a dosage 
of ≤ 20 mg/kg steroids (n=69), from those who underwent steroid treatment. This cut off value for 
the two groups was pre-defined by clinicians. Within the group of patients with no steroid (or low) 
treatment, we studied the changes in gene expression patterns based on the different variables.  
* 






Genes t-value p-value ( < 0.05) 
IL33 -2.400 0.018 
  
p-value (<0.15) 
CXCL16 1.647 0.120 
CXCL8 -1.522 0.130 









3.5.3.1   Effect of clinical GI GvHD grade on gene expression patterns of the 
selected genes in patients with no steroid treatment
*
 
In table 3.8, we compared the gene expression during clinical GI aGvHD in patients with no or less 
steroids. Several genes were significantly increased based on the clinical scores in patients with 
aGvHD. Genes that were most strongly regulated were the chemokine receptors, CCR5, CCR4, 
CCR1 and CXCR3. In addition, CXCR4 and the chemokines CCL4, CCL5 and CXCL8 were 
significantly increased. The Th1 and Th2 cytokines IL2 and IL6 respectively were also increased. 
Other regulated genes included genes associated with activation and regulation of Tregs, IL2RA and  
TGFB1, genes associated with activation of B and T cells, PSTPIP1, PIK3AP1, PTPN7, HCLS1, 
FCGR3 and FCER1G and genes regulated by IFN-γ, LST1 and MSR1.   
Considering most of these genes are not regulated based on the histological scores, it is perceivable 
that these genes are important for the clinical symptoms in patients such as skin rash, weight loss 
etc., most likely due to inflammation, and a heightened immune response post transplant. Activation 
of alloreactive T cells and infiltration of T cells in the GI tissue, as a result of inflammation, explains 
the heightened clinical symptoms. Most of the regulated genes were also regulated in patients with 
steroids (Table 3.4), suggesting that the administration of steroids had no or little effect on the 
regulation of these genes. The main difference between the two groups was in the regulation of 
MSR1, the macrophage scavenger receptor 1. It could be that infiltration of macrophages in the GI 















Table 3.8: Genes regulated in clinically 
scored GI aGvHD (grade 1-4) biopsies 
versus no aGvHD (grade 0) in patients 
with no steroids*. Genes significantly 
regulated (p < 0.05) based on histological aGvHD 
in human GI biopsies. Additionally, genes that 
show a trend of significance ( p < 0.15; n.s.) are 
listed. t-values represent the size of the relative 
difference to variation of the sample data; t > 0 
shows upregulation and t < 0 shows 
downregulation. 
*
Patient group consisting of 
patients who were treated with a 20 mg/kg or less 


















Genes t-value p-value ( < 0.05) 
CCR5 3.482 0.0006 
CCR4 3.478 0.0006 
CXCR3 3.416 0.0008 
CCR1 3.314 0.0012 
FCGR3 3.257 0.0014 
HCLS1 2.948 0.0037 
TGFB1 2.862 0.0048 
FCER1G 2.861 0.0048 
IL2RA 2.746 0.0067 
VCAM1 2.726 0.007 
MSR1 2.703 0.008 
IL6 2.631 0.009 
LST1 2.583 0.011 
IL2 2.464 0.014 
CXCR4 2.241 0.026 
CCL4 2.221 0.028 
CXCL8 2.123 0.035 
PIK3AP1 2.117 0.036 
PTPN7 2.106 0.041 
HTRA1 2.052 0.042 
CCL5 2.051 0.042 
PSTPIP1 2.049 0.042 
    p-value (<0.15) 
C1QTNF7 1.78 0.077 
IL15 1.67 0.097 
UBD 1.5 0.13 





3.5.3.2   Effect of histological aGvHD score on gene expression patterns of the 
selected genes in patients with no steroid treatment
*
 
3.5.3.2.1 Histological aGvHD grades 2-4 versus no or low aGvHD (grades 0-1) 
Table 3.9: Genes regulated in severe 
histological GI aGvHD (grade 2-4) versus 
no or low aGvHD (grade 0-1) in patients 
with no steroids*. Genes significantly regulated 
(p < 0.05) based on histological aGvHD in human 
GI biopsies. Additionally, genes that show a trend 
of significance ( p < 0.15; n.s.) are listed. t-values 
represent the size of the relative difference to 
variation of the sample data; t > 0 shows 
upregulation and t < 0 shows downregulation. 
*
Patients group consisting of patients who were 
treated with a 20 mg/kg or less steroid dosage and 
those who were not treated with steroids. 
 
Since the administration of steroids in patients, as part of treatment post-transplant has a significant 
effect on the gene expression, we studied the regulation of our selected genes in patients that were 
not given steroids. In patient biopsies with histological grade 2-4, we observed a significant 
upregulation of the Th2 cytokine, IL4 and the chemokines and chemokine receptor, CX3CR1 and 
CXCL16 respectively. The chemokines CCL4 and CXCL8, and PSTPIP1 were decreased in patients 
with severe aGvHD. Moreover, LILRA5, CXCR4 and CXCL9 were decreased in patients with severe 
aGvHD but did not reach statistical significance (Table 3.9). Interestingly, these genes were 
regulated in the same way even in the presence of steroids, suggesting that the presence of steroids 
did not have a significant effect on these genes. On the other hand, the genes ENPP1 and the 
NKG2D ligand, ULBP3 were significantly regulated in the presence of steroids (Table 3.5).  
No significant changes in the expression of genes were observed in this subgroup analysis between 





Genes t-value p-value ( < 0.05) 
CX3CR1 3.173 0.0018 
CXCL8 -2.988 0.003 
CCL4 -2.638 0.009 
CXCL16 2.159 0.032 
IL4 2.058 0.041 
PSTPIP1 -1.973 0.05 
    p-value (<0.15) 
LILRA5 -1.914 0.057 
CXCR4 -1.612 0.109 





3.5.3.3   Effect of gene regulation on transplant related mortality (TRM) in 





Table 3.10: Effect of gene regulation on 
TRM in patients with no steroids. Genes 
significantly regulated (p < 0.05) based on 
histological aGvHD in human GI biopsies. 
Additionally, genes that show a trend of 
significance ( p < 0.15; n.s.) are listed. t-values 
represent the size of the relative difference to 
variation of the sample data; t > 0 shows 
upregulation and t < 0 shows downregulation. 
* 
Patients group consisting of patients who were 
treated with a 20 mg/kg or less steroid dosage and 
those who were not treated with steroids. 
 
 
The presence of steroids had a significant effect on regulation of genes associated with TRM. 
Several genes were regulated differently in patients that died due to transplant when no steroids 
were administered. The DNAM-1 ligand, PVRL2 was higher in patients that died due to transplant 
compared to patients that were still alive or those that died due to other causes. Moreover, several 
genes associated with innate immune responses, such as C1QTNF7, LGALS7 and HTRA1 were also 
increased. The expression of several genes that were associated with clinical aGvHD symptoms in 
patients (Table 3.8), were also correlated with death due to transplant, such as HTRA1, CXCL8, 
TGFB1, IL2RA and PSTPIP1 (Table 3.10).  
 
3.5.4 Regulation of NK receptors and their ligands during clinical GI aGvHD 
To determine how the genes KLRK1, CD226 and their ligands are regulated in aGvHD in humans, 
we analyzed the gene expression of these genes as univariate analysis.  
 
 
Genes t-value p-value ( < 0.05) 
LGALS7 2.711 0.007 
PVRL2 2.538            0.012 
IL1R1 2.474 0.014 
CXCL8 2.466 0.0148 
C1QTNF7 2.194 0.029 
HTRA1 2.103 0.036 
TGFB1 2.05 0.041 
    p-value (<0.15) 
IL2RA 1.91 0.058 
CCL4 1.819 0.07 
TGFB2 1.702 0.09 
IL1R2 1.592 0.113 
CCR4 1.567 0.119 
PSTPIP1 1.477 0.141 









Figure 3.22: Gene expression of KLRK1 (NKG2D) and its ligands in clinical GI aGvHD 
biopsies.                                 
Regulation of genes in human GI aGvHD (grades 1-4) compared to patients with no GvHD (grade 0). None of 
the genes reached statistical significance. A. KLRK1 (p=0.548) B. MICA (p=0.505) C. MICB (p=0.049)  D. 
ULBP1 (p=0.828) E. ULBP2 (p=0.972) F. ULBP3 (p=0.322)  
KLRK1 mRNA expression was upregulated during aGvHD in patients, but was not statistically 
significant. We observed differential expression patterns of its ligands, of which MICB was 
significantly downregulated. 
 
3.5.4.2   Regulation of CD226 and its ligands in clinical GI aGvHD 
   
Figure 3.23: Gene expression of CD226 and its ligands in clinical GI aGvHD biopsies.         








































































































































the genes reached statistical significance. Increased mRNA expression of A. CD226 (p=0.394) B. PVRL2 
(p=0.471) and C. PVR (p=0.59) were observed. 
The expression of CD226 and its ligands was not statistically different, but a trend of 
downregulation was observed a trend of upregulation of CD226, which followed a similar trend in 
expression as in the mouse during aGvHD.   
 
3.5.4.3   Effect of regulation of KLRK1, CD226 and their ligands on TRM in 
HSCT patients with clinical GI aGvHD 
 
A              B 
  
Figure 3.24: Effect of gene regulation of KLRK1, CD226 and their ligands on TRM in human 
GI aGvHD.                  
The p-values and fold changes are shown for all the genes, however only the significant results are plotted in 
the graphs.  Increased mRNA expression of A. MICA and downregulation of B. PVRL2 was observed in 
patients that died due to TRM compared to patients who are still alive or died due to unrelated causes (others). 
On performing a univariate analysis on the expression of NK receptor genes and their ligands in 
patients, we observed that patients who died due to transplant related causes had a higher expression 
of MICA and a lower PVRL2 expression compared to patients that were still alive or those who died 

































Table 3.11: Effect of gene regulation of 
KLRK1, CD226 and their ligands on TRM 
in clinical GI aGvHD. Genes significantly 
regulated (p < 0.05) based on histological aGvHD 
in human GI biopsies. Additionally, genes that 
show a trend of significance ( p > 0.05; n.s.) are 
listed. t-values represent the size of the relative 
difference to variation of the sample data; t > 0 




3.5.4.4   Effect of steroids on the regulation of KLRK1, CD226 and their 
ligands in clinical GI aGvHD 
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Genes Fold change p-value ( < 0.05) 
MICA 5.15 0.027 
PVRL2 0.84         0.009 
   
p-value  
(>0.05; n.s.) 
KLRK1 1.66 0.647 
MICB 2.22 0.548 
CD226 0.47 0.974 
ULBP1 0.113 0.592 
ULBP2 0.119 0.567 





Figure 3.25: Effect of steroid on gene expression of KLRK1, CD226 and their ligands in human 
GI aGvHD.                  
The p-values and fold changes are shown for all the genes, however only the significant results are plotted in 
the graphs. Increased mRNA expression of A. MICA and downregulation of B. ULBP1, C. CD226 and D. 
PVR was observed in patients that were treated with steroids compared to patients who were not treatment 
with steroids.  
 
In patients that were treated with steroids, we observed a higher mRNA expression of MICA and a 
lower expression of ULBP1, compared to patients that were not given steroids as part of treatment 
after transplant. Similarly, patients who received steroids also showed a significant reduction in the 




Table 3.12: Effect of steroids on the 
regulation of KLRK1, CD226 and their 
ligands in clinical GI aGvHD. Genes 
significantly regulated (p < 0.05) in patients who 
were treated with steroids compared to those 
who were not treated with steroids. Additionally, 
genes that show a trend of significance ( p < 
0.05; n.s.) are listed. t-values represent the size 
of the relative difference to variation of the 








Genes Fold change p-value ( < 0.05) 
MICA  2.84 0.019 
ULBP1 0.22         0.022 
CD226 0.29 0.05 
PVR 0.62 0.0001 
    
p-value  
(> 0.05; n.s.) 
KLRK1 2.84 0.682 
MICB 0.22 0.126 
ULBP2 0.62 0.229 
ULBP3 2.84 0.603 






4.1 Comparison of gene expression in different target organs of the same 
species 
 
4.1.1 Comparison of genes associated with different immune responses in the 
different aGvHD mouse target tissues compared to healthy controls 
We compared the differences in regulation patterns of cytokine and chemokine genes associated 
with the different immune responses in the mouse tissues affected by aGvHD, compared to healthy 
control tissues. In Figure 4.1, the hierarchical cluster shows two distinct groups; the first group 
depicts a close relationship between gene expression patterns in the small and large intestine 
(p<0.0001, R
2
=0.5619) followed by the spleen (p=0.003, R
2
=0.3275) and lung (p=0.048, 
R
2
=0.056), whereas the second group shows the expression patterns between the skin and liver 
(p=0.0411, R
2
=0.059) followed a similar pattern of expression. A number of genes were similarly 
regulated in the different tissues. Several genes were upregulated in all the tissues in mice with 
aGvHD compared to healthy control mice, such as Ifng, Il2ra, Il6 and Ccr1, whereas a number of 
genes were downregulated in the different tissues, such as Ccl5, Cx3cl1, Tgfb2 and Cxcr4. Other 
genes were found to be regulated in the same direction in all but one tissue, or in some instances 
showed a mixed pattern of expression. For example, Cxcr3 was significantly upregulated in mice 
with aGvHD in all the tissues, but was downregulated in the liver, compared to healthy controls.  
 
Overall, we observed that in mouse aGvHD, the Th1, Th2 and Th17 cytokines were mostly 
regulated predominantly in the lung and large intestine of aGvHD mice compared to controls. 
Moreover, the genes associated with Tregs were also significantly regulated mainly in the liver, 
lung and both small and large intestines. The trend in expression was similar in the different 
tissues, whereby a significantly increased Th1, Th2 and Th17 cytokine expression, in addition to an 








Figure 4.1: Hierarchical cluster of genes associated with immune responses in the different 
tissues of mouse aGvHD compared to healthy controls.                                         
The x-axis represents cluster of gene expression patterns in different tissues. The y-axis represents clusters of 
regulated genes during aGvHD. The tissues are clustered in two main groups; large and small intestine, lung 
and spleen versus liver and skin. The color key represents the scaled fold changes from -2 (downregulated) to 
+2 (upregulated). All fold change values are shown (even those with p-value = ns) 
 
Interestingly, the expression patterns of the chemokines and their receptors were more consistent in 
the different target organs. The chemokines Cxcl9, Cxcl10 and Cxcl11 were mostly regulated in all 

















































Cxcr3 (Bouazzaoui et al., 2009) and its ligands, Cxcl9, Cxcl10 and Cxcl11 are increased in mouse 
liver during aGvHD (Sadeghi et al. 2013; Ichiba et al. 2003). Our results were in line with the 
previous data. CXCR-3 is expressed on T cells and is important in recruitment of lymphocytes, and 
its ligands, CXCL-9, -10 and -11 are induced by IFN-γ and TNF-α (Groom and Luster, 2011) and 
are involved in recruiting leukocytes expressing CXCR-3 to sites of inflammation (Baggiolini, 
1998; Flier et al., 2001). CXCL-9 is expressed by effector CD4
+
 Th1 cells and CD8
+
 CTLs, and 
affects the migration of effector T cells to inflamed tissue during progression of GvHD (Groom and 
Luster, 2011).  
 
Moreover, the conditioning regimens significantly altered the expression of several chemokines, 
however the cytokines remained unchanged. Several chemokine receptors such as Ccr1, Ccr4, 
Ccr5, Cxcr4, Cx3cr1 and chemokines Ccl4, Ccl5 and Ccl9 were regulated due to the 
preconditioning, and their regulation was further augmented due to aGvHD. CCL-4, CCL-5 
(RANTES) and CCL-9 are expressed by several different cell types such as T cells, NK cells, 
endothelial cells, epithelial cells, fibroblasts, neutrophils and APCs, and are associated with Th1 
type responses. They bind to their receptors CCR-1, CCR-4 and CCR-5 that are expressed on NK 
cells, T cells, macrophages and DCs (Wysocki et al., 2005a). These chemokines are induced by 
inflammatory cytokines such as IFN-γ and TNF-α (Moser et al., 2004). CCR-5 serves as a co-
receptor for HIV infection (Liu et al., 1996) and is associated with Th1 responses (Sallusto et al., 
1998), whereas CCR-4 is expressed by Th2 cells (Campbell et al., 1999; Sallusto et al., 1998). 
Interestingly, Ccr1, Ccr5, Ccl4 and Ccl9 were significantly increased in the different mouse 
aGvHD tissues compared to healthy controls, whereas, the expression of Ccr4 and Ccl5 was 
significantly downregulated.  
 
Similarly, the expression of Cxcl16 was significantly increased in the aGvHD mouse compared to 
the controls, however Cxcl15 and Cxcr4 were significantly reduced. CXCL-16 is expressed both on 
lymphoid and non-lymphoid tissues (Wysocki et al., 2005a). CXCR-4 is a chemokine receptor that 
binds to its ligand CXCL-12 or stromal derived factor-1 (SDF-1) that is involved in trafficking of 
hematopoietic stem cells (Moll and Ransohoff, 2010). Increased CXCR-4 expression could result 
in better engraftment (Brenner et al., 2004), suggesting that an increased Cxcr4 expression is 
beneficial for an attenuated aGvHD response. High levels of CX3CL1 have been associated with 
intestinal damage due to recruitment of CD8
+
 T cells to the intestine during aGvHD (Ueha et al., 
2007). A reduction of CD8
+
 T cells was observed on administration of a CX3CL1 antibody, which 
was associated with improved survival rates and reduced aGvHD (Ueha et al., 2007). However, we 
observed a downregulation of Cx3cl1 in mice with aGvHD compared to the BM controls, whereas 
its receptor, Cx3cr1 was significantly increased in aGvHD tissues compared to the BM control 





to the healthy controls. ICAM1 is an adhesion molecule expressed on endothelial cells and are 
critical for the migration of leukocytes to tissues during inflammation (Ren et al., 2010). IL-15 is a 
critical mediator for T cell function during aGvHD (Blaser et al., 2005). In aGvHD affected tissues, 
we observed Il15 to be downregulated compared to healthy controls.  
 
Several gene expression profiling studies have been carried out to determine the expression 
patterns of cytokines and chemokines previously (Jaksch et al., 2005; Poloni et al., 2011; Tanaka et 
al., 1995). Our study highlights the differences in the gene expression patterns between the 
different target aGvHD tissues in mouse with aGvHD. An important aspect of our findings is that 
mice with aGvHD had an exacerbated chemokine regulation, in addition to the proinflammatory 
cytokines. Thus aGvHD in the mouse tissues was associated with a stronger regulation in the 
chemokine genes across the different tissues, compared to several cytokines.   
 
Furthermore, we observed a distinct expression pattern of the genes associated with Tregs. In the 
large intestine, we observed an upregulation of most Treg associated genes such as Foxp3, Il2ra, 
Il10, Ido1, Arg1, Tgfb1, Il1rl2 and Lgals3 in aGvHD mouse compared to healthy controls or BM 
controls. Moreover, several genes were also significantly upregulated in the liver, lung and small 
intestine, including Il2ra, Arg1, Ido1, Il1rl2 and Tgfb1. Aside from the presence of Foxp3 mRNA, 
which is the marker for Tregs, the regulation of the other genes associated with Tregs were strongly 
indicative of an expanding Treg population in the different target tissues, mainly the large intestine.  
These genes included Il2ra, encoding Cd25, which is expressed by Tregs and activated T cells and 
Il1rl2 and Lglas3 which are expressed on human Treg subsets (Ocklenburg et al. 2006, Pfoertner et 
al. 2006). LGALS3 can change the cytokine profile of T cells and is therefore involved in regulated 
effector cells and homeostasis of immune cells (Demetriou et al., 2001). Furthermore, Ido1 is 
linked to the differentiation of Tregs and contribute to their suppressive capacity. IDO-1 is 
constitutively expressed in the GvHD target organs, lung and intestine, and can be up regulated due 
to inflammation (Jasperson et al., 2009).  
 
Furthermore, ARG-1, another metabolic enzyme is activated during inflammation and reduces T 
cell responses at the sites of inflammation (Highfill et al., 2010; Rodriguez et al., 2004) and is 
important in Treg function. Arginase activity is increased by IL-10. Furthermore bone marrow 
myeloid-derived stem cells (MDSCs) inhibit GvHD in mouse via an arginase-1 dependent 
mechanism that is upregulated by IL-13 (Highfill et al., 2010). Finally, we observed an increased 
mRNA expression of the chemokine receptor Ccr5, in the different tissues. Ccr5 is a chemotactic 
receptor for Tregs, and is involved in regulating the balance between Tregs and Th17 cells in sites 





of a Treg population at sites of tissue inflammation. Based on our results, we postulate that the 
increasing Treg population is indeed iTregs.   
 
The expression of Treg markers and other genes associated with the activation and regulation of 
Tregs in these tissues, suggest a possible infiltration of T cells, and specifically Tregs in the tissue 
sites of Foxp3 mRNA expression. This could be due to an increased need for the suppressive 
function of Tregs in response an increased inflammation as a result of tissue injury in the large 
intestine. Our results are similar to previous results that found Foxp3
+
 cells to be increased in 
intestinal mucosa during aGvHD (Lord et al., 2011), as well as in patients with a more severe grade 
of GvHD (Ratajczak et al., 2010). On the other hand, previously several reports showed an inverse 
relationship between expression of Foxp3 mRNA and progression of GvHD. For example, a 
decreased Treg frequency was observed in patients that had severe aGvHD or incidence of cGvHD 
(Magenau et al., 2010; Li et al. 2010; Zorn et al. 2005). Similarly, increase in the number of donor 
Tregs were associated with a lower incidence of cGvHD (Miura et al., 2004) and aGvHD severity 
(Miura et al. 2004; Wolf et al. 2007; Rezvani et al. 2006). Furthermore, the mRNA expression of 
FOXP3 was increased in patients there were responsive to anti-GvHD therapies (Cuzzola et al. 
2012), and inducing selective expansion of Tregs by the daily administration of low doses of IL-2, 
showed an improvement in clinical cGvHD symptoms in patients (Koreth et al., 2011).  An 
explanation for the contradictory results could be due to the inability to discriminate between 
natural and induced Tregs. It is likely that natural Tregs are decreased during aGvHD, which could 
explain the therapeutic effects of administered Tregs to reduce GvHD. On the other hand, the 
increase in Foxp3 mRNA seen in our study in aGvHD mouse compared to healthy and BM 
controls, as well as previous reports during aGvHD (Lord et al. 2011; Ratajczak et al. 2010), could 
be due to an increase in induced Treg population. We hypothesize that the depletion of natural 
Tregs could cause the tissues to induce Tregs that rapidly expand to compensate for the 
exacerbated inflammation. Perhaps, it is this induced Treg population that we most likely observe 
in the large intestine. It would be interesting to distinguish the Treg populations in the large 
intestine, which would give us a more comprehensive explanation about the pathology in the 
intestine during aGvHD.  
 
Further evidence of a potential iTreg expression in the gut, is the increase in Tgfb1 and Tgfb2 
mRNA expression. Since iTreg are induced in the presence of TGF-β (Cobbold et al., 2004), and 
the TGF-β induced Tregs are more stable and functional than nTregs in mice with established 
autoimmunity (Kong et al., 2012), it may as well be that during aGvHD, an expansion of iTregs is 
observed in relation with an increased aGvHD response, perhaps to compensate for a decrease in 
nTreg population. Moreover, it is likely that this mechanism is expansion is mainly tissue 





The differences in the regulation of genes in different target organs can primarily be attributed to 
the difference in their expression under normal conditions. Transcriptional patterns and biological 
processes shared by certain organs could also explain the similarities and differences in gene 
regulation. Also, genes that are highly correlated or co-expressed possibly belong to the same 
functional pathway (Stuart et al., 2003). The pathogenesis of aGvHD mainly involves the skin, 
lung, liver and gastrointestinal tract. We already observed differences in genes expressed in the 
target organs in the mouse compared to the spleen, which is not a major target of aGvHD. An 
interesting example was the difference in the regulation of Th1 associated cytokines, which are 
considered the key regulators of aGvHD. Th1 cytokines, Il2, Tnf and Il12a were increased in the 
aGvHD target organs, whereas they were significantly decreased in the spleen.  
In summary, we observed an upregulation of Th1, Th2, Th17 and Treg responses in the different 
tissues. Several chemokines were also significantly regulated. Many genes showed similarities in 
their regulation patterns in the different tissues, including Ifng, Il6, Il2ra, Ccr1, Ccl4, Il4 and Icam1 
which were upregulated in all the different tissues and Ccl5, Cx3cl1, Tgfb2, Tnf, Enpp1 and Cxcr4 
that were decreased in all the tissues.  
 
4.1.2 Comparison of previously identified candidate genes in the different 
aGvHD target tissues in mouse and rats 
 
In Figure 4.2, the expression patterns of the previously identified candidate genes were similar in 
the small intestine and spleen, followed by the large intestine, liver and then lung and skin. 
However, it is interesting to note that several genes were regulated in the same direction in the 
different tissues. Several genes such as Lst1, Msr1, Lilra5, Tgm2 and most importantly Ubd and 
Hcls1 were upregulated in all the aGvHD tissues compared to healthy controls. LST1 is encoded 
within the class III region of the MHC, (de Baey et al., 1997) and is implicated in inflammatory 
and infectious diseases (Mulcahy et al., 2006). It has previously been reported that MSR1 is 
involved in the regulation of anti-inflammatory responses (Fulton et al., 2006).  In addition, 
LILRA5 is an activating receptor expressed on immune cells and is associated with the release of 
pro-inflammatory cytokines. (Brown et al., 2004). Moreover, UBD is a downstream regulator of 
Tregs (Ocklenburg et al., 2006). These genes are all associated with inflammation and thereby 







                 A             Mouse aGvHD  B              Rat aGvHD 
 
Figure 4.2: Hierarchical cluster of candidate genes in different tissues of mouse and rat 
aGvHD.               
A. Gene expression patterns of candidate genes in different mouse aGvHD tissues compared to healthy control 
mouse B. Gene expression patterns of candidate genes in different rat aGvHD tissues compared to syngeneic 
mouse. The x-axis represents cluster of gene expression patterns in different tissues. The y-axis represents 
clusters of regulated genes during aGvHD. The color key represents the scaled fold changes from -2 
(downregulated) to +2 (upregulated). All fold change values are shown (even those with p-value = ns) 
 
Several of these genes are known to be regulated by IFN-γ, therefore are induced as a consequence 
of inflammation. More importantly, Hcls1 and other genes, such as Pstpip1 and Ptpn7 are also 
increased in several tissues due to aGvHD compared to controls, though in some cases, the 
regulation did not reach statistical significance. These genes are associated with activation and 
regulation of T and B cells. The lack of HCLS1 on B and T cells causes a defect in proliferation 
and antigen receptor induced apoptosis (Fukuda et al., 1995), whereas PSTPIP1 is involved in the 
downregulation of CD2 triggered adhesion and activation of T cells (Li et al., 1998), and PTPN7 is 
involved in T and B lymphocyte development and reduces TCR-induced transcriptional activation 
(Saxena et al., 1998). These genes are most likely induced as a result of infiltrating T cells in the 
target tissues or due to the activation of alloreactive T cells in the organs. Other genes such as 
Ptger2, were either increased or remained unchanged in the different tissues. Prostaglandin E 
receptor 2 (PTGER2) or Prostaglandin E2 can modulate cytokine responses by CD4
+
 T cells 
directly and increases the expression of IL-17 and decreases IFN-γ production by acting on T cells 
directly (Napolitani et al., 2009), and can inhibit T cell responses by blocking the proliferation of T 





by DCs (Weaver et al., 2007). Also, Pik3ap1 mRNA expression was consistent between the 
different target organs in both mouse and rats. Phosphoinositde-3-kinase adaptor protein 1 
(PIK3AP1) is involved in the development of B cells (Yamazaki and Kurosaki, 2003) and PI3K 
activation of NK cells (Ni et al., 2012). 
 
On the other hand, several genes such as C1qtnf7, Tap1, Card11 and Htra1 were significantly 
downregulated in the different target tissues. CARD11 is known to mediate activation of T cells 
(Pomerantz et al., 2002) and C1q and Tumor Necrosis Factor Related Protein 7 (C1QTNF7) is a 
protein coding gene that is indirectly impacted by the glucocorticoid receptor gene, NR3C1 (Lu et 
al., 2007). NR3C1 is involved in cellular proliferation and inflammatory responses (Ray and 
Prefontaine, 1994). In addition, HTRA1 induction in the presence of LPS, increases the incidence 
of collagen-induced arthritis in mouse (Hou et al., 2013). Moreover TLR-4 ligands induce the 
expression of HTRA1 in macrophages and fibroblasts (Hou et al., 2013).  
 
Most importantly, these set of previously identified genes are very similarly regulated in the 
different tissues in mouse aGvHD compared to controls. In contrast, they show a more mixed 
expression pattern in the different rat aGvHD target organs compared to syngeneic rats. Several 
genes are differentially regulated between the different target organs such as Trem2, which is 
upregulated in the small intestine, but downregulated in the liver. TREM2 is downregulated by 
IFN-γ (Zhao and Ivashkiv, 2011) and is known to attenuate macrophage activation (Turnbull et al., 
2006). However, several genes were regulated in the same direction, but the regulation of most of 
these genes in rats was not statistically significant. 
 
In contrast, genes including Tgm2 were significantly increased in all mouse tissues, but were either 
reduced or unchanged in the rat. Transglutaminase 2 (TGM2) is induced by retinoic acid and is 
involved in apoptosis. Furthermore, TGM2 is also involved in inflammation and tumor biology 
(Griffin et al., 2002). Similarly, Anp32a showed a mixed expression pattern in the different mouse 
tissues. Acidic Nuclear Phosphoprotein 32 Family, Member A (ANP32A) is protein coding gene 
involved in several cellular processes including proliferation, differentiation and apoptosis. It is 



















SKIN SKIN SKIN SKIN 
ANP32A down* down* down NA 
C1QTNF7 down* down* down* up 
CARD11 up* up* down NA 
CXCL9 up* NA up* up 
HCLS1 up* up* up* up 
HTRA1 down* down* down down 
LGALS7 down* down* down down 
LILRA5 up* NA up* down 
LST1 down* up* up* down 
MSR1 up* up* up* down 
PIK3AP1 up* up* up down 
PSTPIP1 up* up* up* down 
PTGER2 up* up* down up 
PTPN7 up* up* up up 
TAP1 up* up* down down 
TGM2 up* up* up* down 
TREM2 up* up* up down 
UBD up* up* up* up 
 
Table 4.1: Comparison of candidate genes regulated in previous human (Norden et al. 
unpublished data) and rat skin biopsies (Dressel et al., 2013; Novota et al., 2011) and in 
mouse and rat aGvHD skin in our study.                    
The regulation patterns of genes from the previous studies (in blue) have been compared to the regulation of 
the candidate genes in the mouse and rat aGvHD skin in this study. Up shows upregulation of genes in 
aGvHD tissues compared controls, down shows downregulation. * indicates significant p-values for 
regulated genes. Genes regulated similarly in the mouse and/or rat aGvHD skin compared to the previous 
results have been shown in bold. 
 
On comparing the gene expression profiles of the candidate genes from previous studies to the rat 
and mouse aGvHD skin in our study, we observed that the regulation of several genes was similar 
in all three studies. We observed a trend of upregulation in the expression of CXCL9, HCLS1, 
PTPN7 and UBD in all the tissues (Table 4.1). Moreover, HTRA1 and LGALS7 were 
downregulated in all the tissues affected with aGvHD. The gene expression in mouse aGvHD 
tissues was compared to healthy controls, and in rat aGvHD tissues, to syngeneic rats.  
 
On comparing the previous results with the genes regulated in mouse aGvHD tissues, we observed 
a similar trend in upregulation of the genes CXCL9, HCLS1, LILRA5, MSR1, PIK3AP1, PSTPIP1, 





aGvHD tissues compared to the previous results, such as ANP32A, C1QTNF7, HTRA1 and 
LGLAS7.  
 
Taken together, we have successfully validated the regulation of these novel candidate genes in 
different aGvHD models and species, making their expression during aGvHD significantly 
important. These genes could be potential targets for aGvHD therapy. Even though their exact 
functions during aGvHD are not clear, several of these genes have been implicated in numerous 
other diseases, and different molecular pathways. Further studies need to be carried out to 
determine their functional role in HSCT outcome and onset of aGvHD.  
 
In summary, the gene expression patterns in the different target organs were mostly similar, but we 
observed a few important differences, which could be significant in differentiating therapeutic 
strategies targeting the different target organs. 
 
4.2 Differences in gene expression due to conditioning 
Most often mice and rats are subjected to TBI prior to transplant, whereas in the clinic, patients are 
mostly given chemotherapy, and only a few patients are given TBI (Hülsdünker and Zeiser, 2015). 
The difference in conditioning regimens between the different species could play an important role 
in the differences in gene expression. It has been shown previously, that TBI has a role in distinct 
differences in gene expression of different immune cell populations (Garg et al., 2010). In their 
study, they reported a significant regulation in the mRNA expression of several inflammatory 
mediators and chemokines, such as Tnf, Cxcl9, Il2, Il6, Ccl9 and chemokine receptor Cxcr3 in 
mouse jejunum as a result of TBI (Garg et al., 2010). Furthermore, it was reported that both 
conditioning and genetic factors altered the expression of chemokines (Mapara et al., 2006). 
 
We observed a number of genes in this study, whose regulation was altered as a result of 
preconditioning in the mouse tissues. Mostly, the genes were significantly regulated as a result of 
preconditioning in the BM control mouse, compared to the healthy control mouse, and this 
regulation was further augmented in the aGvHD mouse compared to healthy control and BM 
control mouse. In some cases, however, the direction of regulation was altered between the two 
groups. For example, in several genes in the liver, the gene expression of several genes including 
Ifng, Cxcl9, Cxcl10 and Il2ra was increased significantly as a result of preconditioning, however 
this regulation was decreased slightly between BM control mouse and aGvHD mouse (Figure 4.3). 
In most cases, however the overall expression pattern between in the aGvHD mouse stayed the 






The differences in the gene expression patterns between BM control mice due to preconditioning, 
and aGvHD mice compared to the BM control mice could be attributed to a number of factors. It is 
possible the regulation of several genes is exacerbated as a result of preconditioning alone during 
the initial phase of aGvHD, and is reduced during aGvHD onset. Furthermore, even in the human 
GI aGvHD biopsies, the type of conditioning, and the presence of steroids were important 
covariates for gene regulation during aGvHD. For example, the gene expression of CD226, IL1R1, 
TAP1, TGM2 and IL6 were affected by type of conditioning regimen, whereas LGALS7 and 
CX3CR1 mRNA expression was affected by administration of steroids (Table 3.2).  
 
Taken together, we identified genes that are regulated during aGvHD alone, as well as genes that 
are induced due to preconditioning. This difference in timing of gene resgulation after transplant 
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Figure 4.3: Hierarchical clustering of mRNA expression of genes in mouse aGvHD compared 
to preconditioning, in different organs.                          
Hierarchical cluster of genes in the mouse during aGvHD and preconditioning in the different organs, A. 
Liver B. Lung C. Skin D. Spleen E. Small intestine F. Large intestine. The x-axis represents cluster of gene 
expression patterns in different tissues. The y-axis represents clusters of regulated genes during aGvHD. The 
color key represents the scaled fold changes from -2 (downregulated) to +2 (upregulated). All fold change 









4.3   Comparison of gene expression in different target organs in different   
species 
4.3.1 Comparison of gene expression between mouse and rat aGvHD 
First, we compared the gene expression profiles of the previously identified candidate genes in the 
mouse and rat tissues (Figure 4.4). The expression of genes was very similar in the lung (p=0.02, 
R
2
=0.349), skin (p=0.0122, R
2
=0.394) and the small intestine (p=0.0122, R
2
=0.394). In contrast, 
the genes are differentially expressed in the liver (p=0.78, R
2
=0.007). The similarities in gene 
expression between the mouse and rat models are significant as the aGvHD models that we used 
for the mouse and rat were different. The aGvHD mouse model is fully mismatched and leads to a 
more severe aGvHD response compared to the rat MHC congenic model that is only MHC 
mismatched and aGvHD response is less severe, therefore we expected a more profound regulation 
of genes in the mouse. This was in line with our results, whereby, several genes that were 
significantly regulated in the mouse showed a similar trend in expression in the rat but were not 
necessarily significantly regulated.   
 
In the liver, we observed an increased regulation in the candidate genes regulated by IFN-γ in both 
the mouse and rat. In contrast, genes associated with T and B cell activation showed a trend of 
downregulation in the rat but were upregulated in the mouse liver. Moreover, Htra1 and C1qtnf7, 
which are significantly increased in the mouse liver but reduced in the rat. In contrast, the other 
three tissues showed a significant correlation in the gene expression patterns between the two 
species. Overall, the liver seems to follow a significantly different pattern of gene expression 
between the different species, as well as to other target organs of the same species.  
 
In all the tissues, we observed an increased trend of regulation in the mRNA expression of genes 
such as Ubd, Lst1 and Lilra5. However several genes have a mixed gene expression pattern in the 






Figure 4.4: Hierarchical clustering of mRNA expression of genes between mouse and rats in 
different organs.                       
A.  Hierarchical cluster of genes in the mouse and rat liver during aGvHD B. Hierarchical cluster of genes in 
the mouse and rat lung during aGvHD C. Hierarchical cluster of genes in the mouse and rat skin during 
aGvHD D. Hierarchical cluster of genes in the mouse and rat small intestine during aGvHD. The x-axis 
represents cluster of gene expression patterns in different tissues. The y-axis represents clusters of regulated 
genes during aGvHD. The color key represents the scaled fold changes from -2 (downregulated) to +2 
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Figure 4.5: Hierarchical clustering of mRNA expression of genes between human GI GvHD 
(histological grades 1-4) compared to patients with no GvHD (grade 0) and mouse intestinal 
aGvHD. 
Hierarchical cluster of genes in the small and large intestine in aGvHD mouse and GI aGvHD human 
biopsies. The x-axis represents cluster of gene expression patterns in different tissues. The y-axis represents 
clusters of regulated genes during aGvHD. The color key represents the scaled fold changes from -2 
(downregulated) to +2 (upregulated). All fold change values are shown (even those with p-value = ns)  
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The gene expression profile of GI aGvHD biopsies compared to either aGvHD-affected mouse 
small or large intestines was not very similar. However, a large proportion of genes were regulated 
in the same direction. Based on the hierarchical grouping of genes, two groups were separated. One 
population of genes were increased, mainly involving Th1 chemokines, whereas the other group 
was downregulated, mainly involving Th2 cytokines (Figure 4.5). Overall, the aGvHD in both the 
human GI aGvHD biopsies, as well as in the small and large intestines, was strongly associated 
with a chemokine-mediated aGvHD response. There was a strong upregulation of CXCR3, and its 
ligands, CXCL9, CXCL10 and CXCL11. Other chemokines such as CCL5, and chemokine 
receptors, CCR1 and CCR5 were increased too. The chemokines CXCL8 (Cxcl15), CXCL16, and 
other cytokines, mostly associated with Th2 responses, such as IL4, IL4R, IL33 and IL5 were 
decreased.  
 
4.3.3 Comparison of gene expression between mouse, rat aGvHD in small 
intestine and human GI GvHD 
           
Figure 4.6: Hierarchical clustering of mRNA expression of candidate genes between mice, rat 
and human GI aGvHD small intestine.                                              
Hierarchical cluster of genes in the mice, rat and human GI aGvHD small intestines. The x-axis represents 
cluster of gene expression patterns in different tissues. The y-axis represents clusters of regulated genes 
Human GI 
GvHD  
































during aGvHD. The color key represents the scaled fold changes from -2 (downregulated) to +2 
(upregulated). All fold change values are shown (even those with p-value = ns) 
Of the candidate genes, we observed a correlation between the gene expression in the aGvHD 
mouse and rat small intestine, but it did not significantly correlate to the mRNA expression in the GI 
aGvHD biopsies.  However, several genes were similar expressed in all three species, such as 
HTRA1, TGM2, TREM2, TAP1, MSR1, LILRA5 and PIK3AP1. Most of the genes similarly regulated 
were either regulated by IFN-γ (Figure 4.6).  
The variations of the gene regulation patterns observed in this study could be due a number of 
reasons. The human aGvHD is completely different to the aGvHD animal models in terms of 
treatment before and after transplant, the timing of the transplant and heterogeneity of the sample 
population. In addition, pre-existing conditions prior to transplant, and infections such as CMV 
might also significantly alter the regulation patterns of the genes. Nevertheless, several genes were 
successfully validated to be regulated in the same manner in all the three species.  
Also, important species differences need to be considered when comparing gene expression in 
multiple species (Mestas and Hughes, 2004). For example, marked differences in the anatomy, 
physiology, metabolism, pharmacology and microbiota composition play an important role in the 
pathophysiology of aGvHD (Schroeder and DiPersio, 2011). In addition, age plays an important role 
in influencing the efficacy of the immune reconstitution post transplant, effects of long-term 
therapy, as well as susceptibility to GvHD (Ordemann et al., 2002). Opportunistic infections are also 
important in affecting transplant outcome that are not modeled in rodents kept in specific-pathogen-
free (SPF) conditions.  
Another important difference in gene expression could be a result of the homogenous genetic 
composition of inbred rodents, in contrast to the heterogeneity in humans (Schroeder and DiPersio, 
2011). Moreover, the immune cell populations vary in the different species. The T cell expansion is 
also homogeneous in rodents, contrary to the heterogeneous T cell response in humans (Seok et al., 




 and Tregs, between the different 
species can remarkably influence the aGvHD pathophysiology (Schroeder and DiPersio, 2011). In 
addition, the Th1 and Th2 paradigm is of concern, as the polarization is relatively easy to observe in 
rodents, however it is more difficult to make clear distinctions in humans, as both T cell types are 
typically generated simultaneously (Allen and Maizels, 1997; Gor et al., 2003). In addition, 
differences have emerged between chemokines and their receptors in human and murine systems, 






Moreover human endothelial cells constitutively express both MHC class I and II molecules, 
whereas murine endothelial cells only express MHC I class molecules (Choo et al., 1997). 




 T cells 
(Mestas and Hughes, 2001; Murphy et al., 1999; Pober JS, Kluger MS, 2001), whereas mouse 
endothelial cells can only activate CD8
+
 T cells (Kreisel et al., 2002), but not CD4
+
 T cells. 
It is well known that conditioning prior to HSCT causes tissue damage and induction of pro-
inflammatory responses that affect the GvHD outcome (Gendelman et al., 2004; Mabed et al., 
2005). Therefore, the time of transplant and different conditioning regimens significantly affect the 
transplant outcome (Schwarte and Hoffmann, 2005). Murine models frequently involve TBI as the 
conditioning, as in our aGvHD model, whereas in the clinical setting, patients are usually subjected 
to chemotherapy, and only a few patients receive TBI (Hülsdünker and Zeiser, 2015). Also, it is 
known that steroids affect gene regulation, which would explain some of the difference in gene 
expression in the human GI aGvHD biopsies. 
The extent of MHC mismatch also plays a role in observed variations of gene expression. For 
example, in our study, our mouse aGvHD model (C57BL/6 (H2
b
)  BALB/c (H2
d
)) is mismatched 
for MHC and mHags, whereas our rat aGvHD model (PVG.7B (RT1
c 
)  PVG.1N (RT1
n
)) is only 
MHC-mismatched. On the other hand, patients that eventually develop aGvHD, are differently well 
matched for HLA prior to transplant.  
Taken together, these differences could explain the variations in the gene expression patterns 
between our different rodent models compared to human GI aGvHD.  
 
4.4  Gene expression pattern of KLRK1 and its ligands in aGvHD tissues in 
different species 
Considering the presence of several ligands for NKG2D, it is likely that the ligands are regulated 
differently via stress pathways. Presumably, the regulation of distinct ligands, as a response to cells 
undergoing different types of stress, could allow the receptor to stimulate a response in different 
contexts. The diversity in ligands makes immune evasion by viruses that inhibit or destroy the 
ligands, more difficult.  The affinity of the ligands to the receptor could alter their function on the 
receptor under different conditions, or the way they are secreted or shed from cells. Moreover, 
ligands could exert different effects on different cells that express them, even in the absence of 





could engage other receptors aside from the NKG2D making it possible for them to have a wide 
range of functions (Kriegeskorte et al., 2005).  
The functional interaction of several SNPs within the MICA gene could explain the varying 
expression intensity of MICA for different MICA alleles (Isernhagen et al., 2015, 2016a; Shafi et al., 
2011). The relevance of NKG2D signaling for HSCT outcome was further shown in an aGvHD 
mouse model that developed an ameliorated aGvHD response on transient blockade of NKG2D on 
donor CD8
+
 T cells after transplantation (Karimi et al. 2015). Furthermore, clinical studies 
demonstrated the effects of RAET1L genotypes, encoding the NKG2D ligand, ULBP6 and the 
NKG2D encoding gene KLRK1 (Espinoza et al., 2009) and MICA genotypes (Isernhagen et al., 
2015, 2016a) on overall survival of patients post transplant.  
We observed a significantly differential regulation of both NKG2D and its ligands in different 
aGvHD target organs, i.e., the liver, lung, skin, small and large intestines, as well as the non-target 
organ spleen. Moreover, the Klrk1 expression were significantly regulated due to preconditioning in 
the BM control mouse compared to the healthy controls, and its expression was further  in mouse 
with aGvHD, suggesting that conditioning regimens that reduce induction of these molecules, could 
ameliorate aGvHD. The expression of the KLRK1 gene was increased in all the tissues in the mouse 
and rat, except in the rat it was decreased in the small intestine, as well as in the human GI aGvHD 
clinical biopsies, although it did not reach statistical significance in the rat or human biopsies. This 
could indicate an infiltration of NKG2D expressing lymphocytes in the different organs, or 
activation of alloreactive donor T cells in the organs.   
The NKG2D ligands, on the other hand, had a more diverse pattern of expression in the different 
tissues. Rae1 mRNA was significantly reduced in aGvHD mouse in all the tissues. Interestingly, it 
was possible to clearly differentiate the regulation of Rae1 in the BM control mouse due to 
preconditioning, as well as the aGvHD mouse compared to the controls. The expression of the gene 
was reduced significantly as a result of preconditioning, after which its expression increased in the 
small intestine and spleen as a result of aGvHD, which could be explained by increased tissue injury 
to these organs, since an increase in RAE-1 protein expression has been shown to be associated with 
increase in aGvHD and tissue damage in the colon of mouse after transplant (Karimi et al. 2015). 
The overall expression of Rae1, however, was downregulated in the aGvHD tissues compared to the 
healthy controls. On the other hand, H60a showed a more mixed expression pattern in the different 
aGvHD tissues compared to the healthy controls. On the other hand, Ulbp1 mRNA was significantly 
increased in the different aGvHD mouse tissues compared to the healthy controls. In the rat, we 
observed a significant increase in the expression of Rae1l mRNA in the liver, but reduced 
significantly in the skin. Similarly, Rrlt was also increased in the liver, but did not reach statistical 





upregulation of ULBP1 and a downregulation of MICB. Additionally, ULBP3 was significantly 
increased in severe (grade 2-4) aGvHD compared to low or no aGvHD (grade 0-1). Also, the 
expression of MICA was higher in patients who died due to transplant related causes compared to 
patients who died due to unrelated causes or patients that are still alive. In addition, patients who 
were treated with steroids had a higher mRNA expression of MICA and lower expression of ULBP1, 
than patients who were not given steroids. Moreover, the KLRK1 and MICA mRNA expression was 
significantly dependent on the EBMT risk score, suggesting that an increased expression of both the 
genes was associated with an increased risk of aGvHD incidence.  
 
4.5   Gene expression pattern of CD226 and its ligands in aGvHD tissues in 
different species 
DNAM-1 is another activating NK receptor, which also serves as a costimulatory molecule on CD8
+
 
T cells (Zingoni et al., 2012). DNAM-1 or CD226 is expressed on NK cells and CD8
+
 T cells in 
humans (Shibuya et al., 1996), as well as CD4
+
 T cells and monocytes whereas in mouse DNAM-1 
is expressed by only approximately 40-50 % NK cells, all CD8
+
 T cells and activated CD4
+
 T cells 
(Dardalhon et al., 2005). DNAM-1 binds to its ligands CD112 encoded by poliovirus receptor 2 
(PVRL2), expressed on epithelial cells, and CD155 encoded by PVR expressed on epithelial cells, 
endothelial cells and APCs (Bottino et al., 2003; Tahara-Hanaoka et al., 2004). Blockade or 
deficiency of either DNAM-1 on donor cells, has been shown to reduce the intensity of acute graft 
versus host disease (aGvHD) in mouse (Nabekura et al., 2010). 
We observed an elevated expression of CD226 mRNA in all the mouse aGvHD tissues compared to 
healthy controls. Similarly, an increase in gene expression of its ligands Pvr in the mouse and Pvrl2 
in mouse and rat, across the different aGvHD tissues was observed. In the human GI aGvHD 
biopsies, we saw a similar increase in the expression of CD226 and its ligands, but the regulation 
was not statistically significant. Moreover, patients who died due to transplant related causes had a 
lower expression of PVRL2 compared to other patients who were still alive or died due to unrelated 
causes. In addition, both CD226 and PVR were decreased in patients who were treated with steroids 
compared to patients who were not given any steroids. Overall, an elevated expression of CD226 
and its ligands was observed in the different aGvHD tissues. DNAM-1 expressing T or NK cell 
infiltration in the different tissues is the most likely explanation for this expression pattern. Another 
explanation could be the activation of alloreactive T cells in the peripheral organs, leading to an 






4.6 Gene expression in human GI aGvHD biopsies  
We found several genes that were differentially regulated between patients with and without 
steroids. Interestingly, the presence of steroid treatment in patients significantly altered the gene 
expression in patients with aGvHD compared to controls. In the overall patient cohort, the clinical 
patient aGvHD scores (1-4) were associated with an increased expression of HCLS1, VCAM1, 
CCR5, CXCR3, CCR1, IL2 and IL6, compared to patients with no aGvHD (grade 0). The genes that 
were associated with an increase in clinical symptoms of aGvHD in patients were mostly 
chemokines and genes associated with activation of B and T cells. This is in line with T cell 
infiltration in the skin and gut, which in turn leads to heightened clinical aGvHD symptoms prior to 
taking a biopsy of the gut. Interestingly, the gene regulation patterns due to histological and clinical 
scores were very different. In biopsies with histological aGvHD grades 1-4, compared to no aGvHD 
(grade 0), we observed an upregulation of IL2RA (CD25), which is present on activated T cells and 
Tregs. This suggests a strong infiltration of T cells in the patient GI biopsies, as well as heightened 
alloreactive T cell activation. On further grouping the patient biopsies based on grade 2-4 vs. grade 
0-1, we could identify several genes that were differentially regulated in the severe aGvHD biopsies 
compared to patients with low or no aGvHD. We observed a more chemokine-based regulation of 
genes, whereby CXCL16 and CX3CR1 were significantly upregulated, whereas CXCL8 and CCL4 
were significantly downregulated. Interestingly, this pattern of expression was the similar to mouse, 
where the expression of Cxcl16 and Cx3cr1 was upregulated in the intestines whereas Cxcl15, a 
homolog to CXCL8 and Ccl4 was significantly decreased in the intestine. Furthermore, we found 
IL33 to be increased in patients that died due to TRM compared to patients who were still alive or 
died due to unrelated causes.  
It is possible that several of the genes were significantly regulated due to the administration of 
steroids, instead of aGvHD. To better separate the changes in the gene expression patterns in the 
biopsies due to aGvHD, we separated the patients who did not receive steroids, from the entire 
patient group. In the patient group without steroids, several genes were still regulated in the same 
manner, whereas certain genes were additionally regulated, for example PSTPIP1 was significantly 
downregulated in patients with severe aGvHD (grade 2-4) compared to grade 0-1.  
Taken together, the gene expression data from patient biopsies is of crucial importance. Identifying 
genes that are similarly expressed in all three species would be of more significance. Genes such as 
UBD, that are upregulated in all the different tissues in all the species, could be an important target 
to better understand mechanisms of aGvHD and possibly a therapeutic target. Further functional 
studies using knockout rodent models of aGvHD could be the next step in elucidating the 
importance of the function of these genes during aGvHD.  




5 Summary and conclusions  
Several studies focussing on mRNA expression profiling in aGvHD tissues have been carried out in 
the past. Such mRNA profiling studies are important in understanding the pathophysiology of 
aGvHD in the different target organs affected by aGvHD. While most studies have been carried out 
in 1 to 2 tissues, we had the unique opportunity to study the mRNA expression profiles of several 
focus genes in different target organs of aGvHD, and in different species simultaneously. We 
showed that in mice, aGvHD was associated with an increase in the Th1, Th2 and Th17 responses 
and the regulation of these genes was more pronounced in the lung and intestinal biopsies. 
Moreover, genes associated with Treg regulation and activation were overexpressed in the different 
target organs, most notably in the intestinal biopsies. These results give us an idea on lymphocyte 
migration patterns in the different target tissues during aGvHD. 
In all the aGvHD target tissues, we observed a pronounced chemokine response to aGvHD. A 
similar chemokine response was observed in the human GI aGvHD biopsies. Several candidate 
genes, mainly associated with T and B cell activation, and inflammatory responses were also 
increased in the mouse tissues and showed a similar trend of regulation in the rat and human aGvHD 
biopsies as well. Notably, a number of genes were significantly altered as a result of preconditioning 
alone, and their expression was further regulated due to aGvHD. Furthermore, the gene expression 
patterns in the target organs of aGvHD, such as intestine and liver, were significantly different from 
the non-classical aGvHD target organs, such as spleen.  
We also found an increased trend in expression of KLRK1, encoding NKG2D and CD226, encoding 
DNAM-1 in all the mice and rat tissues, however in the human biopsies KLRK1 mRNA showed a 
trend of upregulation, whereas CD226 remained unchanged. The expression patterns of their ligands 
were most interesting. On one hand, mRNA expression of the NKG2D ligand Ulbp1 was 
upregulated in the different mouse tissues, whereas H60a was upregulated in the intestinal biopsies, 
whereas downregulated in the skin, and Rae1 was significantly downregulated in the different 
mouse aGvHD tissues. Similarly, Rae1l was upregulated in the aGvHD rat liver, whereas it was 
downregulated in the skin. On the other hand, the expression of most of these genes were not 
changed during human GI aGvHD, however MICB was significantly downregulated, whereas we 
observed a trend of upregulation of MICA. The expression patterns of the DNAM-1 ligands were 
more similar between the different species. In the mice, both Pvr and Pvrl2 were significantly 
increased, and in the rats they showed a trend of upregulation. On the other hand, in the human GI 
biopsies, they were not significantly altered.  
Moreover, an increased expression of MICA, and decreased PVRL2 expression was associated with 
TRM in patients. Similarly, MICA was upregulated in patients that were treated with high doses of 




steroids, whereas the expression of ULBP1, CD226 and PVR was downregulated in these steroid-
treated patients. The regulation of several of these genes in mice due to preconditioning and 
transplant, suggests that preconditioning, significantly alters the expression of KLRK1, CD226 and 
their ligands during aGvHD, suggesting that conditioning regimens which lead to less induction of 
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7.1 Expression of genes in aGvHD mice compared to healthy controls in 
different tissues 
All fold changes for genes regulated in mice with aGvHD compared to healthy controls have been 
listed in Table 7.1 for all the tissues. Fold changes > 1 represent upregulation and < 1 represent 
downregulation of the genes. The gene-tissue combinations for which the regulation was 
significant (p <0.05) are in bold and in red. All genes are listed alphabetically.   
Table 7.1 Fold changes of regulated genes in aGvHD mice compared to healthy controls in 
the different tissues 





Anp32a 1.17 0.29 0.58 6.25 5.68 0.75 
Arg1 9.5 22.69 2.09 1.02 7.29 59.31 
Bmpr1a 3.15 7.94 1.86 1.83 0.99 1.67 
C1qtnf7 0.02 0.01 2.7 0.01 0 0.3 x 10
-3
 
Card11 0.06 0.05 0.85 0.2 x 10
-3
 0.23 0.31 
Ccl4 2.8 8.02 8.5 x 10
7
 2.06 16.93 11.87 
Ccl5 0.65 0.9 1.06 0.15 0.96 0.37 
Ccl9 1.51 31.98 29.18 5.97 3.78 11.61 
Ccr1 17.84 6.62 47.37 4.64 4.5 6.62 
Ccr4 1.57 0.35 0.31 0.05 0.41 1.57 
Ccr5 3.01 5.07 0.52 1.56 3.82 3.15 
Cd226 1 4.25 10.54 0.97 10.66 4.89 
Cx3cl1 0.16 0.47 1.65 0.26 1.36 0.36 
Cx3cr1 0.24 0.97 0.31 13.34 49.71 265.77 
Cxcl10 2.22 47.87 21.77 0.97 10.46 21.32 
Cxcl11 0.11 65.72 15.71 2.99 133.73 64.82 
Cxcl15 0.07 0.3 0.29 0.19 2.57 1.08 
Cxcl16 2.97 5.2 4.52 0.55 2.17 5.66 
Cxcl9 10.54 9.07 20.17 0.31 3.18 10.54 
Cxcr3 0.41 21.16 1.9 x 10
6
 1.2 12.59 4.4 x 10
10
 
Cxcr4 10.11 0.27 0.42 0.51 0.07 0.25 
Enpp1 0.07 0.17 0.76 0.71 3 2 
Fcer1g 2.31 3.66 6.92 0.91 1.6 2.15 
Fcgr3 1.04 1.24 3.19 0.79 1.65 2.24 
Foxp3 0.15 0 1062.95 0.42 3.68 37.9 




Hcls1 3.95 8.61 44.39 1.37 1.83 3.18 
Htra1 1.6 1.75 0.94 0.49 1.28 1.28 
Icam1 5.66 3.54 10.13 1.5 4.13 10.55 
Ido1 0.71 36.57 3.52 1.08 93.18 30.82 
Ifng 67.99 33.76 3 x 10
6
 5.63 1.16 x 10
8
 43.6 
Il10 0.03 0.08 0 65.51 143.75 63.27 
Il12a 32.25 0.62 0 0.11 106.86 1.84 
Il13 17.93 1.52 0.37 2.15 164.39 6.85 
Il15 0.64 0.79 1.78 0.52 0.5 0.44 
Il17a 208.1 2.78 3.88 17.88 786.77 14.56 
Il1r1 6.64 1.07 1.49 0.42 2.33 1.36 
Il1rl2 7.22 15.08 1.06 1.21 1.2 1.82 
Il2 1.13 5.4 34.42 0.65 239.65 3.31 
Il22 11.56 6.4x10
4
 0.1 116.23 30.85 1.4 x 10
2
 
Il23a 0.24 0.01 0.38 11.35 5.1 4.9 x 10
3
 
Il2ra 38.77 7.49 1987.75 0.69 3.53 10.21 
Il33 0.71 6.06 3.44 0.37 2.03 4.78 
Il4 133.21 0.15 59.98 2.2 x 10
2
 2.84 5.48 
Il4ra 1.18 19.28 4.1 0.78 3.23 4.91 
Il5 409.74 0.29 1135.55 20.66 2378.45 684.19 
Il6 36.49 4.57 555.19 1.95 791.68 3.2 x 10
2
 
Klrk1 2.32 15.55 7.2 1.45 4.29 3.12 
Lgals3 7.63 10.86 2.1 4.35 1.76 0.91 
Lgals7 19.67 0.01 0.22 2.59 6.4 x 10
2
 4.56 
Lilra5 6.84 4.01 128.6 8.58 9.8 x 10
2
 168.91 
Lst1 4.04 9.63 8.38 65.59 734.91 37.68 
Msr1 1.06 5.29 106.48 9.34 9.65 13.69 
Pik3ap1 1.35 4.04 1.37 0.73 1.03 1.68 
Pstpip1 9.47 1.66 1.15 1.01 2.12 4.34 
Ptger2 1.18 0.39 0.61 0.39 1.78 1.91 
Ptpn7 8.14 1.19 1.38 1.43 1.81 4.09 
Pvr 1.85 0.52 2.56 1.06 3.38 1.41 
Pvrl2 2.32 2.43 1.14 2.39 2.83 1.92 
Rae1 0.05 0.02 1.4 0.55 0.09 0.1 
Tap1 0.07 1.31 0.73 0.01 0.01 1.3 
Tgfb1 1.76 5.06 2.15 0.78 1.06 2.01 
Tgfbr1 0.08 7.88 1.24 0.41 1.03 1.41 
Tgfb2 1.02 0.8 1.31 0.24 1.03 0.64 
Tgm2 5.05 26.28 3.07 3.22 9.91 8.76 
Tnf 0.32 2.06 0.46 0.14 1.4 3.15 






Ubc 6.12 13.97 6.04 2.04 6.74 3.29 
Ubd 2.17 10.32 59.3 59.28 11.25 7.55 
Ulbp1 4.46 4.82 0.76 1.87 1.09 1.45 
 
7.2 Expression of genes in aGvHD mice compared to BM controls in different 
tissues 
All fold changes for genes regulated in mice with aGvHD compared to BM controls have been 
listed in Table 7.2 for the different tissues. Fold changes > 1 represent upregulation and < 1 
represent downregulation of the genes. The gene-tissue combinations for which the regulation was 
significant (p <0.05) are in bold and in blue. All genes are listed alphabetically.   
Table 7.2 Fold changes of regulated genes in aGvHD mice compared to BM controls in the 
different tissues 





Anp32a 20.76 7.38 0.89 8.78 4.39 4.53 
Arg1 1.48 2.04 6.16 0.45 9.92 24.65 
Bmpr1a 1.14 0.99 2.84 1.63 0.97 1.44 
C1qtnf7 20.11 0.02 26.66 0.11 0.01 0.01 
Card11 0.05 0.11 3.15 0.34 0.52 0.57 
Ccl4 3.23 4.09 25.25 0.52 11.97 14.42 
Ccl5 2.81 3.37 8.78 0.46 2.1 6.28 
Ccl9 0.95 3.68 4.95 1.39 3.48 9.26 
Ccr1 6.92 3.57 4.3 2.64 5.31 2.57 
Ccr4 6.19 0.95 1.65 0.11 1.29 2.99 
Ccr5 1.08 3.46 0.06 0.95 7.42 3.95 
Cd226 1.44 2.67 9.16 1.61 8.52 10.8 
Cx3cl1 0.57 0.79 1.32 0.15 0.89 1.42 
Cx3cr1 0.24 0.16 0.83 0.86 3.52 17.42 
Cxcl10 0.17 2.6 3.45 0.12 7.07 3.4 
Cxcl11 0.1 3.29 0.68 0.13 18.33 31.09 
Cxcl15 0.17 0.51 2.77 0.26 1.41 0.47 
Cxcl16 1.88 0.94 2.23 0.32 2.08 3.09 
Cxcl9 0.22 1.16 4.19 0.53 3.02 2.41 
Cxcr3 2.19 49.15 92.4 2.95 51.31 2.2 x 10
4
 
Cxcr4 4.21 0.67 1.22 1.12 1.24 1.87 
Enpp1 0.11 0.43 0.41 0.58 2.6 0.78 




Fcgr3 1.42 1.24 0.71 0.55 1.84 2.37 
Foxp3 0 0 18.91 0.3 1707.92 8.89 
H60a 0.7 0.56 2.03 0.14 2.73 3.11 
Hcls1 2.17 0.87 4.37 0.5 3.28 2.47 
Htra1 40.4 0.49 1.08 0.33 2.64 1.71 
Icam1 1.92 1.07 5.09 1.02 10.5 5.38 
Ido1 2.03 1.16 5.48 0.77 12.03 2.75 
Ifng 0.77 5.41 1361.09 0.78 235.18 95.52 
Il10 0.23 1.9 0 1 215.6 7334.52 
Il12a 5.08 0.99 0.31 1.07 92.56 5.3 
Il13 0.99 2.14 10.76 0.82 2.52 5.22 
Il15 0.73 0.69 1.96 0.71 0.5 0.88 
Il17a 161.28 0.4 0.45 5.8 1.11 0.71 
Il1r1 3.24 0.76 1.77 0.47 5.4 1.92 
Il1rl2 1.2 1.3 1.86 1.66 2.69 1.89 
Il2 0.03 1.69 0.03 0.21 0.88 1.65 
Il22 0.04 0.64 1.44 0.01 0.49 1.4 
Il23a 5.85 14.58 0.27 0.14 1.19 3.8 x 10
2
 
Il2ra 4.07 4.33 10.12 0.4 8.77 10.08 
Il33 1.73 2.09 2.26 0.28 3.55 4.37 
Il4 0.12 0.1 3.7 x 10
6
 6.6 3.13 2.76 
Il4ra 1.53 0.7 1.91 0.91 2.18 1.93 
Il5 0.47 2.72 1.13 4.39 7.42 1.37 
Il6 0.64 3.25 2.9 0.36 3.37 2.66 
Klrk1 0.78 2.14 6.42 0.69 4.64 3.67 
Lgals3 1.57 1.17 2.53 1.32 1.26 1.63 
Lgals7 64.07 1.96 0.16 0.38 107.56 1.24 
Lilra5 2.37 0.54 0.14 1.06 134.34 1.2 
Lst1 1.55 1.02 5.22 1.6 5.48 3.2 
Msr1 1.09 0.87 0.16 1.15 3.73 1.45 
Pik3ap1 1.42 0.63 0.62 0.36 2.02 1.78 
Pstpip1 10.73 1.36 1.43 1.28 5.66 5.13 
Ptger2 1.74 0.54 1.23 0.6 3.26 3.2 
Ptpn7 10.73 0.95 3.63 1.12 5.66 5.13 
Pvr 2.23 1.35 8.32 1.25 4.1 5.89 
Pvrl2 1.3 0.63 1.48 0.51 1.82 1.21 
Rae1 0.52 0.96 2.11 4.29 20.05 1.86 
Tap1 0.001 0 0.01 0 0.07 0.03 
Tgfb1 1.62 0.68 1.02 0.54 1.97 2.03 
Tgfbr1 0.1 0.65 0.89 0.56 1.19 1.23 




Tgm2 1.59 0.85 1.25 0.64 3.44 3.94 
Tnf 0.79 2.93 2.49 0.41 5.5 5.63 
Trem2 0.04 3.07 0 6.93 0.03 1.81 
Ubc 0.79 1.24 4.91 1.74 3.67 3 
Ubd 2.17 10.32 59.3 0.83 11.25 7.55 
Ulbp1 2.14 0.74 1.99 1.36 2.32 1.39 
 
7.3 Expression of genes in BM mice compared to healthy controls in different 
tissues 
All fold changes for genes regulated in mice as a result of preconditioning and transplantation in 
BM control mice compared to healthy controls have been listed in Table 7.3 for the different 
tissues. Fold changes > 1 represent upregulation and < 1 represent downregulation of the genes. 
The gene-tissue combinations for which the regulation was significant (p <0.05) are in bold and in 
green. All genes are listed alphabetically.    
Table 7.3 Fold changes of regulated genes due to preconditioning and transplantation 
procedure in BM control mice compared to healthy controls 





Anp32a 0.06 0.04 0.65 0.71 1.29 0.17 
Arg1 6.4 11.1 0.34 2.28 0.74 2.41 
Bmpr1a 2.76 7.99 0.66 1.12 1.02 1.16 
C1qtnf7 0 0.52 0.1 0.04 0.05 0.04 
Card11 1.37 0.47 0.27 0.38 0.44 0.55 
Ccl4 0.87 1.96 3.3 x 10
5
 3.98 1.41 0.82 
Ccl5 0.23 0.27 0.12 0.31 0.45 0.06 
Ccl9 1.58 8.69 5.9 4.28 1.09 1.25 
Ccr1 2.58 1.86 11.02 1.76 0.85 2.58 
Ccr4 0.25 0.37 0.19 0.46 0.32 0.52 
Ccr5 2.81 1.47 8.41 1.64 0.51 0.78 
Cd226 0.69 1.59 1.15 0.6 1.25 0.45 
Cx3cl1 0.28 0.59 1.26 1.69 1.53 0.26 
Cx3cr1 1.01 6.25 0.37 15.57 14.13 15.25 
Cxcl10 13.08 18.44 6.31 8.03 1.48 6.28 
Cxcl11 1.1 19.99 23.11 22.98 7.3 2.08 
Cxcl15 0.4 0.59 0.1 0.73 1.82 2.28 




Cxcl9 48.67 7.83 4.82 0.59 1.05 4.37 
Cxcr3 0.2 0.43 2.1 x 10
4
 0.41 0.25 1.9 x 10
6
 
Cxcr4 2.4 0.4 0.34 0.46 0.05 0.13 
Enpp1 0.64 0.39 1.85 1.23 1.15 2.55 
Fcer1g 2.52 2.72 3.4 2.46 0.91 0.96 
Fcgr3 0.73 1 4.48 1.42 0.9 0.94 
Foxp3 78.95 0.6 56.22 1.39 0 4.26 
H60a 5.26 0.3 1.45 0.58 0.32 1.11 
Hcls1 1.82 9.9 10.16 2.75 0.56 1.29 
Htra1 0.4 3.56 0.86 1.5 0.49 0.75 
Icam1 2.94 3.32 1.99 1.47 0.39 1.96 
Ido1 0.35 31.43 0.64 1.4 7.75 11.19 
Ifng 88.01 6.25 2206.47 7.23 4.9 x 10
4
 0.45 
Il10 0.15 0.04 0.07 65.33 0.67 0.01 
Il12a 6.34 0.62 0.01 0.1 1.15 0.35 
Il13 18.05 0.71 0.03 2.62 65.21 1.31 
Il15 0.88 1.14 0.91 0.74 0.99 0.51 
Il17a 1.29 6.88 8.61 3.08 709.71 20.37 
Il1r1 2.05 1.4 0.84 0.89 0.43 0.71 
Il1rl2 6.03 11.62 0.57 0.73 0.44 0.96 
Il2 41.47 3.19 1262.54 0.13 273.49 2.01 
Il22 293.51 1.04 x 10
4
 0.07 1.04 x 10
4
 62.82 91.4 
Il23a 0.04 0.7 x 10
-3
 1.42 79.06 4.28 12.84 
Il2ra 9.53 1.73 196.44 1.01 0.4 1.01 
Il33 0.41 2.9 1.52 1.35 0.57 1.09 
Il4 214.13 1.48 0 33.94 0.91 0.18 
Il4ra 0.77 27.39 2.15 0.87 1.49 2.54 
Il5 865.17 0.11 1001.57 4.71 320.54 498.43 
Il6 56.92 1.41 191.63 5.43 234.62 1.2 x 10
2
 
Klrk1 2.97 7.27 1.12 2.09 0.93 0.85 
Lgals3 4.87 9.3 0.83 3.29 1.4 0.56 
Lgals7 0.31 0.01 1.37 6.83 5.95 3.67 
Lilra5 2.89 7.4 892.92 8.1 7.28 140.76 
Lst1 2.6 9.48 1.61 41.07 134.08 11.76 
Msr1 0.98 6.09 663.75 8.13 2.58 9.47 
Pik3ap1 0.95 6.4 2.21 2.03 0.51 0.95 
Pstpip1 0.88 1.22 0.8 0.8 0.37 0.85 
Ptger2 0.68 0.71 0.5 0.66 0.55 0.61 
Ptpn7 0.76 1.26 0.38 1.28 0.32 0.94 
Pvr 0.83 0.39 0.31 0.84 0.83 0.25 




Rae1 0.1 0.02 0.66 0.13 0 0.05 
Tap1 129.22 603.45 127.02 0.25 0.11 43.17 
Tgfb1 1.09 7.42 2.1 1.44 0.54 0.99 
Tgfbr1 0.75 12.06 1.4 0.73 0.86 1.14 
Tgfb2 0.37 1 1.35 0.41 0.64 0.33 
Tgm2 3.72 30.82 2.46 5.02 2.88 2.22 
Tnf 0.41 0.7 0.18 0.35 0.26 0.56 
Trem2 393.05 0.03 1.5 x 10
4
 0.01 0 0.57 
Ubc 7.7 11.26 1.23 1.18 1.84 1.1 
Ubd 28.71 10.65 0.56 4.56 0.78 1.17 
Ulbp1 2.08 6.53 0.38 1.37 0.47 1.04 
 
7.4 Expression of genes in aGvHD rat compared to syngeneic rats in different 
tissues  
All fold changes for genes regulated in aGvHD rats compared to syngeneic rats have been listed in 
Table 7.4 for the different tissues. Fold changes > 1 represent upregulation and < 1 represent 
downregulation of the genes. The gene-tissue combinations for which the regulation was 
significant (p <0.05) are in bold and in blue. All genes are listed alphabetically.    
Table 7.4 Fold changes of regulated genes in aGvHD rats compared to syngeneic rats in 
different tissues 
Genes  Liver Lung Skin 
Small 
intestine 
C1qtnf7 0.4 1.06 1.36 0.68 
Cd226 10.63 0.61 4.33 1.24 
Hcls1 5.28 2.34 1.3 1.71 
Htra1 0.77 0.53 0.54 0.85 
Lgals7 26.12 1.19 0.61 2.06 
Lilra5 20.51 3.87 0.63 1.59 
Lst1 172.84 4.69 0.8 1.94 
Msr1 8.54 0.86 0.89 1.08 
Klrk1 94.31 1.11 1.95 0.7 
Pik3ap1 3.01 1.06 0.61 3.33 
Pstpip1 3.48 4.56 0.97 4.65 
Ptger2 6.98 1.67 9.83 1.16 
Ptpn7 3.67 2.02 4.39 1.2 
Pvr 0.43 0.77 0.58 1.27 
Pvrl2 1.42 0.76 2.21 2.87 
Rae1l 185.78 4.89 0.01 0.33 
Rrlt 15.75 0.27 0.1 0.23 
Tap1 2.98 2.12 0.78 3.3 
Tgm2 3.17 0.97 0.36 1.57 
Trem2 1.59 4.65 0.54 2.84 
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